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Abstract 
 
Alzheimer’s disease is a chronic, neurodegenerative disease characterised by 
amyloid plaque accumulation, neurofibrillary tangles and eventual neuronal cell 
loss. The complex aetiology exhibited in late-onset Alzheimer’s disease 
presents a considerable challenge in the field of genetics, with identified 
variants from genome-wide association studies collectively only explaining 
about a third of disease incidence. As such, new avenues are being explored to 
elucidate underlying mechanisms associated with disease onset and 
progression. 
 
In 2014, the first epigenome-wide association studies in Alzheimer’s disease 
were published,  identifying several, novel differentially methylated loci in the 
nuclear genome in cortical brain samples, highlighting that epigenetic 
mechanisms may play a role in disease aetiology. Further, a growing body of 
evidence has implicated mitochondrial dysfunction as an early feature of 
disease pathogenesis. Despite this, few studies have investigated the role of 
mitochondrial DNA epigenetics in Alzheimer’s disease. Indeed, the relatively 
nascent field of mitochondrial epigenetics has largely been restricted to 
candidate-based gene approaches to identify differential methylation associated 
with disease.  
 
The main aim of this thesis was therefore to design an experimental and 
bioinformatic pipeline for the analysis of mitochondrial DNA methylation in post-
mortem human brain tissue; first in healthy non-demented control donors, and 
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subsequently in individuals with Alzheimer’s disease. Our work therefore 
represents the first epigenome wide studies of mitochondrial DNA methylation 
at single nucleotide resolution, providing a framework not only for mitochondrial 
DNA methylation in Alzheimer’s disease, but also in a number of complex 
diseases characterised by mitochondrial dysfunction. 
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MBD Methyl-CpG Binding Domain Proteins 
MeDIP-Seq Methylated DNA Immunoprecipitation Sequencing 
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MELAS 
Mitochondrial Encephalomyopathy With Lactic Acidosis And 
Stroke-Like Episodes 
MM Mixed Model 
mPT Mitochondrial Permeability Transition 
mPTP Mitochondrial Permeability Transition Pore 
mtDNA Mitochondrial DNA 
mt-SNPs Mitochondrial Single Nucleotide Polymorphisms 
NASH Non-Alcoholic Steatohepatitis 
ncDNA Nuclear DNA 
NGS Next Generation Sequencing 
NUMTs Nuclear-Mitochondrial Pseudogenes 
OMM Outer Mitochondrial Membrane 
OXBS Oxidative Bisulfite 
OXPHOS Oxidative Phosphorylation 
PCA Principal Component Analysis 
PD Parkinson’s Disease 
QQ Quantile-Quantile 
PCR 
qRT-PCR 
Polymerase Chain Reaction 
Quantitative Real-Time Polymerase Chain Reaction 
RLGS Restriction Landmark Genomic Scanning 
ROS Reactive Oxygen Species 
RPKM Reads Per Kilobase Of Transcript Per Million Mapped Reads 
RRBS Reduced Representation Bisulphite Sequencing 
rRNA Ribosomal RNA 
SAM S-adenosyl L-methionine 
SMRT Single-Molecule Real-Time Sequencing 
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SS Simple Steatosis 
SNP 
STG 
Single Nucleotide Polymorphism 
Superior Temporal Gyrus 
TET 
TF 
TFR 
tRNAs 
Ten-Eleven Translocase 
Transcription Factor 
Transcription Factor Receptor 
Transfer RNA 
VDAC1 Voltage Dependent Anion Channel 1 
WGBS-Seq Whole Genome Shotgun Bisulphite Sequencing 
ZMW Zero-mode Waveguide 
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Chapter 1. Introduction 
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The work presented in this chapter is based on two published reviews; 
Devall et al., 2014  and Devall et al. 2016 (1,2), which can be found in 
Appendix 1 and 2, respectively. 
 
1.1.  Epigenetics  
Since initial studies in the field by Conrad Waddington (3), epigenetics has been 
increasingly investigated. Specifically, since the recent advances in genetic 
technology, there has been an exponential increase in the number of epigenetic 
studies published (Figure 1.1).  
 
Figure 1.1:  Bar  chart  to  show  the  number  of  publications  per  year  in 
the  field  of epigenetics. For  each  year,  the  keyword  search  term 
“epigenetic” was  entered  into  Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/) and  the  resulting  number  of  
publications  for  that  year  were plotted. 
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Epigenetic processes mediate the reversible regulation of gene expression, 
occurring independently of DNA sequence and acting principally through 
chemical modifications to DNA and nucleosomal histone proteins. There are a 
number of epigenetic modifications, including phosphorylation, ubiquitination, 
SUMOylation, histone (de)acetylation and methylation of both DNA and protein. 
However, due to the relative stability of DNA methylation as a mark, and owing 
to the development of technologies capable of genome-wide DNA methylation 
profiling, this epigenetic modification is currently the most widely studied (1,4). 
 
1.1.1. DNA Methylation 
DNA methylation refers to the covalent addition of a methyl group to the fifth 
carbon of cytosine, resulting in the creation of 5-methylcystosine (5-mC). The 
majority of nuclear DNA (ncDNA) methylation in eukaryotes occurs in a CpG 
dinucleotide context, with 60-90% of total cytosines at these sites being 
methylated (5). A notable exception to the high proportion of methylated 
cytosines in a CpG context can be seen in CpG islands (CGIs), regions over 
500bp with greater than 50% GC content. These regions are commonly 
associated with gene promoter regions and are generally unmethylated (6,7). 
DNA Methylation has been shown to be present in non-CpG contexts in somatic 
cells. However, modifications in this context generally appear to occur with low 
abundance and in specific cell types (8-10). It has been generally accepted that 
DNA methylation is associated with gene silencing (11,12); however, recent 
studies have found that this relationship is impacted by factors such as genic 
location of DNA methylation as well as the effect on the overlapping chromatin 
structure (13). For example,  whilst  methylation changes in regions of low-CG 
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content DNA at alternate promoters show a strong, inverse correlation with 
gene expression (14), the vast majority of CGIs within promoters are 
unmethylated, regardless of gene expression. Further, whilst methylation at 
intergenic regions has also been suggested to lead to decreased gene 
expression through regulation of DNA enhancers (15), gene body methylation 
has been shown to be positively correlated with expression in a number of 
studies (16). 
 
 1.1.1.1. Mechanisms of DNA Methylation 
The transfer of a methyl group from the methyl donor S-adenosyl L-methionine 
(SAM) to create 5-mC is catalysed by a conserved group of enzymes called 
DNA methyltransferases (DNMTs) (17). Importantly, two classes of DNMTs 
exist in eukaryotic organisms. DNMT3A and DNMT3B are important for 
establishing de novo methylation and, as such, are highly expressed in cells 
during processes involving differentiation and development (18), whereas 
DNMT1 plays a fundamental role in the maintenance of hemi-methylated DNA 
during semi conservative replication and is ubiquitously expressed regardless of 
a cell’s spatiotemporal state (18). Methylated DNA is then ‘read’ by a number of 
different protein classes, with the most commonly researched being the methyl-
CpG binding domain proteins (MBD), which affect gene expression through 
their interactions with histone and chromatin modifying proteins, typically 
leading to a closed chromatin structure and reduced transcription factor binding 
(Figure 1.2) (19). 
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Figure 1.2: An overview of DNA methylation machinery. Methylated 
cytosines at a CpG dinucleotide recruit MBDs, which bind preferentially to single 
methylated cytosines and contain a transcriptional repressor domain, aiding in 
gene silencing. Figure taken from (20). Abbreviations: Methyl binding domain 
proteins (MBDs), Transcription factor (TF), Transcription Factor Receptors (TF-
R). 
 
 
 
 
 
 
 
 1.1.1.2. Other Methylation Marks 
A number of technologies can be used to interrogate ncDNA methylation; the 
most commonly used in epigenetic studies are bisulfite (BS) based approaches 
(2). Briefly, this methodology allows for the distinction of methylated and 
unmethylated cytosines through the addition of BS. This converts unmethylated 
cytosines to uracil, which are then converted to thymine after a further 
desulphonation step. Methylated cytosines remain unaffected by this process 
and can therefore be distinguished based on their sequence and the base 
pairing of the now modified thymine. One limitation of using BS based 
sequencing or microarray based approaches are their inability to distinguish 
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between 5-mC and another DNA modification, namely 5-
hydroxymethylcytosine, (5-hmC) (4). The potential role of 5-hmC as an 
independent epigenetic mark was initially met with controversy after a number 
of early contradictory findings (21). However, the discovery of Ten-eleven 
translocation 1 (TET1), which catalyses the oxidation of 5-mC into 5-hmC, has 
led to a number of studies investigating its role in the epigenome (22), 
particularly as 5-hmC appears to be enriched in the brain (23). Additional DNA 
modifications have also been identified, namely 5-formylcytosine (5-fC) and 5-
carboxylcytosine (5-caC), which are thought to be intermediates in the DNA 
methylation pathway, as levels of both modifications are far lower than 5-mC 
and 5-hmC, (see (24) for review). 
 
1.2. Mitochondria: The Powerhouse of the Cell 
Being the site of adenosine triphosphate (ATP) generation, the mitochondria 
provide the cell with the energy required to properly function; as such 
mitochondria are often described as ‘the powerhouse of the cell’. Mitochondria 
are cylindrical organelles containing ~16.6kb of DNA (mtDNA) (25), which is 
separate to the nuclear genome and inherited in a maternal, non-Mendelian 
fashion. The mitochondrial genome consists of 37 genes, 13 of which encode 
for polypeptides required for the electron transport chain (ETC), in addition to 
two ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs) (Figure 1.3). 
MtDNA also exists as a multi-copy genome, with 2-10 copies of mtDNA per 
mitochondrion, and multiple mitochondria per cell (26). 
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Figure 1.3: The structure of the mitochondrial genome. Shown is the 
mitochondrial genome (ChrM), with the position of protein coding ETC genes 
and two rRNAs highlighted. Known mtDNA variants are shown in red and black 
lines highlight the predicted CpG sites. PH and PL represent the heavy and light 
strand promoter regions and OH and OL represent the origins of heavy-strand 
and light-strand replication respectively.  Image taken from (27). 
 
 
 
 
 
 
 
 
 
 
 
1.3.  Mitochondrial Structure 
The mitochondria are made of five distinct components, the cristae, matrix, 
inner mitochondrial membrane (IMM), inter-membrane space (IMS), and the 
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outer mitochondrial membrane (OMM), with the OMM acting to separate the 
IMS from the cytosol (28) (Figure 1.4).  
 
Figure 1.4: Diagram to show the inner compartments of the mitochondria. 
The dual membrane structure of the mitochondria separates the matrix from the 
cytosol. Folds of the IMM form the mitochondrial cristae, which provide a 
greater surface area for aerobic respiration and thus, ATP generation to occur. 
Image taken from (29). 
 
 
 
 
 
 
 
Transport into the IMS, through the OMM is mediated by two pathways and is 
dependant upon molecular size. Small molecules less than 6kDA can pass 
through the OMM using porins, which are beta barrel proteins present on the 
membrane surface (28); whilst molecules greater than 6kDa can only enter after 
binding to translocase proteins on the OMM (30). Mitochondrial cristae are folds 
in the IMM which provide a greater surface area to facilitate the chemical 
reactions that occur during ATP production. Being the site of oxidative 
phosphorylation (OXPHOS), cristae shape has been found to have dramatic 
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effects on the kinetics of chemical reactions occurring in the ETC (31). The 
mitochondrial matrix plays a vital role in calcium (Ca2+) buffering, which is 
required for correct neuronal transmission. Increased levels of Ca2+ in the 
mitochondrial matrix leads to increased levels of Krebs cycle enzymes and 
increased ATP production. Further, mitochondria can also aid in the regulation 
of Ca2+ levels, for example through the opening of the mitochondrial 
permeability transition pore (mPTP). As such, mitochondria are critical 
determinants of neuronal stability, not only through ATP production, but also 
through their ability to buffer calcium (32), with changes in correct mitochondrial 
function often accompanied by neuronal dysfunction and neurodegeneration 
(1). 
 
1.4. Mitochondria, mtDNA and their Relationship to Complex- and Age-
Related Disorders 
With the exception of mature red blood cells, mitochondria are present in every 
cell within the human body. However, despite the importance of maintaining 
correct mitochondrial function for cellular respiration, mtDNA is subjected to 
approximately 100x the mutagenic stress of ncDNA (33). Reactive oxygen 
species (ROS) are a major source of mutagenic stress and an ever-growing 
body of evidence indicates a relationship between the production of ROS and 
subsequent mitochondrial damage, associated with some of the adverse effects 
of ageing. It is important to note that ROS play important roles as secondary 
messengers between mitochondria and the rest of the cell (retrograde 
signalling) and also from the cytosol to the mitochondria (anterograde 
signalling) (34).  However, the mitochondrial theory of ageing states that, over 
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time, an increase in ROS creates a positive feedback loop, leading to oxidative 
damage in the mitochondria and further ROS production. In turn, these free 
radicals then contribute to the development of a number of degenerative 
diseases characterised by mitochondrial dysfunction. (35).  
 
1.4.1. Mitochondria and Cell Death 
Importantly, changes in ROS levels and mitochondrial function have been 
associated with both apoptosis and necrosis by altering the permeability of the 
mitochondrial double membrane (36). Dramatic changes in IMM 
permeabilisation, the mitochondrial permeability transition (mPT), are caused by 
the opening of the mPTP, allowing solutes greater than 1.5kDa to pass through 
the IMM (37). If open for a short period, this change not only allows for the 
release of more Cytochrome C, a component of the ETC which acts to transfer 
electrons from Complex III – IV (38), but also leads to further increases in ROS 
production. A short-term release of cytochrome C leads to the activation of 
caspases, permeabilisation of the OMM and programmed cell death in a 
pathway mediated by BCL2 Associated X Protein (BAX) and BCL2 
Antagonist/Killer 1 (BAK) (39). In some cases this transition persists and 
spreads, leading to further depolarisation of the mitochondria. This loss of 
mitochondrial membrane potential has been shown to lead to the complete loss 
of ATP generation, given that the ETC requires an electrochemical gradient to 
function (37). The absence of ATP generation leads to mitochondrial swelling, 
changes in ion homeostasis and eventual necrosis (36). A multitude of factors 
are associated with the opening of the mPTP and the widespread development 
of necrosis across cell populations, but the two most studied are oxidative 
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stress and excessive calcium accumulation in the mitochondrial matrix (40). 
Abnormalities in apoptosis and necrosis have been associated with 
mitochondrial dysfunction in a range of complex diseases (40-42); however, a 
full mechanistic understanding about the onset of this dysfunction is still 
unclear.  
 
1.4.2. Mitophagy, Fission and Fusion 
In response to external stimuli, such as high levels of oxidative stress within 
dysfunctional mitochondria, a process of mitochondrial autophagy (mitophagy) 
may be evoked to degrade the organelle. A number of possible mitophagic 
pathways have been suggested. The most extensively characterised pathway 
includes the mitochondrial kinase PTEN Induced Putative Kinase 1 (PINK1) 
(43). Changes in mitochondrial permeability lead to an accumulation of this 
kinase on the mitochondria, phosphorylating ubiquitin and subsequently 
recruiting Parkin, a ligase. Parkin serves to add more ubiquitin chains to the 
mitochondria. Upon ubiquitination, chains are further modified via 
phosphorylation by PINK1, leading to the subsequent recruitment of 
autophagosome components and Microtubule-Associated Protein 1 Light Chain 
3 (LC3) to engage the dysfunctional mitochondria in lysosomal degradation 
(43,44). As such, mitophagy acts to reduce the mitochondrial aspect of ageing 
by removing dysfunctional mitochondria. Interestingly, genetic changes in both 
PINK1 and PARKIN have been associated with Parkinson’s disease (PD), an 
age-related disease (45). 
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Mitochondrial quality is maintained not only through mitophagy, but also by a 
number of other processes, most notably mitochondrial fission and fusion. 
Essentially, extensively damaged mitochondria are fragmented through fission 
before eventual degradation by the process of mitophagy (46). Alternatively, 
during mitochondrial fusion, damaged mitochondria are fused with healthy 
mitochondria, thus reducing the overall percentage of the genetic mutational 
load within the mitochondria, stabilising mtDNA copy number and preserving 
mtDNA fidelity (47). 
 
Mitochondrial fission is mediated by Dynamin-related Protein 1 (DRP1), a 
ubiquitously expressed protein, which is recruited from the cytosol and binds to 
Mitochondrial Fission 1 (FIS1), Mitochondrial Fission Factor (MFF), 
Mitochondrial Dynamics Protein of 49 kDa (MID49) and Mitochondrial Dynamics 
Protein of 51 kDa (MID51), which are proteins on the OMM (48,49). DRP1 is 
regulated by a number of epigenetic, post-translational modifications. Following 
binding to the OMM proteins, DRP1 oligomerises into a ring like structure, and 
upon constriction, divides mitochondria (49).  
 
Mitochondrial fusion occurs at two levels, at the OMM, which is predominately 
mediated by Mitofusion 1 and Mitofusion 2, (MFN1 and MFN2 respectively), and 
subsequently at the IMM, which is mediated by Optic Atrophy 1 (OPA1) (Figure 
1.5). In mouse embryonic cells, deletion of Mfn1 or Mfn2 leads to partial 
reduction in mitochondrial fusion, whilst a double deletion mouse model has 
complete loss of fusion (50). Therefore, current evidence suggests that a select 
number of ncDNA genes are directly responsible for adequate fission and fusion 
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of the mitochondrion and that dysregulation of these genes can have severe 
consequences on mitochondrial homeostasis. 
 
Figure 1.5: Overview of mitochondrial fusion and fission. Despite their co-
ordinated balance to control mitochondrial copy number, the two events are 
regulated by different proteins. The fusion of two or more mitochondria is 
regulated by three major proteins, MFN1 and MFN2 which reside at the OMM, 
and OPA1, residing in the IMM. The regulation of mitochondrial fission is 
regulated by several other proteins acting initially on the OMM. Most 
importantly, DRP1 is recruited by FIS1, which oligomerises and constricts 
around the mitochondria. Figure taken from (51). 
 
 
 
 
 
1.4.3. Mitochondrial Genetics 
Parental transmission of mtDNA occurs in a non-Mendelian, maternal fashion. 
As opposed to ncDNA, mtDNA contains no histone structure and is instead 
organised in protein-DNA complexes named nucleoids. This lack of protective 
histones has been associated with the increased level of mtDNA mutations that 
occur throughout ageing. 
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Each mitochondrion contains between 2-10 copies of mtDNA. However, not all 
mtDNA in each mitochondrion share the same DNA sequence. Mutations that 
affect all copies are referred to as homoplasmic (52). However, mutations may 
also arise in a small proportion of the mtDNA molecules in each mitochondrion, 
creating a mosaic of different sequences known as mitochondrial heteroplasmy. 
Mitochondrial heteroplasmy has been linked to various mitochondrial diseases, 
(53), and poses a real issue when studying mitochondrial diseases. On a larger 
scale, mutations in mtDNA can be used to help group populations. Throughout 
evolution, collections of mutations in mtDNA may be conserved and passed on 
through maternal inheritance, thus allowing for the tracing of common ancestral 
lineages, these groups are referred to as haplogroups. Whilst many studies 
have investigated the risk associated with different mitochondrial haplogroups 
and complex diseases (54-56), investigations into individual mitochondrial 
single nucleotide polymorphisms (mt-SNPs) are limited, primarily as many 
genome-wide association studies (GWAS) often discard reads associated with 
the mitochondrial genome. This is in part due to the lack of genome-wide 
coverage that many single nucleotide polymorphism (SNP) microarrays offer 
(57) and that mitochondrial heteroplasmy may have large effects on current 
genotype calling algorithms, due to the possibility that there may be more than 
two minor alleles in highly heteroplasmic cells, requiring custom analysis 
pipelines for mtDNA variant analysis (58). Further, given the tissue-specific 
nature of heteroplasmy and sequence-specific mutational threshold required to 
drive mitochondrial dysfunction (59,60), and as many GWAS use easily 
accessible tissue such as blood, it is possible one may not observe peripheral 
changes in mtDNA genome stability contributing to disease in other tissues (2).  
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 1.4.3.1. Homology to the Nuclear Genome    
A major factor influencing mitochondrial genetic studies is the presence of 
nuclear-mitochondrial pseudogenes (NUMTs). NUMTs are regions of the 
mitochondrial genome that, over an evolutionary period of time, have 
translocated to the nuclear genome and therefore, share a high sequence 
homology with their mitochondrial paralogue. Failure to account for these 
regions has led to misinterpretations of genetic sequencing data (61,62), and is 
one pitfall of using publicly available data, although bioinformatic approaches to 
account for these regions are being developed (63,64). Further, the presence of 
NUMTs can cause major issues in genomic analyses using pre-sequencing 
enrichment methods such as custom capture or long-range polymerase chain 
reaction (PCR) as the likelihood of NUMT co-amplification, or even preferential 
amplification, increases due to the strong sequence similarity between the two 
segments of genome (65).  Ideally to avoid misinterpretation of data, 
mitochondria should be isolated from the tissue of choice prior to sequencing 
(1) and nominated loci should be further assessed using programs such as the 
Basic Local Alignment Search Tool (BLAST), a program used to look for 
similarity between two regions of DNA (66).  
 
1.5.  Mitochondrial Epigenetics  
The diverse range of mitochondrial functions coupled with their importance in 
the governance of cellular energy demands means that the expression of 
mitochondrial proteins requires sophisticated levels of fine-tuning. Although 
~99% of mitochondrial proteins are encoded by the nuclear genome, 
differences in mtDNA methylation have been associated with a range of 
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complex diseases (1,2). Given the fact that mitochondria are not associated 
with histone proteins, it is unlikely that histone modifications will have a direct 
impact on mtDNA regulation. MtDNA methylation, on the other hand, may play 
an important role in regulating mitochondrial function, either independently, or 
via a complex mechanism involving nuclear-mitochondrial crosstalk (1). 
 
1.5.1. MtDNA Methylation: The Controversial Mark 
Despite rapid progress in the field of nuclear epigenetics, the field of 
mitochondrial epigenetics has received little attention since initial, but 
contradictory studies published in the 1970’s (67-69).  These controversies 
continue, with one recent report concluding an absence of ‘biologically 
significant levels’ of mtDNA methylation in four regions of mtDNA analysed in 
human HEK293 cells and publicly available data (70). However, given the low 
sequencing depth of mtDNA in the publicly available data used in this study 
(94x), and the multi-copy nature of the mtDNA genome present in any given 
cell, it is possible that the true extent of mtDNA methylation was not determined. 
Despite this, DNMT1 and DNMT3B have been identified in the mitochondria of 
human and murine cell lines and may play an important role in methylation of 
the mitochondrial Displacement loop (D-LOOP) (71). The same study also 
identified TET1 and TET2 in the mitochondria, which alongside the presence of 
5-hmC in the mitochondrial D-LOOP, strengthens evidence suggesting that 
methylation and demethylation could have important roles in defining 
mitochondrial function. Both 5-mC and 5-hmC have also been identified in a 
number of mammalian mitochondria from cell lines (72). Furthermore, 5-mC has 
been found to co-localise in motor neurons with the mitochondrial marker 
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Superoxide Dismutase 2 (SOD2) (73). In addition, the identification of Dnmt3a 
in mitochondria isolated from a mouse motor neuron cell line (73), as well as in 
mitochondria isolated from mouse brain and spinal cord (72), suggests a 
potential tissue-specificity for mtDNA methylation. As well as displaying signs of 
tissue specificity, mtDNA methylation also correlates well with other factors 
strongly associated with ncDNA methylation, such as age and sex in BS 
pyrosequencing studies (74).  
 
1.5.2. MtDNA Methylation: A Role in Complex Disease 
Despite little being known about the physiological impact of variation in mtDNA 
methylation, some recent studies have shown that it may be associated with a 
variety of diseases. The majority of studies have focussed on diseases where 
mitochondrial dysfunction is known to be prevalent, for example in cancer (75) 
and also in Down’s Syndrome (DS) (76). Particularly, for the purpose of this 
thesis, mitochondrial dysfunction and mtDNA methylation aberrations in DS 
cells are interesting given that these patients have an increased likelihood of 
presenting with Alzheimer’s Disease (AD)-like phenotypes throughout ageing 
(77,78), due to possessing an extra copy of the amyloid precursor protein (APP) 
gene. An overview of studies of mtDNA epigenetics in disease is given in Table 
1.1. 
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Table 1.1: An overview of current studies of mitochondrial epigenetics in disease. New abbreviations: Quantitative Real-
Time PCR (qRT-PCR), simple steatosis (SS), non-alcoholic steatohepatitis (NASH), Liquid chromatography-electrospray 
ionization tandem mass spectrometry (LC-ESI-MS), Liquid chromatography mass spectrometry (LC-MS), Immunofluorescence 
(IF), Amyotrophic lateral sclerosis (ALS).                                        
Research Question Techniques Main Findings Ref 
The effect of different environmental 
exposures (metal-rich particulate matter, 
air benzene levels and traffic derived 
elemental carbon levels) on mitochondria 
Pyrosequencing 
 
 
 
qRT-PCR 
Increased exposure to particulate matter increases MT-
RNR1 and MT-TF gene methylation 
 
Increased MT-RNR1 methylation is associated with a 
significant increase in mtDNA copy number. 
(79) 
The effect of mtDNA methylation in the 
mitochondrial D-LOOP on gene expression 
in colorectal cancer cells. 
Methylation-
specific PCR 
 
Western blotting 
Significant hypomethylation in the D-LOOP of tumour 
cells is strongly associated with increased MT-ND2 
expression and mtDNA copy number. 
(75) 
The effect of methylation in the  D-LOOP , 
MT-ND6 and MT-CO1 on disease 
progression in SS and NASH 
Methylation-
specific PCR 
 
qRT-PCR 
Increased MT-ND6 methylation and DNMT1 and 
decreased MT-ND6 protein in NASH compared to SS. 
Physical activity reduced MT-ND6 methylation in 
NASH. 
(80) 
The effect of decreased SAM on mtDNA 
methylation in DS lymphoblastoid cells 
LC-ESI-MS 
 
LC-MS/MS 
Decreased SAM availability in DS lymphoblastoid cells 
reduces methyl uptake to mitochondria and leads to 
mtDNA hypomethylation. 
(81) 
The tissue specificity of DNMTs and 5-mC 
in the mitochondria in relation to ALS 
models. 
IF 
 
Pyrosequencing 
 
Increased methylation at six cytosine sites in the 16S 
rRNA gene in the spinal cord of an ALS mouse cell line. 
 
Reduced levels of mtDNMT3a protein in skeletal 
muscle and spinal cord early in disease. 
(82) 
The effect of mtDNA methylation on 
mtDNA copy number in gastric cancer. 
qRT-PCR 
 
 
Pyrosequencing 
 
Reduced mtDNA copy number levels in late 
clinicopathological stages. 
 
Demethylation of mtDNA demethylation increases 
mtDNA copy number. 
(83) 
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1.5.3. MtDNA Methylation: Regulation of Gene Expression 
The role of mtDNA genetic variation on underlying mitochondrial function has 
become increasingly studied in recent years. MtDNA haplogroups and genetic 
variation have been found to have pronounced effects on mitochondrial 
functions, leading to altered ETC functions and ROS levels, which are 
associated with increased breast cancer risk (84). However, given that a single 
mitochondrion can contain up to 10 copies of the mitochondrial genome (85), 
and as there are multiple mitochondria in any given cell, the extent of 
heteroplasmic mutations and their effect on mitochondrial function is far from 
clear (53). Further, relatively few of the studies investigating mtDNA methylation 
have related identified changes to alterations in gene expression.  
 
One recent study showed significant hypermethylation of the D-LOOP is 
negatively associated with expression of three mitochondrial-encoded ETC 
genes, Mitochondrially Encoded Cytochrome B (MT-CYB), Mitochondrially 
Encoded NADH: Ubiquinone Oxidoreductase Core Subunit 6 (MT-ND6) and 
Mitochondrially Encoded Cytochrome C Oxidase II (MT-CO2) in retinal 
microvessels derived from diabetic retinopathy donors (86). However, the group 
failed to find significant differences in the methylation of MT-CYB and concluded 
that, given the importance of the D-LOOP in replication and transcription of the 
mitochondrial genome, changes in D-LOOP methylation may result in 
transcriptional changes across the mitochondrial genome, potentially 
contributing to the pathogenesis of diabetic retinopathy (86).  
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However, a recent in vivo study showed D-LOOP methylation did not correlate 
with the expression of mitochondrial-encoded genes during inflammation (87). 
Briefly, it was found that lipopolysaccharide (LPS)-mediated inflammation in 
mice led to significant changes in mtDNA transcript levels, which were reversed 
upon treatment with α-Lipoic acid (LA), an agent with anti-inflammatory 
properties. However, despite these transcriptional changes, neither treatment 
altered D-LOOP methylation. Taken together, these two studies suggest that 
mitochondrial transcription may be driven by mtDNA methylation of the D-
LOOP; however, this phenomenon is not the sole driver of mitochondrial gene 
expression. Further studies should potentially employ a more holistic approach 
to investigate the relationship between mtDNA methylation, mtDNA gene 
expression and potential nuclear-encoded effectors of mtDNA transcription. To 
better understand the relationship between mtDNA methylation and gene 
expression, the use of whole DNA methylome sequencing at single base 
resolution should be considered.  
 
1.5.4. The Bi-directionality of Mitoepigenetics 
As research into the field of mitochondrial epigenetics gains momentum, studies 
have focused on a potential trans-acting role of mtDNA in the epigenetic 
regulation of ncDNA, whereby covalent modifications across the mtDNA 
genome may affect not only the expression of a gene in cis, but also have trans-
acting effects on the transcription of genes in the nuclear genome. A recent 
study found DNA methylation levels in the nuclear-encoded, mitochondrial-
specific transcription factor DNA polymerase gamma A (POLGA) inversely 
correlate with mtDNA copy number in pluripotent and multipotent cell types (88). 
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The removal of mtDNA (89), or changes in mtDNA haplogroups (90), have been 
found to be associated with differences in ncDNA methylation levels, suggesting 
an important interplay between the two genomes and a bi-directionality to 
mitoepigenetics (91).  
 
Cytoplasmic hybrids (cybrids) are an important cell type for studying 
mitochondrial function as they contain identical nuclei to the parent cell but 
different mtDNA, allowing for a controlled investigation into the role of mtDNA 
variants. Using Restriction Landmark Genomic Scanning (RLGS) and Rho0 
cells, a form of cybrid cell line designed for investigating mtDNA depletion, one 
study found that mtDNA depletion significantly altered DNA methylation at CGIs 
in nuclear encoded genes (89), indicating that there are functional interactions 
between the two genomes. Re-introduction of wild-type mtDNA restored DNA 
methylation levels at some RLGS spots, suggesting that, at least for some 
genes, mitochondria may play a role in ncDNA methylation. Other cybrid studies 
have shown that mtDNA derived from haplogroup J had consistently higher 
levels of global ncDNA methylation than haplogroup H, suggesting that mtDNA 
variants may play an important role in influencing ncDNA methylation (92). This 
difference in DNA methylation was accompanied by significant decreases in the 
expression of six of the 11 nuclear-encoded genes assayed that are involved in 
DNA methylation and acetylation processes, as well as significant increases in 
the transcription of Methionine Adenosyltrasferase 2B (MAT2B) and MBD4, 
both of which are important for DNA methylation. Given the importance of these 
two processes in epigenomic regulation, this further illustrates how mtDNA 
genetic variation can impact on the nuclear genome. Another recent study 
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investigating the mitochondrial 3243A>G heteroplasmy, which causes several 
clinical phenotypes including mitochondrial encephalomyopathy with lactic 
acidosis and stroke-like episodes (MELAS), showed that changes in 
heteroplasmy levels led to large and widespread changes in mitochondrial and 
nuclear transcriptional regulation, including changes in transcripts involved in 
DNA methylation and histone acetylation. Interestingly, high levels of this 
heteroplasmic variant (50-90%) resulted in ncDNA gene expression changes 
that are similar to those seen in AD, PD and Huntington’s disease (HD).   
 
Each mitochondrion is comprised of approximately 1500 proteins; however, of 
these, only 13 are encoded by the mitochondrial genome. The remainder are 
encoded by the nuclear genome and imported into the mitochondria. A recent 
study found that over 600 of these genes have tissue-specific differentially 
methylated regions (DMRs), ultimately leading to changes in mitochondrial 
function, dependent upon tissue type (93). This suggests that there is an 
additional level of complexity to consider in the study of mitochondrial 
epigenetics, whereby epigenetic changes in one genome may affect 
transcriptional control in another in a tissue-specific manner. With alterations in 
ncDNA methylation in neurodegenerative disorders now well established (4,94-
97), future studies may aim to study mtDNA and ncDNA epigenomes in parallel 
to gain an understanding of the complete cellular epigenetic landscape.  
 
 
 
                                                                                                                    
50 
 
1.5.5. Current Methodologies for MtDNA Methylation Analysis  
An important consideration in mtDNA methylation is defining the most 
appropriate method for which to study the epigenetic mark. A host of different 
platforms have been developed that are capable of assessing DNA methylation 
in the nuclear genome. However, given the relative nascence of the field of 
mtDNA epigenetics, the appropriateness of the wide range of genomic 
technologies available and their utility for this field has yet to be reviewed. 
Advances in genomic technologies has seen ncDNA methylation studies move 
from profiling methylation at a handful of candidate CpG sites to epigenome-
wide association studies (EWAS). However, the current workhorse for such 
studies, the Illumina 450K methylation array, provides no coverage of the 
mitochondrial genome. Given that mtDNA methylation is now becoming 
increasingly investigated, an understanding of the technologies available to 
assess genome-wide changes in mitochondrial DNA methylation is of upmost 
importance. An overview of genomic technologies that could be utilised to 
measure mtDNA methylation is provided in Table 1.2. 
 
To capture an accurate and precise representation of potential mtDNA 
methylation changes, a technique should ideally be able to detect DNA 
modifications with low error rate and at single nucleotide resolution. This is 
more pertinent to studies of mtDNA epigenetics than in studies of ncDNA 
methylation given the low levels of mtDNA methylation identified in recent 
studies (79,98). Currently, the only published genome-wide studies investigating 
mtDNA 5-mC and 5-hmC levels have utilised publicly-available methylated DNA 
immunoprecipitation sequencing (MeDIP-Seq) data (63,99). Whilst the study of 
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5-mC was able to identify spatio-temporal patterns of mtDNA methylation in a 
variety of cells and tissues, the coverage was relatively low (5x). Given 
sequencing and genomic biases, low levels of coverage may result in some 
bases not being sequenced adequately for analysis. Further, the resolution of 
MeDIP-Seq also remains a limitation. Despite high levels of concordance 
between MeDIP-Seq data, which averages the methylation values across a 
region, and other technologies that focus on single CpG sites (100), it is 
possible that a correlation may not be observed across every region of the 
mitochondrial genome. For example, averaging methylation in regions as small 
as 100bp in the mitochondrial genome could include averaging methylation 
across many gene boundaries of tRNAs in some regions and could greatly 
mask the true methylation status at specific regions within these genes.  
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Method General Overview Advantages Disadvantages 
MeDIP- & 
hMeDIP-Seq 
(NGS) 
MeDIP-Seq is an IP based 
method. In brief, purified 
genomic DNA is sheared by 
sonication to produce 
random fragments. These 
fragments are then 
denatured and 
immunoprecipitated, 
followed by PCR 
amplification. Using high-
throughput sequencing at a 
depth of two Gb, around 70-
80% of CpGs in the human 
genome can be identified 
(101). 
1. Staining with anti-5-hmC antibodies allows for 5-
hmC Stroud et al. (102), which is not only present 
in the brain and significantly reduced in AD (103), 
but is also present in brain mitochondria (104). 
 
2. Sequencing produces files typically less than 
6GB (fastq format) 
 
3. Cost-effective relative to most BS based 
approaches (105). 
 
4. Only regions of interest are investigated. 
 
 
 
1. Investigation of both 5-
mC and 5-hmC is costly 
and requires several μg 
mtDNA (102,106). 
 
2. Resolution reduced to 
methylated windows. 
Analysis of single 
cytosine methylation 
sites is not possible 
(107).  
 
3. Count based data 
means that reads must 
be normalised for CpG 
density and total read 
counts (108), although 
pipelines are now more 
capable of accounting for 
this (109). 
Table 1.2: An overview of sequencing technologies that could be utilised to study mtDNA methylation in 
neurodegenerative diseases. New abbreviations: Hydroxymethylated DNA Immunoprecipitation sequencing (hMeDIP-
Seq), Immunoprecipitation (IP), Reduced Representation Bisulphite Sequencing (RRBS), Enhanced Reduced 
Representation Bisulfite Sequencing (ERRBS), Oxidative Bisulphite (OXBS), Single-molecule real-time sequencing 
(SMRT), Zero-mode Waveguide (ZMW), Next-Generation Sequencing (NGS). 
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Method General Overview Advantages Disadvantages 
Custom 
Capture 
(NGS) 
Custom capture kits 
available allow for a custom 
design of a library for the 
enrichment of specific DNA 
target regions.  
 
In brief, DNA undergoes 
standard NGS pipelines 
approaches of sonication, 
end repair, A-tailing and in 
this case, methyl-adaptor 
ligation before being bound 
by custom baits, bisulphite 
treated and amplified. 
Samples can then be run on 
a sequencer such as the 
Illumina HiSeq. 
1. Single base resolution for DNA methylation 
analysis 
 
2. Customised library to capture 100% of mtDNA 
further enriches mtDNA, reducing risk of NUMT 
amplification. 
 
3. Can use as little as 1μg mtDNA (Nimblegen). 
 
4. Small target genome would likely generate small 
output files from sequencing. 
 
5. Simultaneous analysis of CpG and non-CpG 
methylation. 
 
6. Small size of the genome allows for ample 
space on a Mi-Seq lane for high (>1000x) coverage 
of over 100 samples at a time. 
1. Currently the process 
is not supported by 
Agilent. 
 
2. Typically cost exceeds 
that of non-bisulphite 
experiments.  
 
3. Reduced complexity of 
sequence due to 
bisulphite conversion 
(110). 
 
RRBS & 
ERRBS 
(NGS) 
RRBS makes use of MspI 
restriction enzymes for 
selective digestion of 
genomic DNA. This 
produces fragments of 
genomic regions enriched 
for CpG sites, which can be 
BS treated and sequenced 
irrespective of their 
methylation status (111).  
1. Requires less DNA input than WGS-BS, and 
most other techniques, with RRBS requiring ~10ng 
(112) and  Enhanced RRBS requiring ~50ng (113) 
 
2. Can provide coverage of CpG promoters and 
CpG islands at a fraction of the cost of WGS-BS at 
single base resolution.  
 
3. Has been modified to allow for single cell 
epigenomic analysis (114,115) . 
1. Targets CpG islands, 
however the 
mitochondrial genome 
contains no CpG islands, 
therefore could give a 
very poor coverage of 
the mitochondrial 
methylome. 
 
2. Reduced complexity of 
sequence due to 
bisulphite conversion 
(110). 
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Method General Overview Advantages Disadvantages 
WGS-BS & 
OxBS-Seq 
(NGS) 
WGS-BS converts cytosines 
to uracil bases by BS 
treatment, After PCR 
amplification, 5-mC will be 
read as thymine in a 
sequencer, and can thus be 
distinguished from 
unmethylated sites. The 
reads can then be aligned to 
recreate the DNA sequence 
(116). 
 
OXBS adaptation converts 
5hmC base to 5fC before 
BS treatment. This enables 
a direct measurement of 
5mC, and an indirect 
measurement of 5hmC at 
base-pair resolution (117).   
1. Single base resolution for DNA methylation 
analysis 
 
2. Simultaneous analysis of CpG and non-CpG 
methylation  
 
3. The development of OxBS-Seq allows for the 
identification of both 5-hmC and 5-mC when used 
in combination with standard BS-Seq (118,119). 
 
4. OxBS-Seq can be further combined with RRBS 
to characterise 5-mC, 5-hmC and 5-fC (120). 
 
 
 
 
 
 
 
 
 
1. Sequences whole 
genome, including many 
repetitive, non-
methylated AT-rich 
regions.  
 
2. Vast quantities of data 
generated leads to 
massive (100GB+ files) 
following sequencing, 
leading to time 
consuming processing 
(121).  
 
3. High cost of 
sequencing to improve 
sensitivity makes it 
unsuitable for large 
studies (110). 
 
4. Reduced complexity of 
sequence due to 
bisulphite conversion 
(110) 
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Method General Overview Advantages Disadvantages 
PacBio 
(Generation 
2.5) 
SMRT by Pacific 
Biosciences uses a single 
DNA polymerase molecule 
attached to the bottom of a 
ZMW hole (tens of 
nanometers in diameter). By 
illuminating only the bottom 
30nm of the ZMW with a 
laser, single nucleotide 
addition to the DNA can be 
measured. Each nucleotide 
fluoresces when bound to 
the DNA polymerase, which 
is detected by a camera 
before being cleaved off. 
Bases can be identified by 
corresponding fluorescent 
colours (122).   
1. SMRT avoids potential PCR bias by using pre-
amplified DNA as an input for sequencing (123).  
 
2. Optimised for circular genomes  
 
3. Increased library complexity to BS based 
methods as DNA modifications are determined 
based upon changes to polymerase kinetics 
specific to modification present (124). Potentially, 
this may be developed to accurately characterise all 
methylation marks in one simultaneous run. 
 
4. Longer read length could lead to improved 
coverage and accuracy for processes such as 
variant calling (125). 
 
5. Ideal for de novo sequencing as capable of reads 
at a length of 8kbp (126) 
 
6. Can detect strand specific patterns of 5hmC, 
after selective chemical labelling, in a high 
throughput manner (127) 
 
 
 
 
1. The RSII platform is 
capable of producing 
continuous long reads 
and circular consensus 
reads, at present, these 
reads are typically 
associated with high 
error rates (128).  
However, given the 
random nature of the 
errors, with sufficient 
depth SMRT can give an 
accurate read of the 
genome if sequenced at 
high coverage (129).  
 
2. The cost and size of 
PacBio RSII, coupled 
with the need for 
specialist technical and 
bioinformatic support 
may limit much research 
to outsourcing data to 
specialist sequencing 
services.  
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Method General Overview Advantages Disadvantages 
Nanopore 
Third 
Generation 
The nanopore technique 
makes use of either 
biological nanopores or solid 
state nanopores, which are 
embedded in a membrane 
immersed in salt solution. 
To create a flow of ions 
through the pore, an 
electrical current can be 
applied. A single stranded 
DNA molecule passing 
through the pore will create 
measurable changes in the 
intensity of the current, and 
different DNA bases could 
be distinguished by the 
degree and duration of 
modulation of the current 
(130). 
1. Although still in alpha testing, nanopore 
technologies such as Oxford’s MinIONTM allow for 
sequencing analysis to be done on a portable, 
benchtop device in real-time (131). 
 
2. Identification of 5-hmC and 5mC 
 
3. Systems like the Oxford MinIONTM allows for the 
activation of hundreds of nanopores in parallel to 
reduce time of sequencing large genomes versus 
single pore technologies. 
 
4. Sample preparation steps are reduced as no 
amplification or cloning is necessary, and use of 
enzymes is limited. This in turn reduces costs of 
sequencing (132). 
 
1. Observed per base 
error rates for 
applications such as 
DNA sequencing have 
reduced in recent years, 
but are still very high, 
recently reported at 30% 
(131). 
 
2. Some nanopore 
technologies utilise the 
binding of MBD1 to 5mC, 
altering current flow 
through the Nanopore, to 
detect the methylation 
mark (133); MBD1 has 
not yet been identified in 
mitochondria. 
 
3. Although nanopore 
sequencing could use < 
1 μg of genomic DNA, an 
estimated 700 μg is 
needed due to the 
concentration-limited rate 
at which DNA molecules 
can be captured (132) 
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Although this study was able to utilise publicly available data that had been 
generated to inexpensively assess ncDNA methylation, studies to specifically 
assess mtDNA methylation would ideally investigate DNA methylation at single 
base resolution. BS sequencing (BS-Seq) is another source of publicly available 
data that could be exploited to investigate mtDNA methylation; however, 
although this allows the interrogation of DNA methylation at single nucleotide 
resolution, data with an appropriate depth of sequencing is lacking due to the 
expense of sequencing the entire ~3,000 Mb human genome. An alternative, 
and more appropriate next generation sequencing (NGS), approach would 
specifically capture the entire mitochondrial genome prior to sequencing and 
due to its relatively small size, would allow for inexpensive sequencing at single 
base resolution analysis. Currently, two custom capture methylation 
technologies are available from Agilent and Nimblegen, and coverage can be 
tailored to suit the researcher’s needs and allow for the interrogation of 
epigenetic variability within the mitochondrial genome. Despite costing 
considerably less than Whole genome BS sequencing (WGBS-Seq), a targeted 
capture of the mitochondrial genome is still relatively expensive and requires a 
higher input of DNA. This therefore, is a particular limitation in studies of brain 
tissue, as it would require the isolation of large quantities of mtDNA from small 
amounts of frozen post-mortem tissue (134).  
 
Finally, the dependence of NGS technologies on PCR amplification prior to 
sequencing leads to a potential PCR bias and over-representation of some 
sequences. Given the tissue-specific nature of mitochondrial heteroplasmy, it is 
possible that these amplifications could influence findings. As such, the 
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development of new generations of sequencing systems such as the Pac-Bio 
RS II and Oxford Nanopore Technologies’ MinIONTM is an appealing prospect. 
Furthermore, despite both technologies being associated with a high individual 
base call error rate at present, the Pac-Bio’s long read based deep sequencing 
has been used to accurately map complex regions of the human genome (135) 
as well as mitochondrial genomes in other species (136-139). Interestingly, 
given that both technologies use native DNA, both technologies provide the 
possibility of simultaneous genetic and epigenetic analyses, including a range of 
DNA modifications (124,140-143). The circular consensus reads of PacBio RS 
II could provide an interesting platform for the simultaneous identification of the 
four major epigenetic marks in real time at a high coverage. However, isolation 
of high quality mtDNA from the range of frozen tissues commonly used in 
nuclear epigenetics could prove to be difficult and would require further 
investigation. The continual development of more accurate calling algorithms 
and likely future cost reductions may therefore lead to these third-generation 
sequencing technologies being the optimal choice for providing specific, deep 
and targeted analyses of the mitochondrial (epi)genome 
 
1.5.6. Caveats Associated with MtDNA Methylation Analysis 
Despite the potential importance of mitochondrial DNA modifications in disease, 
there are a number of technical challenges specific to interrogating the 
mitochondrial epigenome that have hampered widespread studies to date. 
These issues can be broadly summarised as encompassing genetic issues and 
specificity issues, which are summarised briefly with potential solutions in Table 
1.3. 
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Table 1.3: A summary of the major issues and potential solutions in the 
field of mitochondrial epigenetics. New abbreviations: Quality Control (QC). 
 
Caveat Potential Issues Potential Solutions 
NUMT Wrongful 
determination of 
pseudogenes as 
mtDNA will affect 
the validity of 
results. 
 
Isolate mitochondria before mtDNA 
extraction to avoid nuclear contamination 
of the mitochondria. 
The use of QC and more specific primers 
designed with the consideration of NUMT 
amplification (144). 
BLAST searches to identify known NUMTs 
and can be used to compare sequence 
similarity of results and NUMT to avoid 
misrepresentation. 
Isolation of 
Mitochondria 
The most common 
methods of 
mtDNA 
isolation/extraction 
(precipitation/ 
ultracentrifugation) 
are time 
consuming and 
labour intensive 
and may still leave 
ncDNA. 
A range of kits are available for 
mitochondrial isolation from tissue, which 
have been used to isolate and store 
mtDNA for further analysis in recent 
mitochondrial epigenetic studies (72); 
(145). 
 
No standard 
isolation protocol 
for mitochondria 
from blood. 
Other methods may be adapted and 
employed to preferentially bind to circular 
genomes such as the mitochondria 
instead of linear nuclear DNA (146). 
Those wishing to analyse mtDNA 
methylation in blood samples, would have 
to develop an accurate and efficient 
protocol for isolating mtDNA prior to 
carrying out their study. 
Heteroplasmy Genetic mutations 
in mtDNA may 
have specific 
mtDNA signature. 
Studies of differential methylation between 
different mitochondria and the functional 
effects that they present in AD. 
Percentage of heteroplasmy in the sample 
should be considered alongside results. 
Differentiating 
between 
epigenetic 
marks 
Not all methods 
(i.e. BS) can 
distinguish 5-mC 
from 5-hmC 
Using oxidative bisulphite-sequencing 
(OXBS), 5-hmC is oxidised to 5-fC unlike 
5-mC, allowing for a distinction to be made 
between the two marks at single-base 
resolution due to an initial lack of 
deamination by 5hmC (119). 
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 1.5.6.1. Genetic Issues 
 
  1.5.6.1.1. Nuclear pseudogenes  
By far the greatest concern when analysing mtDNA methylation arises from 
regions of homology between the mitochondrial genome and NUMTs.  These 
genes are nuclear paralogs of mtDNA which have been translocated and 
inserted into the nuclear genome during the evolution of both genomes (147). 
These insertions were thought to typically occur in non-coding regions; 
however, more evolutionary recent translocations have actually been shown to 
prefer integration into coding regions, thus leading to potential alterations in 
gene function with implications for disease (148). NUMTs are generally small 
and typically comprise ~0.1% of the nuclear genome (149). However in 
humans, it has been shown that some NUMTs can be as large as 14.7kb, 
representing a significant portion of the ~16.6kb human mitochondrial genome 
(150). As such, the presence of NUMTs can cause major issues in genomic 
 
Caveat 
 
Potential Issues 
 
Potential Solutions 
Cell 
Specificity 
Different brain 
regions have 
differential 
methylation 
patterns and  
different cell 
populations 
Large samples sizes on specific brain 
subregions will improve the likelihood of 
determining methylation changes to a 
statistically significant degree if present. 
The use of techniques such as FACS can 
potentially separate cell types such as glia 
and neurons to analyse samples in a cell-
type specific manner. 
Sensitivity Reduced 
methylation levels 
in mitochondria 
Diluted signals 
Comparative analysis of techniques 
should be used to determine the relative 
precision and accuracy of each and allow 
for the determination of their suitability to 
mitochondrial methylation studies. 
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analyses using pre-sequencing enrichment methods such as custom capture or 
long-range PCR as the likelihood of NUMT co-amplification, or even preferential 
amplification, increases due to the strong sequence similarity between these 
segments of the two genomes (65). As such, this sequence similarity can lead 
to the miss-classification of NUMTs as mtDNA during analysis, and has led to a 
number of publications wrongly describing NUMTs as mtDNA (61,62). NUMT 
miss-classification has also been observed in AD genetic studies whereby 
amplification of the NUMT sequence has led to false heteroplasmies being 
reported (151,152). One potential solution is to isolate mitochondria prior to 
DNA extraction in an attempt to reduce the risk of contaminating the nuclear 
genome. However, despite extensive research being dedicated to mtDNA 
analysis, existing methods for mitochondrial isolation and mtDNA extraction via 
the use of fractional precipitation or gradient ultracentrifugation remain time 
consuming and labour intensive (153) and often leave residual nuclear DNA 
contamination following mitochondrial isolation (146).  
 
  1.5.6.1.2. Variation in MtDNA: Haplogroups and Genetic and 
Epigenetic Heteroplasmy  
The multi-copy nature of the mitochondrial genome and the subsequent 
heteroplasmy that arises poses a real issue when studying mitochondrial 
diseases, as inter- and intra-individual heteroplasmic variation can confuse the 
association of a haplogroup with its corresponding phenotype (154). The 
importance of this issue is highlighted by a recent study demonstrating that 
mitochondrial heteroplasmy alters DNA methylation across the nuclear-encoded 
mitochondrial genes, Transcription factor alpha mitochondrial (TFAM) and RNA 
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Polymerase Mitochondrial (POLMRT) (155). Finally, if mtDNA methylation is 
altered across different mtDNA in the same mitochondrion, it could create an 
epigenetic mosaic within the mitochondrion, the cell and across the tissue, 
whereby each copy of mtDNA may possess its own methylation profile. If this 
‘methylomic heteroplasmy’ were to occur, it could be very difficult to tease apart 
the effects of such a mosaic in functional studies. 
 
On a larger scale, mutations in mtDNA can be used to identify haplogroups. 
Throughout evolution, mutations in mtDNA may be conserved and passed on 
through maternal inheritance, thus allowing for the tracing of common ancestral 
lineage by comparing haplogroups. Numerous studies have identified both 
contributory and protective effects of different haplogroups in diseases such as 
AD. For example, haplogroup K reduces the risk of developing sporadic AD 
onset in Apolipoprotein ε4 (APOE ε4) carriers in an Italian population (156), but 
not in the Polish population (157). This presents an additional potential caveat 
in mitochondrial epigenetics, as mitochondrial haplogroups have been found to 
affect global levels of ncDNA methylation (90). As such, extra care should be 
taken to account for haplogroup variability in AD mitochondrial epigenetic 
studies, when possible.   
 
 1.5.6.2. Specificity and Technical Issues 
The brain is a complicated, heterogeneous organ with numerous functionally-
distinct subregions, each with their own individual composition of cell types. 
Unsurprisingly, there are clear tissue-specific epigenetic differences in ncDNA 
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across brain regions (158,159). There is an added level of complexity with 
respect to the mitochondrial epigenome because each mitochondrion contain 
between 2-10 copies of mtDNA and each cell contains varying levels of 
mitochondria; therefore the amount of mtDNA copies in each cell can vary 
between 100-10,000 dependent upon cell type. Further, a recent study using 
laser capture microdissection demonstrated that alterations in mitochondrial 5-
hmC are seen with age in mouse cerebellar purkinje cells, which was not 
evident in whole cerebellar tissue (104), demonstrating the importance of cell-
specific analyses in heterogeneous tissue, particularly when investigating 
functional impact. Currently, the most common method of measuring DNA 
methylation is via the conversion of DNA with sodium BS followed by 
subsequent sequencing analysis. However, these approaches are unable to 
distinguish between 5-mC and 5-hmC (160), an important limitation given recent 
studies confirmed the presence of 5-hmC in mitochondria in brain tissue (104). 
Studies have found that although both DNA modifications are present in the 
mitochondria, they occur at much lower levels compared to in ncDNA (72,161), 
and thus methods used for quantification may need to be more sensitive. 
Furthermore, variation in mitochondrial copy number may lead to the dilution of 
signals and reduce detection if the tissue is largely heterogeneous. Finally, it is 
important to note that 5-mC and 5-hmC in mitochondria have been found to 
predominantly occur at cytosines not preceding a guanine base (non-CpG) 
(71,162). Therefore the use of techniques that primarily investigate CpG 
methylation (69) must be called in to question to the extent by which they can 
depict the true epigenetic landscape of this genome.  
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Given the growing interest in studying epigenetic changes within mtDNA in a 
range of pathologies, there are several important considerations pertinent to this 
field of research. First, tissue-specific effects of DNA methylation mean that 
profiling a disease-relevant tissue is likely to be critical. Further, different cell 
types will have varying levels of mtDNA copy number and different DNA 
methylation levels dependent upon cellular requirements and localised 
environments (1). This is a potentially important issue in mtDNA methylation 
analysis given that a number of studies have implicated an association between 
mtDNA methylation status and mtDNA copy number (163) and that tissue 
homogenates contain a number of different cell types, many with varying levels 
of mtDNA copy numbers. One potential way to solve this problem would be to 
sort cell types from tissue homogenates using Fluorescence-activated cell 
sorting (FACS), however isolating sufficient levels of mitochondria for mtDNA 
methylation analyses using current technologies seems unlikely.  
 
1.5.7. Other MtDNA modifications 
In a recent study, 5-fC and 5-caC, but not 5-hmC were found to lead to modest 
blocks in DNA transcription when mediated by either T7 RNA polymerase or by 
human RNA polymerase II in an in vitro transcription assay, which was also 
replicated in two human cell lines (164). Interestingly, T7 RNA polymerase 
shares a high degree of homology with human mitochondrial polymerases, and 
given the identification of 5-hmC and TET proteins in mitochondria (72,104), this 
study hypothesised a mechanism by which mtDNA demethylation products may 
be important for the regulation of mtDNA transcription. However, at present, no 
study has investigated 5-fC and 5-caC levels in mtDNA and further investigation 
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into the modulation of mtDNA methylation needs to be undertaken. Given the 
huge DNA input requirements for OXBS sequencing, which allows the 
quantification of 5-mC and 5-hmC independently, subsequent analysis of these 
other marks would likely require vast quantities of mtDNA, currently unavailable 
using non-PCR based mtDNA enrichment methods. However, improvements in 
the detection of these bases in newer technologies, such as PacBio RS II, could 
provide novel insights into their role in mtDNA epigenetic regulation of 
mitochondrial function.   
 
1.6. The Role of Mitochondria in the Brain 
The brain accounts for approximately 20% of the human body’s energy 
expenditure during resting metabolism (165). As such, this complex organ 
requires continuous and vast quantities of ATP, ensuring that the correct 
maintenance of mitochondrial function is a constant priority during healthy 
ageing (166). Mitochondria are also implicated in many other important 
neurophysiological functions, for example synaptic mitochondria are believed to 
be involved in the regulation of neurotransmission by buffering extra intracellular 
Ca2+ (167), making the mitochondria a vital organelle in the establishment of 
Ca2+ homeostasis. Further, mitochondrial morphology and dynamics vary 
between synaptically immature and mature cortical neurons, with shorter 
mitochondrial lengths being observed in immature neurons, allowing for 
increased movement and greater ability to meet the high energy demands of 
immature neurons, providing a key role for this organelle in neuronal 
development (168). However, despite being the major site of ROS production, 
the mitochondria lack protective histones and defective mtDNA repair has been 
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suggested to play a role in a number of neurodegenerative diseases (169). As a 
by-product of ATP generation, ROS accumulation in areas of high ATP 
demand, such as post-mitotic neuronal cells, has been associated with neuronal 
loss (170). Mutations in mitochondrial-encoded genes have been shown to 
cause a number of maternally heritable, monogenic diseases. Most notably, 
MELAS syndrome, a disease affecting multiple organs which can lead to the 
development of a number of syndromes, ranging from muscular weakness, 
fatigue and stroke-like episodes to dementia, epilepsy and diabetes in later 
stages (171). As such, mtDNA variants have been shown to be an important 
driver of mitochondrial dysfunction and can have significant neuropathological 
effects (172).  
 
1.7.  Alzheimer’s Disease  
AD, the most common form of dementia accounting for over 60% of all cases, is 
a chronic, currently incurable, neurodegenerative disorder. Current estimates 
predict that over two million people in the United Kingdom will be affected by 
dementia by 2050 (173). The classic neuropathological hallmarks associated 
with AD include the formation of amyloid beta (Aβ) plaques and neurofibrillary 
tangles of hyperphosphorylated microtubule-associated protein Tau. 
Importantly, the continued spread and development of neurofibrillary tangles 
through the brain provides a standardised measure of AD pathology (174). 
Each significant stage of pathology development can be grouped into 
categories known as Braak stages, with Braak stages I and II primarily 
associated with tau tangle accumulation within the transentorhinal cortex. Later 
stages see the spread of tangles to the limbic regions (Braak Stages III and IV) 
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and gradually to more regions of the neocortex (Braak Stages V and VI) (174). 
This well documented development provides a strong post-mortem marker for 
accurate AD diagnosis (175). However, despite the pathological manifestation 
of AD being well documented, currently no anti-Aβ or anti-tau drug has passed 
Phase III trials (1). As such, a number of alternate hypotheses for the 
development of AD have been suggested, including the mitochondrial cascade 
hypothesis (176). 
 
1.7.1. Mitochondrial Dysfunction in AD 
The mitochondria play a vital role in a variety of key biological functions, 
including apoptosis via caspase dependent and independent mechanisms 
(177), the regulation of calcium homeostasis (178,179) and the production of 
ROS (180). As such, the role of mitochondrial dysfunction has been implicated 
in AD pathogenesis (181,182) and forms the basis of the mitochondrial cascade 
hypothesis (183). Proposed by Swerdlow et al, this hypothesis states that an 
individual’s genetic code will determine their basal mitochondrial function and 
that, throughout ageing; this function will decline due to a combination of 
genetic and environmental factors, determining an individual’s time of disease 
onset (183).  
 
Further evidence for a role of mitochondrial dysfunction in AD pathogenesis 
comes from a study demonstrating increased levels of mitochondrial gene 
expression and oxidative damage in a transgenic APP mutant mouse model of 
AD as a compensatory response to either Aβ or the APP mutant protein itself 
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(184). Further, various components of the mPTP have been shown to interact 
with Aβ in a number of murine models of AD as reviewed by Du and Yan (185). 
For example, one recent study found that, in APP transgenic mice, Aβ may act 
to upregulate Voltage Dependent Anion Channel 1 (VDAC1), a component of 
the mPTP, leading to mPTP blockade. (186). Interestingly, the authors also 
found that VDAC1 may interact with hyperphosphorylated tau, suggesting that 
VDAC1 interacts with both tau and Aβ, leading to mitochondrial dysfunction. An 
earlier study found that Aβ present in mitochondria interacts with Cyclophillin D 
(CYPD), another component of the mPTP, in cortical samples from both post-
mortem AD patients and APP transgenic mice (187). In the mouse model, this 
was shown to lead to increased ROS production and neuronal cell death. Taken 
together, this illustrates a variety of mechanisms by which Aβ interacts with the 
mitochondria in AD, and demonstrates how mitochondrial dysfunction can lead 
to changes associated with AD, thus highlighting the need for continued 
research into the field. 
 
1.7.2. The Role of Epigenetics in AD 
Epigenetic mechanisms orchestrate a diverse range of important 
neurobiological and cognitive processes in the brain. As such, epigenetic 
modifications to the nuclear genome have been widely hypothesised to play a 
role in many neurological disorders, including AD (4,188,189). Given that 
mitochondrial dysfunction is a prominent feature of AD, we recently 
hypothesised that epigenetic modifications to the mitochondrial genome could 
be important in disease progression and pathology (1).  
 
                                                                                                                    
69 
 
Given the high heritability estimates for AD (190), considerable effort has 
focussed on understanding the role of genetic variation in disease aetiology, 
although more recently it has been hypothesised that epigenetic dysfunction 
may also be important (191). A number of studies have shown reduced global 
levels of the DNA modifications 5-mC and 5-hmC in AD brain (103,192-194) 
with only a handful of studies having looked at changes occurring at specific loci 
(reviewed in Lunnon and Mill, 2013 (191)). More recently, studies have 
investigated the effect of changes in 5-mC and 5-hmC levels within Triggering 
Receptor Expressed On Myeloid Cells 2 (TREM2), a candidate AD risk loci from 
exome sequencing studies in AD (195,196). Recent methodological advances 
in microarray and genomic sequencing technologies have enabled researchers 
to undertake EWAS in AD brain, identifying several consistent DMRs 
associated with disease (197-199). Many of these DMRs are tissue-specific, 
restricted to regions of the brain associated with AD pathology, and correlate 
strongly with quantitative measures of neuropathology.  As such, a strong case 
is being built for a role of epigenetics in the aetiology of AD. To date none of the 
published EWAS in AD brain have investigated differential DNA methylation in 
mtDNA, as the current workhorse for EWAS, the Illumina Infinium 450K 
Beadarray, has no coverage of ChrM. 
 
1.7.3 MtDNA Methylation: A Role In AD? 
A recent nine year follow up study has shown that individuals with DNA 
methylation levels greater than a set threshold of 10% at ChrM: 932bp (MT-
RNR1), were associated with a two-fold increased risk of mortality in a healthy 
control population study (74). This study suggests that increased mtDNA 
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methylation at specific sites may lead to genomic instability and dysregulation. 
As such, it is possible that low levels of mtDNA methylation are required for 
normal control of mtDNA expression and mitochondrial function. But, given the 
ubiquitous distribution of mitochondria across tissues, when methylation is 
increased passed a threshold, the consequences for the cell could be severe. 
 
However to date, only two studies have investigated the role of mtDNA 
methylation in AD (161,200). This is potentially due to both the technological 
challenges associated with studying mtDNA methylation, and because many 
studies report low levels of mtDNA methylation (2); as such, both studies have 
been limited to candidate gene or global DNA methylation changes. The first 
study published identified a trend towards a significant increase in global levels 
of 5-hmC in the superior and middle temporal gyrus of late stage AD patients 
with respect to age-matched controls (161). The second identified increased 
levels of 5-mC in the D-LOOP between Braak Stages I to II and III to IV of AD 
entorhinal cortex (ECX) (200), but not in Braak Stage V and VI. Despite this, 
significant CG and non-CpG hypomethylation differences in MT-ND1 during 
early AD stages were also observed. These changes were accompanied by an 
increase in MT-ND1 expression levels in ECX in late-stage AD (stages V-VI). 
However, it is important to note that these changes in expression were modest 
and most importantly, were identified in a different cohort of cases. As such, to 
gain a better understanding of the role of mtDNA methylation in AD and its 
effect on mitochondrial gene expression, steps should be taken to investigate 
changes in larger, well matched cohorts using a genome-wide approach. 
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1.8.  Conclusions 
Despite a recent increase in publications in the field of mtDNA methylation, no 
study has investigated genome-wide mtDNA methylation differences at a high 
resolution to determine how these differences may contribute to AD pathology, 
nor any pathology characterised by mitochondrial dysfunction. This lack of an 
in-depth interrogation into the field of mtDNA methylation represents the current 
state of the field of mtDNA methylation, with most studies using candidate-
based methods such as pyrosequencing or looking at global mtDNA 
methylation levels to associate the mark with disease. As such, for the field to 
progress, it is important to design an assay that will allow for accurate and 
precise measurement of mtDNA methylation across the genome and to apply 
this assay to future analysis. Further, the ‘gold standard’ of methylation analysis 
is BS-Seq; however the typical input requirements for this protocol, 1-3 µg, is in 
excess of what could typically be expected from DNA extraction from a small 
genome, unless tissue input quantities were exceedingly high. As such, a 
protocol for BS-Seq of low yields of mtDNA must also be developed. Given the 
role of mitochondrial dysfunction in complex diseases such as AD, the 
development of such a technology would allow for the interrogation of a range 
of relevant diseases in which mitochondrial dysfunction is also a component of 
the aetiology. Further, the vast majority of mitochondrial proteins are nuclear-
encoded and imported into the mitochondria to aid in regulating a variety of 
mitochondrial functions. Despite this and the high levels of crosstalk observed 
between the nuclear and mitochondrial proteins, the two genomes are often 
investigated in isolation. As such, in the future, a more holistic approach to the 
investigation of mtDNA methylation should be considered. 
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1.9.   Aims 
1. To develop a pipeline to make use of current, publicly available genome-
wide sequencing data, which will for allow the analysis of mtDNA 
methylation from whole genome datasets.  
2. To optimise a protocol for reliable isolation of mtDNA from frozen, post-
mortem human brain tissue suitable for downstream epigenetic analysis. 
3. To design a targeted BS-Seq assay to investigate mtDNA methylation 
across the entire mitochondrial genome at single base pair resolution.  
4. To use this assay to investigate whether mtDNA methylation in frozen, 
post-mortem brain shows sex-, age-, disease- and tissue-specific 
differences.  
5. To use this assay to investigate the role of mtDNA methylation and its 
relationship to nuclear encoded mitochondrial gene methylation. 
 
 
                                                                                                  
73 
 
Chapter 2. Materials and Methods 
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2.1 Introduction 
This chapter will describe the general materials and methods used across 
multiple experiments in this thesis. Methods specific to only individual chapters 
will be discussed in detail in the methods within the relevant chapter itself. 
 
2.2. Materials 
 
2.2.1. DNA Extractions 
Lysis Buffer for DNA Extraction: 75mM NaCl, 10mM Tris-HCl, 25mM EDTA, 
0.5% SDS 
 
2.2.2. Agarose Gel Electrophoresis 
SYTO 60: 1µl stock SYTO 60 (Fisher Scientific; Cat No: 10194852), 99µl of 
distilled water (dH2O). 10µl aliquots of this solution were then distributed into 
microcentrifuge tubes, where they were stored in a foil coated 50ml falcon flask 
at -20°C until required.  
 
1x Tris-Borate-EDTA (TBE): 100ml of 10x stock buffer (as provided), 900ml 
dH2O. 
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2.2.3. Miltenyi Biotec Mitochondrial Isolations  
1x Protease Inhibition Buffer: 1ml 10x Solution 2 (Miltenyi Biotec; Cat No: 
130-097-340), 9ml double distilled water (ddH2O), 1 protease inhibitor tablet 
(Sigma-Aldrich: P2308-100MG). 
 
1x Solution 2:  1ml 10x Solution 2 (Miltenyi Biotec; Cat No: 130-097-340), 9ml 
ddH2O.  
 
Extraction Buffer: 40µl Solution1 (Miltenyi Biotec; Cat No:  130-097-340), 1ml 
1x Solution 2 (Miltenyi Biotec; Cat No:  130-097-340). 
 
1x Separation Buffer: 2.3ml 10x Separation Buffer (Miltenyi Biotec; 130-097-
340), 20.7ml ddH2O. 
 
2.2.4. MtDNA Extraction using Qiagen DNA Minikit 
Buffer AW1: 25ml of 96-100% ethanol, 19ml of the concentrated buffer 
(provided in the kit). 
 
Buffer AW2: 30ml of 96-100% ethanol, 13ml of the concentrated buffer 
(provided in the kit). 
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2.2.5. Bisulfite Treatment 
 
EZ DNA Methylation-Gold Kit CT Conversion Reagent: One vial of solid CT 
Conversion Reagent was resuspended in 900µl nuclease-free water, 300µl of 
M-Dilution Buffer and 50µl of M-Dissolving Buffer, after which the vial was 
subjected to frequent vortexing at room temperature for a minimum of 10 
minutes. 
 
2.3. Methods 
 
2.3.1. Total Genomic DNA Extraction 
DNA was isolated from frozen post-mortem human brain for use in a number of 
experiments presented in this thesis. The main objective when isolating DNA 
from such sources is to extract high molecular weight DNA, whilst removing 
contaminants such as proteins and salts. To do this, our group has developed 
an in-house, phenol-chloroform method (201), described below. 
 
All extractions were carried out on 100mg samples of frozen, post-mortem 
human brain tissue. Briefly, tissue was added to 500µl of lysis buffer (see 
Section 2.2.1) in a 2ml microcentrifuge tube and lysed using a plastic pestle and 
motor (Sigma-Aldrich; Cat No: Z359947). After which, 2µl (10mg/ml) RNase-A 
(Sigma-Aldrich; Cat No: R6148-25ML) was added to each solution, which was 
then left to incubate at 37°C for 2 hours. Following RNase-A treatment, 20µl of 
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20mg/ml Proteinase K (Sigma-Aldrich; Cat No: P2308-100MG) was then added 
to each solution and left to incubate at 50°C overnight in a water bath. During 
this incubation, in-house phase lock tubes were made by adding silicone grease 
(Sigma-Aldrich; Cat No: Z273554-1EA) to a fresh 2ml microcentrifuge tube to fill 
the inside of each lid. The microcentrifuge tubes were then centrifuged at 
3500rpm for 10 minutes to pellet the grease. After the overnight incubation, 10µl 
of 20mg/ml Proteinase K (Sigma-Aldrich; Cat No: P2308-100MG) was then 
added to each sample, which were then returned to the water bath for 1 hour at 
50°C. The samples were then heated to 65°C for 30 minutes to heat inactivate 
the Proteinase K, after which samples were stored at 4°C for 5 minutes to allow 
samples to cool to room temperature. Samples were then transferred into a 
phase lock tube and an equal volume of Phenol: Chloroform: Isoamyl Alcohol at 
a ratio of 25:24:1 (Thermo-Fisher; Cat No: 15593049) was added to each. 
Samples were inverted 10 times to mix thoroughly and were then centrifuged for 
15 minutes at 13,000rpm. The top aqueous layer was then removed without 
disturbing the phase lock and added to a fresh microcentrifuge tube before an 
equal volume of chloroform was added to each sample, which were then 
inverted 10 times to mix, and centrifuged at 13,000rpm for 15 minutes. The top 
aqueous layer was then removed and this step was repeated one further time to 
improve purity. To precipitate the DNA, two volumes of 100% ice-cold ethanol 
was added to each sample and mixed by slowly inverting the tube 10 times, or 
until white, solid DNA precipitated out into aggregates. Samples were then left 
at -20°C overnight to aid the precipitation. Samples were then centrifuged at 
13,000rpm for 20 minutes, following which the supernatant was removed, with 
care not to dislodge the pellet. 1ml of 70% ethanol was added to each sample, 
which were then centrifuged at 13,000rpm for 5 minutes. The supernatant was 
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subsequently removed using a pipette and the DNA pellets were left to air dry 
for approximately 30 minutes. Samples were then resuspended in 200µl of 
dH2O and incubated at 37°C for 2 hours. Samples were then vortexed, and 
checked for purity using the Nanodrop ND8000 and Agarose Gel 
Electrophoresis. 
 
2.3.2. Spectrophotometric Analysis Using Nanodrop D8000 
To quantify and check the purity of DNA samples, spectrophotometric analysis 
was performed. Briefly, DNA absorbs light at around 260nm, whilst protein 
contaminants absorb at 280nm and other contaminants, such as ethanol, 
absorb at around 230nm. A greater absorbance at 260nm, compared to 280nm 
or 230nm, is therefore an indicator of highly concentrated DNA. Ratios of 
260/280nm and 260/230nm should lie between the ranges of 1.70-1.90 and 
2.00-2.20 respectively as an indicator of good purity (Figure 2.1). For accurate 
quantification, 1µl of DNA was added to the Nanodrop ND8000 as per the 
manufacturer’s instructions. Further details can be found at: 
http://www.nanodrop.com/Library/nd-8000-v2.2%20-users-manual-
8.5%20x%2011.pdf.   
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Figure 2.1: A typical spectrophotogram produced using Nanodrop 
ND8000. The sample has a peak at 230nm, with a 260/230nm ratio between 
2.00 and 2.20 and a 260/280nm ratio between 1.70 and 1.90, indicating DNA 
with good purity. 
 
 
 
 
 
 
 
2.3.3. Agarose Gel Electrophoresis 
To allow for the separation and visualisation of DNA products, 3% agarose gels 
were made. Typically, 3g of Agarose powder (Sigma Aldrich; Cat No: A9539-
500g) was added to 100ml of 1x TBE (Sigma Aldrich; Cat No: T4415-1L) (see 
Section 2.2.2.) in a conical flask. The mixture was then heated until all agarose 
was dissolved, after which 10 µl of SYTO 60 (see Section 2.2.2.) was added per 
100ml of TBE and the solution was gently mixed. The solution was then poured 
into a gel cassette equipped with a comb and sealed at either end with 
laboratory tape. The cassette was then wrapped in paper towels and placed in 
the refrigerator at 4°C for 15 minutes to allow sufficient time for setting. Once 
set, the cassette containing the gel was then removed from the refrigerator and 
the tape and combs were removed prior to placing in a gel tank. Up to 5 µl (or 
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100ng) of DNA was mixed with 1 µl of 6x Orange G (New England Biolabs; Cat 
No: B7022S). Each sample mixture was then loaded into an individual well. One 
well was left per row for the addition of a 100bp ladder (New England Biolabs; 
Cat No: N3231S) for ncDNA or 1Kb ladder (New England Biolabs; Cat No: 
N3232S) for mtDNA. The gel tank was set to run for 45 minutes at 120V. 
Following this period, gels were visualised on the Licor Odyssey CLx to assess 
DNA quality. For example, good quality, high molecular weight mtDNA will 
appear as a single band around 16.6kb whereas a single smear is indicative of 
degraded DNA or ncDNA contaminants. 
 
2.3.4. Mitochondrial Isolation 
To reduce the risk of nuclear contamination in the analysis of mitochondrial 
methylation, several methods were tested for their efficiency of isolating mtDNA 
from frozen, post-mortem brain tissue (202), which will be discussed later in 
Chapter 4. However, the most efficient method, which was then utilised in 
Chapters 5 and 6, is detailed below. 
 
With a few exceptions, mitochondria were isolated from tissue as per the 
manufacturer instructions. To reduce tissue degradation, centrifugation steps 
associated with the isolation of mitochondria were carried out at 4°C. All 
reagents were prepared fresh and kept on ice.  Briefly, mitochondria were 
extracted from 200mg of human, post-mortem brain tissue using the Miltenyi 
Biotech mitochondria kit for humans (Miltenyi Biotech; Cat No: 130-097-340). 
First, the tissue was rinsed twice in 3-4ml ice cold 1x Solution 2 (see Section 
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2.2.3), The tissue was quickly transferred to a 35mm cell culture dish (over ice), 
containing a further 3-4ml of ice cold 1x Solution 2. Visible sections of fat were 
then resected and the tissue was cut into 1-2mm sections using a scalpel. 
Solution 2 was then aspirated off and the sample was then transferred to a 2ml 
microcentrifuge tube containing 1ml extraction buffer (see Section 2.2.3.) and 
incubated on ice for 30 minutes. After 30 minutes, this solution was then 
centrifuged at 300 x g for 5 minutes at 4°C and the supernatant was discarded. 
2ml ice cold Protease Inhibition Buffer (see Section 2.2.3.) was then added to 
resuspend the pellet. This suspension was then poured into a pre-cooled C 
Tube (Miltenyi Biotec; Cat No: 130-093-237) and an additional 2ml ice-cold 
Protease Inhibition Buffer was added. The C Tube was then closed and the 
tissue was gently homogenised using the gentleMACS dissociator (Miltenyi 
Biotec; Cat No: 130-093-235) by running gentleMACS Program 
h_mito_tissue_01. The C Tube was then centrifuged at 200 x g for 30 seconds 
at 4°C to collect the homogenate at the bottom of the tube. A Pre-Separation 
70um Filter (Miltenyi Biotec; Cat No: 130-095-823) was then placed on a pre-
cooled 15ml conical tube over ice. The homogenate from the C Tube was then 
transferred to the reservoir of the filter, allowing for the homogenate to pass 
through. The filter was then washed twice with 1ml ice-cold Solution 3 (provided 
with the kit). The homogenate was then centrifuged at 500 x g for 5 minutes at 
4°C and the supernatant containing mitochondria was transferred to a 15ml 
conical tube. The pellet containing the nuclear contaminants was stored at -
80°C for later use as an unenriched mitochondrial fraction. Proceeding 
immediately, ice-cold 1x Separation Buffer (see Section 2.2.3.) was added to 
the supernatant to a total volume of 10ml. 100ul Anti-TOM22 MicroBeads 
(Miltenyi Biotec; Cat No: 130-094-532) were added to magnetically label the 
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mitochondria. The solution was then mixed well and incubated for 1 hour at 4°C 
under continuous rotation using the MACS mix Tube Rotator, (Miltenyi Biotec; 
Cat No: 130-090-753) at a permanent run speed of 12rpm. Next, an LS Column 
(Miltenyi Biotec; Cat No: 130-042-401) was placed into the magnetic field of a 
MidiMACS separator (Miltenyi Biotec; Cat No: 130-042-302) and a Pre-
Separation 30μm Filter (Miltenyi Biotec; Cat No: 130-041-407) was placed on 
top of the LS column. The column was then prepared by rinsing with 3ml of 1x 
Separation Buffer. Magnetically labelled mitochondria were added to the column 
in three aliquots of 3.3ml, adding only when the column reservoir was empty. 
After, the column was washed with three lots of 3ml of 1x Separation Buffer 
before being removed from the magnet and placed in a 15ml conical tube. 1.5ml 
of 1x Separation Buffer was immediately pipetted onto the column and the 
enriched mitochondria were flushed out by firmly pushing the plunger into the 
column. The mitochondria were then centrifuged at 13,000 x g for 2 minutes at 
4°C. Following this, the supernatant was aspirated off and the mitochondrial 
pellet was resuspended in 100μl of Storage Buffer. It was then centrifuged 
again at 13,000 x g for 2 minutes at 4°C to improve purity. The supernatant was 
aspirated off and the pellet was taken immediately to the next stage.  
 
DNA was then isolated from the mitochondrial pellet using the QIAamp DNA 
Micro Kit (Qiagen; Cat No: 56304), as per the manufacturer’s instructions. 180µl 
Buffer ATL was added to the mitochondrial pellet and allowed to equilibrate to 
room temperature. 20µl 10mg/ml Proteinase K, (Sigma-Aldrich; Cat No: P2308-
100MG) was then added and mixed using a vortex for 15 seconds. The tube 
was then incubated at 56°C for 3 hours. After incubation, 200µl Buffer AL was 
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added and mixed by pulse-vortexing for 15 seconds. Next, 200µl ethanol (96–
100%) was added and mixed thoroughly by pulse-vortexing for 15 seconds. The 
solution was then incubated for 5 minutes at room temperature and then briefly 
centrifuged. The entire lysate was then transferred to a QIAamp MinElute 
column (in a 2 ml collection tube) and centrifuged at 6000 x g for 1 minute. The 
QIAamp MinElute column was then placed in a clean 2 ml collection tube. 500µl 
Buffer AW1 (see Section 2.2.4.) was then added to the QIAamp MinElute 
column, which was centrifuged at 6000 x g for 1 minute. The QIAamp MinElute 
column was then placed in a clean 2 ml collection tube. 500µl Buffer AW2 (see 
Section 2.2.4) was then added to the QIAamp MinElute column, which was 
centrifuged at 6000 x g for 1 minute. The QIAamp MinElute column was then 
placed in a clean 2 ml collection tube. Following this, the column was 
centrifuged at 20,000 x g for 3 minutes to dry the membrane completely. The 
QIAamp MinElute column was then placed in a clean 1.5 ml microcentrifuge 
tube and 50µl Buffer AE was applied to the centre of the membrane. The lid 
was then closed and the column was left to incubate at room temperature for 5 
minutes before centrifugation at room temperature for 1 minute at 20,000 x g. 
Finally, this step was repeated with a further 50µl Buffer AE, to give a total 
elution volume of 100µl. DNA was then quantified as described in Sections 
2.3.2 and 2.3.3. 
 
2.3.5. MtDNA Copy Number Quantification 
To accurately determine the purity of mtDNA enrichments from mitochondrial 
isolation methods, a qRT-PCR was utilised to simultaneously assess the 
number of mtDNA and ncDNA copies within each sample. NcDNA and mtDNA 
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were extracted simultaneously using the method described in Section 2.3.4. 
Primers specific for a mitochondrial gene (with no known NUMTs), MT-CYB, 
and a nuclear housekeeping gene, human beta 2-microglobulin, (hB2M) were 
utilised to assess mitochondrial purity as previously described (203) see Table 
2.1).  
 
Table 2.1: Primer sequences for mitochondrial copy number 
determination. 
 hB2M MT-CYB 
Forward 
Sequence 
TGCTGTCTCCATGTTTG
ATGTATCT 
CCTCATCCTAGCAATAATCCC
CATCCTCCATATA 
Reverse 
Sequence 
TCTCTGCTCCCCACCTC
TAAGT 
ACTTGTCCAATGATGGTAAAA
GG 
 
To determine the optimal conditions of the assay for use in our laboratory, a 
temperature gradient PCR was performed to determine the annealing 
temperature at five, 2°C intervals between 50-60°C for both primer sets using 
volumes described in Table 2.2 and conditions described in Table 2.3. This 
revealed an optimum temperature at 60°C for both primer sets. qRT-PCR 
reactions were then performed using the same volumes as described in Table 
2.2, checking for a single peak in the melt curve assay, demonstrating the 
specificity of the primers designed. The specificity of the primers was also 
checked using gel electrophoresis (see Section 2.3.2). 
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Table 2.2: Volumes added to each well for a 10µl PCR reaction. 
Reagent Volume (µl) 
Forward primer (10µM) 0.25 
Reverse primer (10µM) 0.25 
EvaGreen (Solis Biodyne; Cat No: 08-26-00001) 2 
ddH2O 5.5 
DNA 2 
Total 10 μL 
 
Table 2.3: PCR conditions for gradient PCR. 
 
We generated standard curves for each gene of interest, by scaling up the PCR 
volumes shown in Table 2.2, to 50μl and by increasing the number of PCR 
cycles to 50.  After PCR we determined the yield of DNA using the Nanodrop, 
and using Avogadro’s constant, the length of the amplicon and the yield of DNA, 
to determine the number of copies of the amplicon in the sample. The sample 
was then diluted to 1010 copies/μl (Standard 10) and a subsequent serial 
dilution was generated. Briefly, 10 μl of Standard 10 was added to 90 μl of 
nuclease-free H2O. The solution was then vortexed for 30 seconds and 
centrifuged. This process of ten-fold dilutions was repeated for each standard 
from Standard 10 (1010 copies/μl) to Standard 1 (101 copies/μl). The standard 
curves for both mtDNA and ncDNA were run in duplicate alongside duplicate 
DNA samples using the conditions described in Tables 2.2 and 2.4 on a 
Taqman 7900HT (ThermoFisher; Cat No: 4329001). 
Stage PCR temperature Time 
Hot start 95oC 15 minutes 
30x 
Cycles 
Denaturing 95oC 10 seconds 
Annealing 50-60oC 30 seconds 
Extension 72oC 1 minute 
Final Elongation 72oC 7 minutes 
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Briefly, qRT-PCR relies on the exponential increase in specific DNA fragments 
during PCR to accurately quantify DNA. DNA is labelled with a fluorescent dye. 
Accordingly, the amount of fluorescence released during amplification is directly 
proportional to the concentration of the amplicon. To avoid the effects of 
background fluorescence, a Ct value is set by the computer software. This is 
deemed the threshold cycle, i.e. the number of cycles of amplification required 
for DNA to exceed background fluorescent levels. Ct values are therefore 
inversely proportional to both fluorescence emission and DNA concentration. 
 
Table 2.4: qRT-PCR conditions used for determination of mtDNA purity. 
 
All analyses were performed in Microsoft excel; samples where duplicate 
variation exceeded a 0.5 Ct difference were excluded and re-run. Further, Ct 
variation between standards in the serial dilution was used to inspect PCR 
efficiencies. Any qRT-PCR efficiency not within 90-110% was also re-run. We 
then calculated the number of mtDNA copies/ncDNA copy by dividing the 
number of copies of MT-CYB by the number of copies of hB2M in each sample.  
 
 
 
Stage PCR temperature Time 
Hot start 95 oC 15 minutes 
30x 
Cycles 
Denaturing 95 oC 10 seconds 
Annealing 60 oC 30 seconds 
Extension 72 oC 1 minute 
Dissociation step 95
 oC 15 seconds 
60 oC 15 seconds 
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2.3.6. Capture of MtDNA Methylome 
To assess mitochondrial methylation status across the mitochondrial genome, a 
custom targeted bisulphite sequencing assay was designed. This Sure Select 
assay (Agilent Technologies; Design ID: 0687721) consisted of 656 probes 
which covered the entire mitochondrial genome using the most stringent repeat 
masking parameters and a 5x tiling density. This was then utilised in Chapters 5 
and 6. 
 
This experiment was carried out in accordance with the manufacturer’s 
specifications for 1µg DNA, with a few exceptions due to both the quantity of 
mtDNA available and the small size of the mitochondrial genome. Briefly, 
mtDNA was concentrated to a final volume of 30µl. Salmon sperm DNA (Sigma-
Aldrich; Cat No: 15632-011) was then added to each sample as a carrier 
DNA to yield a total volume of 50µl (20ng/µl). Each sample was then placed 
on ice for 30 minutes and the DNA was then sheared using a Bioruptor 
(Diagenode; Cat No: B01020001) at 4°C for 60 minutes for 30 second on/off 
cycles. After shearing, DNA quality was assessed and fragment size was 
determined using the Agilent 2200 TapeStation System (Agilent Technologies; 
Cat No: G2964AA) and DNA 1000 Screentape (Agilent Technologies; Cat No: 
5067-5582), as per protocol guidelines. For samples with fragments larger than 
100-175bp, DNA was re-sonicated. After DNA sonication, samples were kept on 
ice whilst End Repair master mix was prepared, as per the manufacturer’s 
instructions. Briefly, 52µl of the master mix was added to each 48µl sample, 
which were then vortexed and briefly centrifuged, before being incubated at 
20°C for 30 minutes in a thermal cycler. 180µl of Agencourt AMPure XP beads 
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(Beckman Coulter; Cat No: A63881) were then added to each 100µl sample, 
ensuring that AMPure XP beads were equilibrated at room temperature for at 
least 30 minutes prior to the addition. Samples and beads were pipette mixed 
10 times and incubated for 5 minutes at room temperature. The plate was then 
placed into a magnetic separation device and further incubated for 7-10 minutes 
until the sample cleared. Whilst the plate was in the magnetic stand, the cleared 
solution was carefully discarded and 200µl of 70% ethanol was added to each 
well containing beads. The beads were allowed to resettle, taking approximately 
1 minute before removing the ethanol. This ethanol wash was then repeated. 
The wells were then sealed and the plate was briefly centrifuged before being 
placed on the magnetic stand to remove any residual ethanol. To ensure the 
complete removal of ethanol, the unsealed plate was then placed on a heat 
block at 37°C for 5 minutes. After ethanol evaporation, 44µl of nuclease free 
water was added to each well, the plate was sealed, vortexed, briefly 
centrifuged and incubated at room temperature for 2 minutes. The plate was 
then placed in the magnetic stand and left for 3 minutes until the solution 
cleared. The cleared supernatant was then removed and placed into a fresh 
well and the beads were discarded.  
 
The samples were then transferred to ice and the 3’ ends of the DNA were 
adenylated. Briefly, 9µl of adenylation master mix, made per protocol 
guidelines, was added to each 41µl sample, and then briefly vortexed and 
centrifuged. The samples were then incubated in the thermal cycler at 37°C for 
30 minutes. Upon removal from the thermal cycler, the samples underwent 
another stage of AMPure clean up. 90µl of AMPure XP beads were then added 
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to each 50µl sample, with AMPure XP beads allowed to equilibrate to room 
temperature for at least 30 minutes prior to the addition. Samples and beads 
were pipette mixed 10 times and incubated for 5 minutes at room temperature. 
The plate was then placed into a magnetic separation device and further 
incubated for 5 minutes until the sample cleared. Whilst the plate was in the 
magnetic stand, the cleared solution was carefully discarded and 200µl of 70% 
ethanol was added to each well containing beads. The beads were allowed to 
resettle, taking approximately 1 minute, before removing the ethanol. This 
ethanol wash was then repeated. The wells were then sealed and the plate was 
briefly centrifuged before being placed on the magnetic stand to remove any 
residual ethanol. To ensure the complete removal of ethanol, the unsealed plate 
was then placed on a heat block at 37°C for 2 minutes. After ethanol 
evaporation, 35µl of nuclease free water was added to each well, the plate was 
sealed, vortexed, briefly centrifuged and incubated at room temperature for 2 
minutes. The plate was then placed in the magnetic stand and left for 3 minutes 
until the solution cleared. The cleared supernatant was then removed and 
placed into a fresh well and the beads were discarded.  
 
The purified DNA was then ligated using a methylated adaptor ligation mix, 
prepared as per the protocol guidelines. Briefly, 16.5µl of the ligation mix was 
added to each 33.5µl DNA sample, which was then briefly vortexed and 
centrifuged before being incubated at 20°C for 15 minutes in a thermal cycler. 
After ligation, DNA was purified using AMPure XP beads. 90µl of AMPure XP 
beads were then added to each 50µl sample (AMPure XP beads were allowed 
to equilibrate to room temperature for at least 30 minutes prior to the addition). 
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Samples and beads were pipette mixed 10 times and incubated for 5 minutes at 
room temperature. The plate was then placed into a magnetic separation device 
and further incubated for 5 minutes until the sample cleared. Whilst the plate 
was in the magnetic stand, the cleared solution was carefully discarded and 
200µl of 70% ethanol was added to each well containing beads. The beads 
were allowed to resettle, for approximately 1 minute, before removing the 
ethanol. This ethanol wash was then repeated. The wells were then sealed and 
the plate was briefly centrifuged, before being placed on the magnetic stand to 
remove any residual ethanol. To ensure the complete removal of ethanol, the 
unsealed plate was then placed on a heat block at 37°C for 2 minutes. After 
ethanol evaporation, 22µl of nuclease free water was added to each well, the 
plate was sealed, vortexed, briefly centrifuged and incubated at room 
temperature for 2 minutes. The plate was then placed in the magnetic stand and 
left for 3 minutes until the solution cleared. The cleared supernatant was then 
removed and placed into a fresh well and the beads were discarded. The DNA 
was then assessed for quality and quantity using the DNA D1000 Assay as 
previously described.  
 
After initial testing within the group, it was determined that the previous method 
of hybridisation (January 2013), provided consistent results across experiments. 
As such this method was utilised for all experiments described in this thesis. 
Briefly, DNA was concentrated to a total volume of 3.4µl using a vacuum 
concentrator at 45°C. The samples were then briefly vortexed and centrifuged. 
Hybridization Buffer and Block Mix were made to specifications indicated on the 
protocol, however a 10% RNase block solution was made using 0.2µl RNase 
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Block and 1.8µl of nuclease free water (as recommended by Agilent technical 
support). Further, given the size of the genome, only 2µl of the custom capture 
library was added to a PCR plate containing 2µl RNase block solution and 3µl 
of nuclease free water (as recommended by Agilent technical support). In a 
separate plate, the 3.4µl samples were added to Row B. 5.6µl of freshly 
prepared Block Mix was then added to the samples, which were pipette mixed 
and the wells were sealed. The PCR plate containing samples and Block Mix 
was then added to a thermal cycler and heated to 95°C for 5 minutes before 
being held at 65°C for 5 minutes, with a heated lid set at 105°C. After 5 minutes, 
7µl capture library mix was added to Row C of the plate, which was then sealed 
and left to incubate at 65°C for 2 minutes. 13µl of Hybridisation buffer was 
added to the Sure Select capture library, which was then followed by the 
addition of the prepared library to the capture library. The contents of the wells 
were then pipette mixed 10 times before being sealed using two layers of 
adhesive tape and left to incubate at 65°C for 24 hours.  
 
Sure Select Wash Buffer 2 (provided with kit) was incubated at 65°C in a water 
bath. Dynabeads MyOne Streptavidin T1 magnetic beads (ThermoFisher 
Scientific; Cat No: 65601) were then prepared prior to removal of the plate from 
the thermal cycler. Briefly, the magnetic beads were vortexed for 30 seconds 
and 50µl per sample was added to a plate containing 200µl of SureSelect 
binding buffer (provided with kit). The beads and buffer were then pipette mixed 
10 times. The plate was then placed on a magnetic separation device and the 
solution was allowed to clear for 5 minutes before removing the supernatant. 
This washing was then repeated two more times and the beads were re-
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suspended in binding buffer (provided with kit). The DNA extraction mixture was 
then immediately transferred into the plate containing the Streptavidin beads 
and incubated at room temperature for 30 minutes, during which time three 
200µl aliquots per sample of Wash Buffer 2 were warmed to 65°C. After the 
DNA-bead hybridisation, the plate was briefly centrifuged and placed in a 
magnetic separator until the solution cleared, at which point the supernatant 
was removed. The beads were then re-suspended in Sure Select Wash Buffer 1 
(provided with kit) and pipette mixed until fully re-suspended. The beads were 
then left at room temperature for 15 minutes, after which the plate was briefly 
centrifuged. Beads were then placed back into the magnetic separator and the 
supernatant was discarded after the solution cleared.  
 
Beads were then re-suspended by pipette mixing in 200µl of Wash Buffer 2, 
which had been pre-warmed to 65°C. Wells were then capped and incubated at 
65°C for 10 minutes, after which they were placed in a magnetic separator and 
the supernatant was removed upon the solution clearing. This wash and 
incubation step was repeated twice more, ensuring that all Wash Buffer 2 was 
removed in the final wash. 20µl of Sure Select Elution Buffer (provided with kit) 
was then added to the beads, the wells were capped and the solution was 
vortex mixed for 5 seconds before being left to incubate at room temperature for 
20 minutes. During this period, one vial of CT Conversion Reagent (Section 
2.2.5.) from the EZ DNA Methylation Gold Kit (Zymo Research; Cat No: D5005) 
was prepared. Following the 20-minute incubation, the beads were placed on a 
magnetic separator and the supernatant was transferred into a new plate upon 
clearing. 130µl of CT Conversion Reagent was then added to each 20µl 
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captured library, which was then vortexed and briefly centrifuged. The plate was 
then placed in a thermal cycler and incubated at 64°C for 2.5 hours.  
 
Following incubation, 600µl of M-Binding Buffer (provided with kit) was added to 
each Zymo-Spin IC Column in collection tubes, followed by 150µl of BS-
converted DNA. The columns were then capped, inverted five times and 
centrifuged at 13,000rpm. The flow through was then discarded and the column 
was placed back in the same collection tube. The column was then washed by 
adding 100µl of M-Wash Buffer (provided with kit), and centrifuged for 60 
seconds at 13,000rpm. The flow through was discarded and the column was 
placed back into the same collection tube. 200µl of M-Desulphonation Buffer 
(provided with kit) was then added to each column, and they were then 
incubated for 20 minutes at room temperature before being centrifuged at 
13,000rpm for 60 seconds. The flow through was then discarded and the 
column was placed back in the same collection tube. Each column was then 
subjected to a further wash step, by adding 200µl M-Wash Buffer, followed by 
another centrifugation step at 13,000rpm for 60 seconds. The column was then 
placed in a fresh 1.5ml microcentrifuge tube and incubated at room temperature 
for 2 minutes. 10µl of M-Elution Buffer (provided with kit) was then added to 
each column, and the samples were then incubated at room temperature for 3 
minutes before being centrifuged at 13,000rpm for 60 seconds. The flow 
through was retained in the collection tube whilst a further 10µl of M-Elution 
Buffer was added to the column. Each column was again incubated at room 
temperature for 3 minutes prior to centrifugation at 13,000rpm for 60 seconds. 
Following desulphonation, samples were immediately taken to the next step: 
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PCR amplification of bisulphite-treated libraries. The PCR reaction mixture was 
prepared as per protocol guidelines, however given the small genome size and 
low DNA input, the number of PCR cycles were increased (see Table 2.5). 
AMPure XP beads were incubated at room temperature for 30 minutes. 180µl of 
homogenous AMPure XP beads were added to each sample and pipette mixed 
10 times before being incubated at room temperature for 5 minutes. The plate 
containing the samples was then placed in a magnetic separator for 10 minutes, 
until the solution had cleared, at which point the supernatant was removed. 
200µl of 70% ethanol was then added to each sample and left to incubate for 1 
minute before the supernatant was removed. The ethanol wash was then 
repeated. At the end of the second wash the plate was placed in a heat block at 
37°C for 4 minutes until residual ethanol had evaporated. 21µl of nuclease-free 
water was then added to each sample, and samples were then pipette mixed 
and left to incubate for 2 minutes at room temperature, after which the plate was 
placed in the magnetic separator and incubated for a further 3 minutes. When 
the solution cleared, the supernatant was removed and placed in a fresh well. 
 
Table 2.5: Bisulfite PCR conditions for mtDNA methylation. 
 
 
Segment Number of Cycles Temperature Time 
1 1 95°C 2 mins 
2 14 
95°C 30 seconds 
60°C 30 seconds 
72°C 30 seconds 
3 1 72°C 7 mins 
4 1 4°C Hold 
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A PCR reaction mixture for sample indexing was then made as per the protocol 
guidelines. 25.5µl of the PCR Indexing Reaction Mix was added to each 19.5µl 
sample with 5µl of the appropriate Indexing Primer. This mixture was then 
subjected to PCR amplification using the Agilent Methyl-Seq protocol conditions 
before being analysed using D1000 High Sensitivity Screentape (Agilent 
Technologies; Cat No: 5067-5584) and pooled, as per protocol guidelines. Prior 
to being sent to the Exeter Sequencing Service 
(http://sequencing.exeter.ac.uk/), the sample pool was analysed using the 
D1000 High Sensitivity Screentape to determine concentration. The sample 
pool was then run on the Illumina HiSeq 2500, high Output format, using 100bp 
paired-end tags. 
 
2.3.7. Determination of MtDNA Methylation State 
For sequencing alignments presented in Chapters 5 and 6, the most current 
version of the human mitochondrial genome, the revised Cambridge Reference 
Sequence, (rCRS), was downloaded from ensemble 
(ftp://ftp.ensembl.org/pub/release-83/fasta/homo_sapiens/dna/). Fastq files 
were unpackaged and indexed using bismark, a BS-specific alignment tool 
which utilises Bowtie and/or Bowtie 2 (204). 
 
Following sequencing, paired-end fastq files were de-multiplexed and quality 
checked with FastQC, using default options. Paired-end fastq files were then 
trimmed for adaptors and for the first base pair from the 3’ end of both reads, to 
improve later alignment mapping efficiencies using trim-galore.  
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Following trimming, files were aligned to rCRS under default settings. Following 
alignments, mapping efficiencies and sequencing depth were recorded and the 
Sequence Alignment/Map files were deduplicated using the shell function 
deduplicate_bismark before methylation levels in each cytosine context were 
determined using the shell function bismark_methylation_extractor, both can be 
found within the Bismark program (204). The percentage methylation at each 
methylated cytosine, for each sample, was then extracted and all further 
analyses were carried out in R statistical environment version 3.2.1 (205).
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Chapter 3. Investigating the use of Publicly Available Data for the 
Determination of MtDNA Methylation Patterns Across Different Tissue 
Types  
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The work described in this chapter is currently in press at the journal 
“Clinical Epigenetics”. A copy of the accepted  article can be found in 
Appendix 3. 
 
3.1.  Aims  
1. To create a pipeline to account for the presence of NUMTs in total 
genomic DNA using publicly available MeDIP-Seq datasets. 
2. To assess the tissue specificity of mtDNA methylation in a publicly 
available MeDIP-Seq dataset. 
 
3.2.  Introduction 
Mitochondria are unique organelles in that they have their own, circular 
genome, approximately 16.6kb in size (25). mtDNA consists of 37 genes, 22 
encoding for tRNAs, two for rRNAs and 13 encoding for proteins important in 
the ETC. However, mitochondria have an array of other important cellular roles 
such as Ca2+ homeostasis (206) and neural stem cell differentiation (207). As 
such, abnormal mitochondrial function, dynamics and trafficking have been 
associated with a number of brain disorders including AD (208,209), 
schizophrenia (210), bipolar disorder (211) and major depressive disorder 
(212).  
 
Epigenetic processes mediate the reversible regulation of gene expression, 
occurring independently of DNA sequence variation, acting principally through 
chemical modifications to DNA and nucleosomal histone proteins to orchestrate 
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a diverse range of important physiological functions. DNA methylation is the 
best characterised and most stable epigenetic modification, modulating the 
transcription of mammalian genomes. Further, as it can be robustly assessed 
using existing genomic DNA resources, it is also the focus of most human 
epidemiological epigenetic research to date (191). The most widely used 
method for epigenome-wide analysis of DNA methylation is the Illumina 450K 
methylation array and a number of studies have recently shown differential DNA 
methylation of ncDNA, between different tissue types (213-215) and also in a 
range of complex diseases, from brain disorders such as AD (198,199,216) and 
schizophrenia (217,218), to systemic diseases such as type 2 diabetes (219) 
and Crohn’s disease (220). However, with no representation of the 
mitochondrial genome on this platform, as well as a lack of analysis on other 
genome-wide platforms, the role of mtDNA methylation has been largely 
neglected (1,221). 
 
Since the identification of 5-mC in mitochondria, research into mtDNA 
methylation as an independent, and potentially relevant, mark has received 
more regular attention (72,73). However, most research is either focussed on 
low resolution, global DNA methylation, or candidate gene DNA methylation 
changes using techniques such as BS-pyrosequencing (1). These recent 
publications have indicated that differences in mtDNA methylation are present 
in a variety of different phenotypes (75,80-83,200) and may have potential utility 
as a biomarker (153). In addition, a recent study has explored the use of 
MeDIP-Seq to investigate changes in mtDNA methylation across 39 cell lines 
and tissues from publicly available data (63). At present, genome-wide 
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sequencing technologies have not yet been used to interrogate alterations in 
the mtDNA methylome across tissues in the same individuals.  
 
A high proportion of current, publicly available, genome-wide DNA methylation 
data has been generated through the use of MeDIP-Seq, a method designed to 
interrogate genome-wide changes in methylation at a high throughput and for a 
low cost (100). However, given the presence of NUMTs, mitochondrial reads 
are often discarded from further analysis. The development of bioinformatic 
pipelines to investigate regions of differential mtDNA methylation from whole 
genome data would provide a novel way in which to interrogate the mtDNA 
methylome in publicly available data. Here, we control for the presence of 
NUMTs in a previously published MeDIP-Seq dataset, to investigate differential 
DNA methylation across the mitochondrial genome in human post-mortem brain 
samples. 
 
3.3 Methods 
 
3.3.1. Data Collection 
We utilised publicly available MeDIP-Seq data from Davies et al (158). In brief, 
this data was generated using 5μg fragmented gDNA, which, following end 
repair <A> base addition and adaptor ligation, was immunoprecipitated using an 
anti-5mC antibody (Diagenode, Liège, Belgium). MeDIP DNA was purified and 
then amplified using adaptor-mediated PCR, with DNA fragments between 220-
320bp subjected to highly parallel 50bp paired-end sequencing on the Illumina 
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Hi-Seq platform. The paired-end, raw fastq files were provided by the authors 
and quality checked using FastQC. Sample information is provided in Table 3.1. 
 
Table 3.1: Demographic information for MeDIP study. MeDIP-Seq data was 
available from post-mortem brain samples obtained from three individuals free 
of any neuropathology and neuropsychiatric disease. Data was available for five 
different regions of the cortex (CTX), Brodmann areas (BA) 8, 9 and 10, 
superior temporal gyrus (STG) and ECX, the cerebellum (CER) and pre-mortem 
blood (BLD). MeDIP-Seq data was available for all individuals from cortical and 
cerebellar samples, however blood MeDIP-Seq data was not available for 
individual 2. Data is freely available to download from 
http://epigenetics.iop.kcl.ac.uk/brain. 
 
Individual Age at Death (Years) 
Age at Bloods 
Sampled (Years) 
Post-Mortem 
Delay (Hours) Sex 
1 82 79 43 Female 
2 92 N/A 17 Female 
3 78 78 10 Male 
 
3.3.2. Quality Control and NUMT exclusion 
Fastq files were subjected to adaptor and Phred score (q<20) trimming. In an 
attempt to remove any potential contamination of possible NUMTs, multiple 
alignments to the reference genome were undertaken. Briefly, paired fastq files 
were aligned to GRCH37 using BWA. Unique and mapped reads aligning to the 
mitochondria were then re-mapped to a custom GRCH37 reference without the 
mitochondrial chromosome. Reads not mapping to the custom reference were 
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then taken forward and realigned to the full GRCH37 reference to eliminate the 
possibility of homologous regions mapping falsely to the mitochondrial genome. 
All alignments were carried out using BWA mem and default settings.  
 
Reads Per Kilobase of transcript per Million mapped reads (RPKM) values for 
each sample were calculated using the MEDIPS R package (222). Methylation 
was averaged across 100bp non-overlapping windows (default parameter 
setting in MEDIPS) and only windows with read counts >10 were considered for 
analysis. Due to the non-normal distribution of all cohorts, RPKM values were 
log2 transformed before statistical analysis. 
 
3.3.3. Statistical analyses 
All analyses were performed in the R statistical environment version 3.2.1 (205). 
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package (224)  corrgram thewithin
 
“corrgram” 
  function R the used   Euclidean using regions brain forvaluesRPKM We
   the upon based samplesorder  to
components.   principal theirofsimilarity 
 
3.4 Results 
 
3.4.1. MtDNA Methylation Patterns are Correlated between the CTX, CER and 
Blood.  
To date, no study has investigated differences in mtDNA methylation across 
different matched regions of human brain and blood samples. Our cohort (Table 
3.1) consisted of MeDIP-Seq data from three individuals, free of any 
neuropathology and neuropsychiatric disease, for five different regions of the 
CTX: BA 8, 9 and 10, STG and ECX, the CER and pre-mortem blood (158).  
 
Given that MeDIP-Seq data has been generated from standardly extracted total 
genomic DNA, and thus contains a mixture of ncDNA and mtDNA (225), we 
initially controlled for regions of high sequence homology between the two 
genomes within our data by realigning mtDNA reads to a series of custom 
reference genomes using an in-house pipeline to specifically analyse mtDNA 
methylation, see Section 3.3.2. 
 
Initially we were interested to investigate whether changes in mtDNA across the 
mitochondrial genome were highly correlated between different tissue types. 
Using principal component analysis (PCA) we found that mtDNA methylation 
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patterns are highly correlated between different cortical regions, (r>0.99, 
p<2.2E-16), with a slightly weaker correlation between CER and CTX (r>0.97, 
p<2.2E-16) (Figure 3.1).  
 
Due to the small number of blood samples available, deriving a significance 
level for the correlations between CER and blood could not be made. Instead, in 
an attempt to explore the similarity between matched blood and CER samples, 
direction of differential methylation from the CTX was used. Here we found that 
93.1% of the windows analysed in CER and blood had the same direction of 
methylation difference from the CTX, further suggesting a strong correlation 
between the two tissue types. 
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Figure 3.1: Correlogram to show similarity between each tissue type. 
Principal components of each sample were determined in R and the correlation 
(R) between these components were plotted to determine the similarity between 
each average tissue type. For each tissue, the mean and standard deviation 
was calculated and shown above and below the respective tissues. 
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3.4.2. Differentially Methylated Regions of the Mitochondrial Genome can be 
Identified between Anatomically Distinct Cortical Regions and CER 
Having identified correlated mtDNA methylation patterns across different brain 
regions, we were interested to investigate whether we could identify DMRs in 
the mitochondrial genome between different regions of the CTX and CER. To 
identify such tissue-specific DMRs within the mitochondrial genome, paired t-
tests were performed within matched cortical and CER samples at 100bp 
windows across the mitochondrial genome. In total, we identified 74 nominally 
significant DMRs (P<0.05) between the five individual cortical regions and the 
CER (Table 3.2; Figure 3.2). Of these DMRs, seven (Table 3.2, bold face) 
were found to be present across all prefrontal CTX areas (BA8, BA9, BA10). 
Furthermore, the direction of methylation difference was maintained in all 
Brodmann area regions, with three conserved regions of hypomethylation and 
four conserved regions of hypermethylation, with respect to CER.  Furthermore, 
four of the seven conserved regions were adjacent to each other within the 
mitochondrial D-LOOP (16201-16600bp), a region associated with gene 
transcription and DNA replication. 
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Table 3.2: List of DMRs identified between five anatomically discreet cortical regions and CER. Shown is the location of 
the DMR within the mitochondrial genome (ChrM) (based on GENCODE), the gene(s) residing within the 100bp window, and 
P value from paired t-tests between each of the five cortical regions: BA8, BA9, BA10, ECX, STG compared to the CER. 
Results are displayed in order of genomic position. RPKM and corresponding P values are shown for windows if P<0.05. Key: 
- denotes data not significant (P>0.05); Results shown in bold represent those found to be present across all prefrontal CTX 
areas (BA8, BA9, BA10). 
Start 
of 
100bp 
Gene(s) 
BA8 BA9 BA10 ECX STG 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
701 MT-RNR1 - - - - - - 0.032 79156 - - 
801 MT-RNR1 0.043 94246 0.029 -43592 - - - - 0.018 95257 
2301 MT-RNR2 0.025 -97351 0.032 -29509 0.043 -82048 - - - - 
2401 MT-RNR2 
8.90E-
03 70950 - - - - - - - - 
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Start 
of 
100bp 
Gene(s) 
BA8 BA9 BA10 ECX STG 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
2501 MT-RNR2 
3.30E-
03 51937 - - - - - - - - 
2901 MT-RNR2 - - - - - - - - - - 
3201 
MT-
RNR2 / 
MT-TL 
- - - - - - 0.021 242424 - - 
3401 MT-ND1 - - 0.015 864685 - - - - - - 
3501 MT-ND1 0.041 1180914 - - 0.017 226066 - - - - 
3601 MT-ND1 0.047 1250436 0.045 1228936 0.037 1183681 - - - - 
3701 MT-ND1 - - - - 0.022 20818 - - - - 
4001 MT-ND1 0.024 -39498 1.55E-02 -38704 - - 0.047 -49753 0.016 243767 
10201 MT-ND3 0.047 -662126 - - - - 0.031 -591067 7.30E-03 -57012 
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Start 
of 
100bp 
Gene(s) 
BA8 BA9 BA10 ECX STG 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
10301 
MT-ND3 
/ MT-TR 
/ MT-
ND4L 
0.036 132719 0.036 135759 0.040 115364 0.014 73063 0.034 105106 
10401 MT-ND4L - - 0.047 -71246 - - - - - - 
10501 MT-ND4L - - - - - - - - - - 
11201 MT-ND4 - - 0.019 -68903 0.018 -79625 0.047 58742 - - 
11301 MT-ND4 - - 0.048 -139847 - - - - - - 
12301 MT-TL2 / MT-ND5 0.047 1787 - -197592 - - - - - - 
12701 MT-ND5 0.021 -5702 - - 0.046 -388706 - - 0.044 -394978 
12901 MT-ND5 - - 0.031 -130016 - - - - - - 
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Start 
of 
100bp 
Gene(s) 
BA8 BA9 BA10 ECX STG 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
13301 MT-ND5 0.015 -175917 - - 9.80E
-03 -144949 0.034 -133694 - - 
13401 MT-ND5 0.036 -104010 - - 0.034 -81264 - - - - 
13701 MT-ND5 0.013 -422610 - - 1.20E
-03 3714 - - - - 
13801 MT-ND5 - - 0.037 708761 0.026 123249 - - - - 
13901 MT-ND5 - - - - 0.022 -75118 - - - - 
14101 
MT-ND5 
/ MT-
ND6 
- - - - - - - - 0.042 -534766 
14501 MT-ND6 - - - - - - - - 0.049 -82767 
15201 MT-CYB - - - - - - 0.012 254183 - - 
15301 MT-CYB - - - - - - - - - - 
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Start 
of 
100bp 
Gene(s) 
BA8 BA9 BA10 ECX STG 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
P 
Value Δ RPKM 
15401 MT-CYB 0.044 10628 - - 0.021 -554527 - - 0.033 -554225 
15501 MT-CYB 0.037 -671707 - - 0.012 -685630 0.038 9301 0.035 -695515 
15601 MT-CYB - - - - 0.043 -746270 - - - - 
16101 D-LOOP - - 3.40E-03 3014 - - - - - - 
16201 D-LOOP 0.046 380407 0.025 1117943 0.037 296890 - - - - 
16301 D-LOOP 0.037 -941720 0.014 -112453 0.027 -177146 - - - - 
16401 D-LOOP 0.043 444051 0.022 1151402 0.017 313156 - - - - 
16501 D-LOOP 0.037 784572 0.021 764994 0.025 836662 - - - - 
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Figure 3.2: DNA methylation differences are seen in the mitochondrial 
genome between brain regions and blood.  (A) Composite plot of mtDNA 
methylation for each brain region. Average RPKM for CER and each cortical 
region alongside matched blood samples were plotted per 100bp window. (B) 
For each 100bp, paired t-tests were performed between each cortical region 
and CER (bottom panel). 
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3.4.3. A Number of Differentially Methylated Regions in MtDNA can be 
Observed between CTX and CER  
We were also interested to see whether total cortical tissue was significantly 
different to matched CER samples. Given the paired nature of the different 
anatomical regions of CTX, we used a multi-level model to compare total CTX 
to CER.  
 
This analysis revealed 48 nominally significant (P<0.05) windows (Table 3.3; 
Figure 3.3), of which eight passed Bonferroni correction (Table 3.3, bold face). 
Interestingly, three of these eight were adjacent to each other, lying between 
10301-10600bp and covering Mitochondrially encoded NADH dehydrogenase 3 
(MT-ND3) / Mitochondrially encoded NADH dehydrogenase 4 (MT-ND4L) and 
Mitochondrially encoded tRNA arginine (MT-TR). We also saw a Bonferroni 
significant difference in DNA methylation in the D-LOOP, where we earlier 
noted DNA methylation changes across all three Brodmann area regions. 
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Table 3.3: List of DMRs identified between total CTX and CER. Shown is the 
location of the DMR within ChrM (based on GENCODE), the gene(s) residing 
within the 100bp window, and P value from a mixed effects model. Results are 
displayed in order of genomic position. RPKM and corresponding P values are 
shown for windows if P<0.05. Key; Bold denotes windows that reached our 
Bonferroni significant threshold of P<7.04E-04. 
 
Start 
(bp) 
Stop 
(bp) Gene(s) P-Value 
401 500 D-LOOP 7.99E-03 
501 600 MT-TF 4.49E-03 
601 700 MT-TF / MT-RNR1 1.16E-02 
701 800 MT-RNR1 3.22E-03 
801 900 MT-RNR1 1.91E-04 
2301 2400 MT-RNR2 8.10E-03 
2401 2500 MT-RNR2 7.50E-03 
2501 2600 MT-RNR2 5.14E-03 
3201 3300 MT-RNR2 / MT-TL 1.51E-03 
3401 3500 MT-ND1 1.37E-02 
3501 3600 MT-ND1 4.27E-03 
3601 3700 MT-ND1 5.56E-03 
3701 3800 MT-ND1 8.21E-03 
4001 4100 MT-ND1 3.07E-06 
10001 10100 MT-TG / MT-ND3 1.81E-02 
10101 10200 MT-ND3 1.39E-02 
10201 10300 MT-ND3 3.53E-04 
10301 10400 MT-ND3 / MT-TR / MT-ND4L 1.19E-05 
10401 10500 MT-ND4L 2.61E-04 
10501 10600 MT-ND4L 9.05E-04 
11201 11300 MT-ND4 8.86E-05 
11301 11400 MT-ND4 1.65E-03 
12701 12800 MT-ND5 1.81E-03 
12801 12900 MT-ND5 1.05E-02 
12901 13000 MT-ND5 8.23E-03 
13301 13400 MT-ND5 1.44E-03 
13401 13500 MT-ND5 9.13E-04 
13501 13600 MT-ND5 1.61E-02 
13601 13700 MT-ND5 3.89E-02 
13701 13800 MT-ND5 2.77E-04 
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Start 
(bp) 
Stop 
(bp) Gene(s) P-Value 
13801 13900 MT-ND5 2.80E-03 
13901 14000 MT-ND5 1.88E-02 
14001 14100 MT-ND5 9.31E-03 
14301 14400 MT-ND6 1.04E-02 
14401 14500 MT-ND6 1.99E-02 
14501 14600 MT-ND6 2.26E-02 
14601 14700 MT-ND6 / MT-TE 3.82E-03 
14701 14800 MT-TE / MT-CYB 1.92E-02 
15101 15200 MT-CYB 3.30E-02 
15401 15500 MT-CYB 8.52E-04 
15501 15600 MT-CYB 7.43E-04 
15601 15700 MT-CYB 1.16E-02 
15701 15800 MT-CYB 2.24E-02 
16101 16200 D-LOOP 2.23E-03 
16201 16300 D-LOOP 5.02E-04 
16301 16400 D-LOOP 1.84E-03 
16401 16500 D-LOOP 1.12E-03 
16501 16600 D-LOOP 2.20E-03 
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Figure 3.3: DNA methylation differences are seen in the mitochondrial 
genome between the CTX and CER. (A) Average RPKM values for CTX and 
CER at each 100bp window were plotted. (B) For each 100p window a mixed 
effects model was used to compare CTX to CER.  
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3.4.4. MtDNA Methylation Patterns Distinguish between Tissue Types 
Although we have shown that mtDNA methylation patterns are highly similar 
between distinct anatomical regions of the human brain and blood, we were 
also interested to identify whether mtDNA methylation patterns could distinguish 
between these tissue types. Through unsupervised hierarchical clustering we 
showed that average mtDNA methylation patterns can segregate these tissues 
(Figure 3.4A).  
 
Importantly, ncDNA methylation profiles in the same samples have also been 
previously shown to separate the CTX, CER and blood (158). Interestingly, 
when we performed unsupervised hierarchical clustering on the individual 
samples we found that, in most cases, intra-individual differences across tissue 
types are greater than inter-individual differences within each tissue-type, as the 
CTX, CER and blood samples clustered with their own tissue type respectively 
(Figure 3.4B).  
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Figure 3.4: Hierarchical clustering of mtDNA methylation. Unsupervised 
hierarchical clustering was performed on the average tissue methylation (A) and 
individual samples (B), which showed mtDNA methylation patterns could 
separate cortical, cerebellar and blood samples. 
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3.5. Discussion 
Publicly available epigenomic data provides a great resource for mitochondrial 
epigenetics, a field that is relatively nascent and has yet to be thoroughly 
investigated in a range of complex diseases. Here, we present evidence that 
mtDNA methylation patterns across mtDNA are brain region specific. However, 
data such as that presented here is confounded by a lack of isolation of mtDNA 
prior to antibody enrichment and sequencing. As such, the potential of including 
NUMTs in datasets derived from data generated using total genomic DNA could 
generate misleading results unless this is taken into account..  
 
Here, we controlled for regions of high sequence homology between the nuclear 
and mitochondrial genomes. However, this approach is likely over-conservative 
and does lead to the generation of a somewhat truncated consensus sequence. 
MtDNA methylation has been shown to be cell line dependent in the past (63). 
Despite our stringent control for nuclear homology, a PCA of the mitochondrial 
epigenome was able to separate individuals belonging to the three main tissue 
types in this study: blood, CTX and CER, based on mtDNA methylation 
variation among tissue types. The tissue-specificity of this mark is further 
highlighted by the identification of eight DMRs that pass Bonferroni correction 
for multiple testing between total CTX and CER in our dataset.  
 
Although overall DNA methylation levels were low in all tissues, it is worth 
noting that the study was performed on non BS-treated DNA. As such, the low 
percentage of mtDNA methylation is not a pitfall due to a lack of total BS-
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treatment efficiency. One limitation of the current study is the lack of publicly 
available MeDIP-Seq datasets of matched cortical and CER tissue from other 
cohorts for validation purposes. Future work would aim to replicate our findings 
in additional study cohorts, and also to investigate the relationship between 
mitochondrial DNA methylation and gene expression. 
 
Despite a number of nominally significant windows being identified between 
each individual cortical region and the CER, these did not pass   either 
Bonferroni  or Benjamani-Hochberg corrections for multiple testing. 
Nevertheless, the conservation of seven nominally significant windows across 
each Brodmann area is interesting to note. Four of these windows lie adjacent 
to each other and correspond to the mitochondrial D-LOOP, a region containing 
the only two mitochondrial promoters, which are typically associated with gene 
transcription and DNA replication.  
 
One limitation of this study is owed to the use of antibody based enrichment, 
resulting in the analysis being limited to a window based approach. Despite this, 
studies of the nuclear genome have shown high correlation between window 
based approaches and, more sensitive, single site assays such as the Illumina 
450K beadarray (100). However, given the small size of the mitochondrial 
genome, and that 23 of the 37 genes present in the genome are below 100bp in 
size, this window based approach may not be the most appropriate for future 
studies designed to specifically assess mtDNA methylation as it can result in a 
window intersecting two genes in the polycistronic transcript.  
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3.6. Conclusions 
This method provides a conservative approach to determine mtDNA 
methylation across the genome for data previously generated using NGS 
approaches such as MeDIP-Seq. Its conservative nature reduces the risk of the 
inclusion of NUMTs in the final analysis of whole genome data, but may also 
lead to the inclusion of false-negatives as well as potential gaps in the reference 
sequence. As such, it is best suited to analysing previously generated whole 
genome data and is not a replacement for the isolation of mitochondrial DNA 
(225) prior to targeted methylation studies, which would be the optimal 
approach for investigating mitochondrial epigenomics. However, our method 
has allowed the identification of novel brain-region specific DMRs in a 
previously generated publicly available dataset. Furthermore, the identification 
of brain region specific mtDNA methylation patterns across the mitochondrial 
epigenome suggests the importance of a focussed, tissue-specific study design 
when investigating mtDNA methylation. As previously discussed, one caveat 
when utilising MeDIP-Seq data is the segregation of data into neighbouring 
windows, meaning that determining the exact corresponding gene of a DMR is 
difficult and, as such, future directed studies should aim to sequence the 
mitochondrial DNA methylome at single base resolution to address this.  
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Chapter 4. A Comparison of Mitochondrial DNA Isolation Methods in Post-
Mortem Archived Human Brain Tissue: Applications for Studies of 
Mitochondrial Genetics in Brain Disorders. 
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The work presented in this chapter has been previously published (202) 
and can be found in Appendix 4.  
 
4.1. Aims:  
1. To isolate mtDNA from frozen, post-mortem human brain tissue using 
methods commonly used to isolate mtDNA from fresh tissue and/or 
cultured cells. 
2. To evaluate the effectiveness of these isolation methods using qRT-
PCR, to compare the methods to each other and to total genomic DNA 
extracted using a phenol-chloroform method. 
 
  
4.2. Introduction 
Mitochondria generate ATP, regulate Ca2+ homeostasis (178,179), mediate 
apoptosis (177), and produce ROS. Mitochondrial dysfunction has been 
implicated in a number of diseases, including in the pathogenesis of brain 
disorders such as AD (181,182,226). Mitochondria are unique mammalian 
organelles in that they contain their own genome; the mitochondrial genome is 
~16.6kb of circular DNA (25), which is separate to ncDNA and inherited in a 
maternal, non-Mendelian fashion.  
 
Because of its role in ROS production, mtDNA has a higher mutation rate than 
ncDNA (227). Mutations in mtDNA are relatively common, with at least one in 
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200 healthy humans harbouring a potentially pathogenic mtDNA mutation (228). 
Indeed more than 300 point mutations in mtDNA are associated with disease 
risk and pathology in MitoMAP (229). Interestingly, as each mitochondrion 
contains 2-10 copies of mtDNA and there are multiple mitochondria in any given 
cell, somatic mutations result in a mosaic of different mtDNA sequences within 
any given tissue. This phenomenon is known as mitochondrial heteroplasmy 
and is linked to various mitochondrial diseases (154). Such heterogeneity is a 
potential confounder in studies of mitochondrial diseases, because inter- and 
intra-individual heteroplasmic variation can confuse the association between a 
haplogroup and its corresponding phenotype. Therefore, unlike studies of 
ncDNA variation, it is important to use the specific tissue of interest for 
aetiological research.  
 
Another interesting feature of the mitochondria is that over evolution, sequences 
of mtDNA have translocated to the nuclear genome. Traditional mitochondrial 
genetic research, and more recently studies of mitochondrial epigenetics, can 
be hampered by the presence of these NUMTs as they share a high homology 
with their mitochondrial paralogs (230,231). Given the interest in studying 
mtDNA genetic and epigenetic changes in the pathology of brain diseases 
characterised by mitochondrial dysfunction, it is imperative that NUMTs are 
correctly accounted for (1). 
 
The specific isolation of mitochondria prior to downstream processing is vital to 
remove issues relating to NUMT contamination. For this purpose, a number of 
methods have been developed to specifically isolate mtDNA, although few of 
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these approaches have been specifically optimised for use on post-mortem, 
archived, frozen, human brain tissue, a major resource in many epidemiological 
studies. In fact, most studies investigating mtDNA use fresh animal tissue or cell 
lines. The insult of freezing tissue prior to isolation will potentially alter the 
effectiveness of these techniques and increase the risk of NUMT inclusion in 
downstream analysis.  
 
In this study, we compared the effectiveness of five different mitochondrial 
isolation methods on human, post-mortem brain tissue using qRT-PCR to 
determine the optimal method for the specific enrichment of mtDNA. The 
methods tested have been previously successful in isolating pure mtDNA from 
fresh animal tissue/cell lines, and included protocols based on A) Percoll 
gradients, B) linear DNA digestion, C) differential centrifugation, D) rapid 
differential centrifugation using a commercial kit (Promokine) and E) magnetic 
isolation of mitochondria using anti-TOM22 antibodies (Miltenyi Biotech). We 
compared these approaches to DNA we had previously extracted (232), using a 
phenol-chloroform protocol, which isolates both ncDNA and mtDNA.   
 
4.3. Methods 
 
4.3.1. Method A 
Method A was a modification of the method by Sims and Anderson (233). 
Briefly, 150mg of tissue was dissociated using the gentleMACS dissociator 
(Miltenyi Biotech; Cat No: 130-093-235) and a mitochondrial extraction kit 
                                                                                                  
126 
 
(Miltenyi Biotech; Cat No: 130-097-340). After removal of the nuclear fraction, 
the supernatant was spun at 13,000 x g for 30 minutes at 4°C to form a crude 
mitochondrial pellet. The pellet was homogenised in a 12% Percoll solution 
(Sigma Aldrich; Cat No: P1644-25ML) and added above two layers (26% and 
40%) of Percoll solution. Samples were spun at 30,700 x g for 5 minutes at 4°C 
with the lower band containing the enriched mitochondrial fraction. Each 
mitochondrial fraction was diluted in four volumes of isolation buffer (0.25M 
sucrose/10mM EDTA/30mM Tris-HCl, pH 7.5) and centrifuged at 16,700 x g for 
10 minutes at 4°C to form a loose mitochondrial fraction. The supernatant was 
discarded, and mtDNA extracted using a DNA Minikit (Qiagen; Cat No: 51304) 
(16).  
 
4.3.2. Method B 
Method B was based on the method by Zhou et al (146) that digests linear DNA 
but leaves circular DNA intact. In brief, 20μg genomic DNA (previously 
extracted using a phenol-chloroform protocol: see section 2.3.1) was treated 
with 4μl lambda exonuclease (5 U/μl) (New England Biolabs; Cat No: M0262S) 
and 12μl RecJf (30 U/μl) (New England Biolabs; Cat No: M0264S) in 400μl 1x 
lambda exonuclease buffer (New England Biolabs; Cat No: B0262S) at 37°C for 
16 hours. Samples were then incubated at 65°C for 10 minutes to inactivate the 
enzymes and subsequently purified using a Qiagen DNA Minikit. 
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4.3.3. Method C 
Method C was based on the method by Clayton and Shadel (234). Briefly, 
100mg brain tissue was homogenized in 1ml chilled homogenisation buffer 
(0.25M sucrose/10mM EDTA/30mM Tris-HCl, pH 7.5). The homogenate was 
centrifuged at 1,000 x g for 15 minutes at 4°C and the supernatant removed. 
The pellet was re-homogenised in 600μl chilled homogenisation buffer and spun 
at 1,000 x g for 10 minutes at 4°C. The supernatant was combined with the 
supernatant from the previous step and centrifuged at 12,000 x g for 30 minutes 
at 4°C to pellet the mitochondria. MtDNA was extracted using a Qiagen DNA 
Minikit (18).  
 
4.3.4. Method D 
Method D was a modification of the method by Clayton and Shadel (234) and 
purchased as a commercial kit (Promokine; Cat No: PK-CA577-K280). Briefly, 
100mg of brain tissue was homogenised with the reagents provided, as per the 
manufacturer’s instructions (18). 
 
4.3.5. Method E 
The final isolation method used was adapted from a commercially available 
mitochondrial isolation kit and protocol from Miltenyi Biotec. Briefly, 200mg of 
tissue was dissociated using the gentleMACS dissociator (Miltenyi Biotech; Cat 
No: 130-093-235) and a mitochondrial extraction kit (Miltenyi Biotech; Cat No: 
130-097-340) and centrifuged to pellet the nuclear contaminants. The 
supernatant was then removed and magnetically labelled anti-TOM22 antibody 
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beads (Miltenyi Biotech; Cat No: 130-094-532) were added. This mixture was 
then incubated at 4°C for 1 hour, after which the mixture was processed through 
a magnetic column. Magnetically bound mitochondria were then removed from 
the column and mtDNA was extracted using a Qiagen DNA Minikit.  Full details 
on this protocol can be found in section 2.3.4. 
 
4.3.6. Method F  
Total DNA was extracted from human brain tissue using a standard phenol-
chloroform extraction protocol routinely used in our group. This method isolates 
both ncDNA and mtDNA and this DNA was thus used to determine the average 
mtDNA/ncDNA ratio from non-enriched samples. Full protocol details can be 
found in section 2.3.1. 
 
4.3.7. QRT-PCR of MtDNA Copy Number 
QRT-PCR was used to quantify the amount of mtDNA relative to ncDNA using 
primers specific to a mitochondrial gene (with no known NUMTs), and a nuclear 
housekeeping gene. Details on the assay and experimental conditions can be 
found in section 2.3.5. 
 
4.3.8. Sequencing of MtDNA 
DNA samples were fragmented by sonication using a Bioruptor (Diagenode; Cat 
No: UCD-200) to an average size of ~240bp. Sequencing libraries were 
prepared using the NEXTflex Rapid DNA-Seq kit (Bioo Scientific; Cat No: 5144-
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01) and ligated to pre-indexed adapters (NEXTflex-96 DNA Barcodes; Bioo 
Scientific; Cat No: 514101). Adapter-ligated DNA was amplified for 10 cycles 
using Herculase II Fusion DNA Polymerase (Agilent Technologies; Cat No: 
600675) and NEXTflex PCR primer mix, then pooled for sequencing on an 
Illumina HiSeq2500 (100bp paired-end, rapid run mode). Raw reads were 
quality and adaptor trimmed using TrimGalore! (235) before being aligned to 
GRCH37. Only high quality (Phred<20) reads, uniquely mapping to the 
genome, were considered and total read counts were taken. The mapping 
percentages to this reference genome and the total number of reads mapped 
for enriched mitochondrial samples and the non-enriched standard were then 
compared.  
 
4.4. Results 
 
4.4.1. Method E Significantly Enriches for MtDNA 
Our data showed that method B (linear DNA digestion) gave the lowest purity 
(1,242 mtDNA copies/ncDNA copy), and method E (magnetic-microbeads) the 
highest purity (14,654 mtDNA copies/ncDNA copy) (Figure 4.1; Table 4.1).  
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Figure 4.1: Enrichment of mtDNA relative to ncDNA. In total five methods 
(Percoll (A), DNase digestion (B), differential centrifugation (C), rapid differential 
centrifugation (D) and magnetic microbeads (E) were compared to a non-
enriched standard (phenol-chloroform (F)). Shown is the ratio of mtDNA/ncDNA 
(±SEM). 
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Table 4.1: An overview of starting material for each isolation technique and resulting yield. In brief we compared five 
methods of isolating mtDNA in post-mortem human brain tissue; (A) discontinuous Percoll gradient, (B) DNase digestion of 
linear DNA (RecJf), (C) differential centrifugation (DC), (D) rapid (commercial) mitochondrial isolation via differential 
centrifugation (provided by Promokine) (E) magnetic labelling and pull-down of mitochondria using an antibody to TOM22 
(MACS kit provided by Miltenyi Biotec). We compared the yield and enrichment to a non-enriched standard (phenol-
chloroform) using an unpaired two-tailed t-test. 
Method A B C D E F 
Quantity of starting Material 
150mg 
(tissue) 
20μg 
(DNA) 
100mg 
(tissue) 
100mg 
(tissue) 
200mg 
(tissue) 
100mg 
(tissue) 
Average concentration (ng/µl) DNA 
collected (±SEM) 
162.4  
(11.6) 
40.3  
(10.1) 
23.7  
(8.0) 
257  
(138.4) 
32.4  
(7.0) 
N/A 
Average yield (µg) DNA collected 
(±SEM) 
8.1  
(0.58) 
2.0  
(0.50) 
4.7  
(1.60) 
13.7  
(6.35) 
3.2 
 (0.70) 
N/A 
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Method A B C D E F 
Average copies of mtDNA (±SEM) 
41,530 
(15,468) 
12,092,501 
(7,742,804) 
28,886,594 
(12,405,939) 
403,381 
(194,557) 
5,321,960 
(1,246,724) 
459,264 
(751,075) 
Number of samples 4 6 4 3 5 55 
Average copies of ncDNA (±SEM) 
155  
(85) 
8,768 
(3,731) 
20,746 
(11,256) 
720  
(449) 
402  
(86) 
4,011 
(585) 
Average ratio mtDNA/ncDNA (±SEM) 
3,337 
(1,988) 
1,242 (309) 2,270 (960) 
3,949 
(3,424) 
14,654 
(2,922) 
1,367  
(35) 
Fold Enrichment mtDNA/ncDNA 
relative to phenol-chloroform (P-value) 
2.44 (0.297) 0.91 (0.725) 1.66 (0.320) 2.89 (0.342) 
10.72 
(1.88x10-3) 
N/A 
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Of particular interest to the study was the relative enrichment compared to a 
standard phenol-chloroform extraction (Figure 4.2). 
 
Figure 4.2: Enrichment of mtDNA relative to phenol: chloroform. In total 
five methods (Percoll (A), DNase digestion (B), differential centrifugation (C), 
rapid differential centrifugation (D) and magnetic microbeads (E) were 
compared to a non-enriched standard (phenol-chloroform (F)).  
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The only method to show no enrichment was Method B (linear DNA digestion). 
All other techniques showed a positive enrichment of mtDNA compared to 
Method F (phenol: chloroform). Method A (Percoll), Method C (differential 
centrifugation) and Method D (rapid differential centrifugation) all gave modest 
positive enrichments of 2.4-, 1.7- and 2.9- fold respectively. Although giving one 
of the lowest yields (3.2µg), the optimal method for enrichment relative to 
ncDNA was Method E (magnetic-microbeads), which gave a 10.7-fold 
enrichment, and was the only method to show significantly more copies of 
mtDNA/ncDNA copy compared to phenol: chloroform extraction (P=1.88E-03). 
Using this method we saw a significant enrichment of mtDNA/ncDNA compared 
to Methods A (P=0.019), B (P=6.97x10-4) and C (P=8.48x10-3). 
 
4.4.2. Validation using NGS Technologies 
To validate our enrichment, two of the biological replicates from Method E were 
compared to a non-enriched standard from phenol: chloroform (Method F) 
extraction using NGS. For the non-enriched standard 1.1% of reads mapped to 
the mitochondrial genome, compared to an average of 18.7% (16.2% and 
21.2% respectively) of reads with Method E, demonstrating an average 16.8 
fold enrichment in mtDNA. 
 
4.5. Discussion 
A previous in vitro study by Hornig-Do et al has shown that magnetic-
microbeads gives greater yields of mitochondria compared to both Percoll and 
differential centrifugation in an osteosarcoma cell line (236). However, although 
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increased yield of mitochondrial organelles was demonstrated, they showed the 
relative purity of mtDNA compared to ncDNA was similar between Percoll and 
magnetic-microbeads. In the context of genomic studies of mtDNA, where the 
exclusion of NUMTs is imperative, the relative enrichment of mtDNA is of far 
greater importance than the yield. Thus, although we saw a lower yield with 
magnetic-microbeads compared to the majority of methods tested, Method E 
gave the greatest purity. The reasons for the observed greater enrichment of 
mtDNA/ncDNA relative to Method A in our study compared to the analysis by 
Hornig-Do and colleagues potentially may include i) our use of qRT-PCR, which 
is more sensitive than western blot and ii) our use of frozen, archived samples, 
rather than fresh samples, which may lead to more fragile mitochondria that 
could degrade at higher centrifugation speeds. 
 
4.6. Conclusion 
To our knowledge this study represents the first to systematically compare and 
contrast methods for isolating mtDNA from small quantities of frozen, archived, 
post-mortem human brain. Our findings suggest that magnetic-microbeads 
provide a significant enrichment of mtDNA compared to any other method 
tested. This may be due to a number of reasons, for example the automated 
homogenisation of tissue in this protocol could provide a more consistent and 
gentle approach than other techniques and the use of magnetically labelled 
antibodies provides a specific capture of intact mitochondria, which may also 
contain less degraded mtDNA. We recommend that given the current interest in 
studying the mitochondrial genome in human brain, that the magnetic-
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microbead method from Miltenyi Biotech is used prior to DNA extraction to 
minimise the inclusion of NUMTs in downstream analyses. 
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Chapter 5. A Genome-wide Interrogation of MtDNA Methylation via NGS 
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5.1. Aims 
1. To develop a methodology capable of interrogating the mitochondrial 
epigenome at single cytosine resolution. 
2. To employ this methodology to investigate the associations between 
mtDNA methylation and each of age, sex and tissue type. 
 
5.2. Introduction 
Mitochondria are unique organelles in that they have their own genome, 
~16.6kb in size. MtDNA consists of 37 genes, 22 encoding for tRNAs, two for 
rRNAs and 13 encoding for proteins in the ETC. The ETC consists of 97 genes; 
in addition to the 13 mitochondrial-encoded genes, an additional 84 are 
encoded by the nuclear genome and imported into the mitochondrion (237). 
ETC proteins are directly involved in the regulation of cellular respiration, 
generating the majority of ATP required for the process. However, mitochondria 
play a vital role in a variety of key biological functions, including apoptosis, as 
reviewed in (238), the regulation of Ca2+ homeostasis (239,240) and the 
production of ROS (241). 
 
Epigenetic processes mediate the reversible regulation of gene expression, 
occurring independently of DNA sequence variation and acting principally 
through chemical modifications to DNA and nucleosomal histone proteins. Of all 
the epigenetic marks, DNA methylation is the most stable and well-studied (4). 
The advent of cost-effective epigenome-wide technologies, such as the Illumina 
450K array and its successor, the Illumina Infinium EPIC Beadchip Array, have 
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led to the identification of differentially methylated genes in a range of complex 
diseases, including AD (95,216,242,243), schizophrenia (244), cancer  
(245,246) and type I diabetes (247). However, one caveat of this approach is 
the complete absence of coverage of the mitochondrial genome. Recent studies 
have suggested a role for differential mtDNA methylation in numerous 
pathologies characterised by mitochondrial dysfunction, including cancer (248), 
amyotrophic lateral sclerosis (249), and AD (1,250). However, until recently 
studies have been limited to low-resolution immunohistochemical techniques 
(72) or candidate based approaches such as BS-pyrosequencing (251). To 
date, the only studies to investigate epigenome-wide mtDNA methylation have 
utilized publicly available MeDIP-Seq datasets (63,64,252). However, these 
studies are limited to a semi-quantitative calling of regional methylation in 
windows. Furthermore, the presence of NUMTs in the nuclear genome leads to 
the requirement for the removal of homologous regions from the analysis 
(63,64) and, as such, only a truncated sequence can be analysed accurately.  
 
We have previously shown in Chapter 4 that a commercially available method 
from Miltenyi Biotec, which magnetically isolates mitochondria using anti-
TOM22 antibodies, gives a significant enrichment of mtDNA to ncDNA (202). 
Here, we combine this method with a customised, targeted bisulphite 
sequencing approach to allow us to specifically investigate mtDNA methylation 
patterns in post-mortem brain samples at single nucleotide resolution along the 
entire 16.569kb genome.  
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5.3. Methods 
 
5.3.1. Sample Demographics for Chapter 5 
200mg sections of brain tissue were obtained from seven donors archived in the 
LBB (http://www.kcl.ac.uk/iop/depts/cn/research/MRC-London-
Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-
Diseases-Brain-Bank.aspx). From each donor we sourced matched superior 
STG and CER brain tissue. The donors were selected based upon a similar 
age, distribution of sex across the group, low post-mortem intervals and no 
evidence of neurodegenerative disease. Sample demographics are provided in 
Table 5.1. 
 
Table 5.1: Demographic information for samples used in Chapter 5. Brain 
tissue was collected from seven donors archived in the LBB. For each donor 
two brain regions, the STG and CER were collected. Samples selected for the 
study had a low-post-mortem interval (compared to other samples available), no 
evidence of neurodegenerative disease and a similar age and distribution of sex 
across the group.  
Individual Age at Death 
(Years) 
Sex Post-Mortem 
Interval (hours) 
1 82 Female 43 
2 81 Female 17 
3 80 Female 3 
4 86 Male 6 
5 87 Female 22 
6 81 Male 18 
7 77 Male 11 
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5.3.2. Mitochondrial Isolation 
Mitochondria were isolated from frozen, post-mortem brain tissue according to 
the protocol outlined in Section 2.3.4. MtDNA was further enriched through the 
use of a custom library designed to amplify the mitochondrial genome (Agilent 
Technologies, California, U.S.A.) as described in Section 2.3.6. To test for the 
effect of enrichment on mtDNA methylation levels, matched nuclear isolates 
from both STG and CER were kept and sequenced for individual 4. MtDNA 
methylation levels in nuclear isolates were then compared to mtDNA 
methylation levels of pre-enriched mitochondria for this individual.  
 
5.3.3. Custom Capture of the Mitochondrial Epigenome 
To capture the mitochondrial epigenome, a custom library of RNA baits (Agilent, 
California, U.S.A.: Design ID 0687721) were designed to provide 100% 
coverage of the genome at 5x tiling density. Isolated mtDNA extracted from 
frozen, archived brain tissue was subjected to an adapted version of the Agilent 
1μg Methyl-Seq protocol (described in detail in Section 2.3.6). After generating 
indexed libraries for each sample, samples were pooled in equimolar 
concentrations and sequenced using the Illumina HiSeq 2500 by Exeter 
Sequencing Service (Exeter, U.K.) to generate 16 fastq files, processed in 
house. 
 
5.3.4. Analytical Workflow  
After sequencing, 100bp paired-end reads were de-multiplexed and, following 
quality assessment using FastQC, were trimmed for adaptor content using 
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TrimGalore (253). Using the same package, we also trimmed the first base-pair 
from the 3’ end of both reads. Trimmed files were then aligned to the reference 
human mitochondrial genome, rCRS, through Bismark, using Bowtie 1 (204). 
Mapped reads were then de-duplicated using the deduplicate_bismark function, 
before CpG and non-CpG methylation was called using 
bismark_methylation_extractor function. All statistical analyses were carried out 
in R (v3.3.0) (254). Our initial analysis aimed to control for the matched nature 
of our different tissue samples by running a mixed effect model.  
 
Briefly, this model used each of the covariates of interest (age, sex and tissue 
type) as fixed effects and the individual as the random effect. To determine the 
significance and effect size of each covariate in isolation at each methylated 
cytosine identified, a second (null) model was created, which didn’t contain the 
covariate of interest. An analysis of variance (ANOVA) was then performed 
between the two models to identify significantly differentially methylated bases 
for each covariate. We also performed post-hoc analyses to determine the 
effect of sex and age within each brain region independently. This analysis 
consisted of two linear regressions, one for each tissue. Quantile-quantile (Q-Q) 
plots were used to check for P-value inflation in all models used for sex (Figure 
5.1.A), age (Figure 5.1.B.) and for tissue (Figure 5.1.C.). Throughout all 
analyses, nominally significant P values were defined as P<0.05. A Bonferroni 
correction value of 5.734E-05 was determined. Q values were also determined 
using a Benjamani-Hochberg correction for multiple testing. To test for 
enrichment of trends found within our cohort, a Fisher’s exact test was carried 
out using an in-built function within the R environment (254), 
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Figure 5.1: Composite quantile-quantile (QQ) plots for P Value dispersion. The expected P values are plotted against those 
observed in the data to check for P Value inflation in our multi-model level analysis. This analysis was performed for (A) sex, (B) age and 
(C) tissue type.  
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5.4. Results 
 
5.4.1. MtDNA Methylation Levels Differ Depending upon Level of Enrichment 
Prior to Sequencing 
On average, 723,765 reads mapped to the mitochondrial reference genome per 
sample, providing an average sequencing depth of 3019 times. To test whether 
methylation levels differ between enriched and non-enriched mtDNA, nuclear 
and mitochondrial isolates derived from matched STG and CER samples from 
one individual were processed at the same time and sequenced. On average, 
58% of reads mapped to the mitochondrial genome, suggesting a large 
enrichment for mtDNA, exceeding levels previously reported through the use of 
antibody-based enrichment alone (202).  
 
In total, 870 variably methylated cytosines sites, sites where varying calls of 
methylation are detected upon sequencing, were captured for all samples. To 
determine the effect of enrichment, the standard error for each site was 
calculated within each enriched sample. DNA methylation levels were then 
compared between the matched enriched and non-enriched samples. Sites with 
differences greater than the standard error for that tissue type were said to be 
enriched. In total, only 167 of 870 sites were unaffected by the enrichment for 
STG. However, 679 of 870 probes were unaffected by the enrichment process 
in CER. 
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5.4.2. MtDNA Methylation Occurs with Distinct Prevalence at non-CpG sites 
NcDNA methylation occurs with a high prevalence in CpG contexts in 
mammalian cell lines and human brain tissue (255). However, a previous study 
has indicated a potential prevalence for non-CpG methylation in mtDNA (256), 
particularly in the D-LOOP. To investigate this further, we found that mtDNA 
methylation occurs at low levels and with a striking prevalence at non-CpG 
sites, with an average of 81% (S.D = 0.74) of all mtDNA methylation sites being 
found in a non-CpG context across the samples in our study (Table 5.2). 
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Table 5.2: Table highlighting sequencing quality of samples. For each 
sample, the mapping efficiency, total number of reads mapped, sequencing 
depth and percentage of non-CpG methylated cytosines were calculated. High 
levels of non-CpG methylated cytosines were found in all samples. NC 
corresponds to samples taken from the nuclear pellet of these isolations prior to 
mitochondrial isolation. Averages were only taken from mitochondrial isolates. 
 
 
 
 
Sample 
Mapping 
Efficiency 
(%) 
Total Reads 
Mapped After 
Deduplication 
Sequencing 
Depth 
Total 
Methylated 
Cytosines 
in Non-CpG 
Context (%) 
1-STG 44.60% 364292 2198.64 80.68 
1-CER 48.20% 364292 2198.64 80.91 
2-STG 60.10% 250010 1508.90 81.62 
2-CER 53.80% 1258516 7595.61 81.94 
3-STG 56.50% 395091 2384.52 81.64 
3-CER 71.30% 351541 2121.68 80.38 
4-STG 84.60% 728332 4395.75 80.63 
4NC-STG 82.90% 687317 4148.21 79.71 
4-CER 83.90% 945709 5707.70 80.24 
4NC-CER 72.90% 1085810 6553.26 79.19 
5A-STG 35.20% 356999 2154.62 81.09 
5B-CER 27.70% 191466 1155.57 81.64 
6A-STG 74.40% 697378 4208.93 81.12 
6B-CER 74.50% 516986 3120.20 81.66 
7A-STG 57.40% 369870 2232.30 81.21 
7B-CER 37.00% 213705 1289.79 80.88 
Average STG 58.97% 451710 2726.24 81.14 
Average CER 56.63% 548888 3312.74 81.09 
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5.4.3. MtDNA Methylation Exhibits Sex-Specific Patterns Across the Genome 
Given that ncDNA methylation patterns can be strongly associated with sex 
(257), we were interested to see whether the mtDNA methylome exhibited sex-
specific patterns. Our initial multi-level model identified 131 nominally significant 
differentially methylated positions (DMPs). Two sites, at 8722bp (MT-ATP6; 
P=2.05x10-06) and 9055bp (MT-ATP6; P=1.95x10-5) passed the strict Bonferroni 
correction for multiple testing (Figure 5.2). In total five sites passed a less strict 
Benjamani-Hochberg correction for multiple testing (Table 5.3): 8722bp (MT-
ATP6; Q=6.562E-03), 9055bp (MT-ATP6; Q=0.0297), 7019bp (MT-CO1; 
Q=0.0297), 499bp (D-LOOP; Q=0.0297) and 14559bp (MT-ND6; Q=0.0395).  
  
To test whether one particular tissue was more responsible for driving these 
changes we ran two linear regression models, one in each tissue type, with age 
and sex as covariates. This allowed for an estimation of the effect of both 
covariates on each position. Our analysis identified a total of 97 nominally 
significant DMPs (P<0.05) for sex in the STG and 32 in the CER (Table 5.3). Of 
these, five were found to be significant in both tissues and shared the same 
direction of methylation between tissue types; 499bp (D-LOOP) and 9055bp 
(Mitochondrially Encoded ATP Synthase 6; MT-ATP6) were found to be 
hypermethylated in females whilst 8722bp (MT-ATP6), 14,269bp 
(Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit; MT-
ND6) and 15,761bp (MT-CYB) were found to be hypermethylated in males.  
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Further, our analysis revealed a tendency towards hypermethylation in females 
in both tissues. In total, 23 of the 33 and 89 of the 97 nominally significant 
differentially methylated positions (DMPs) were hypermethylated in CER and 
STG females respectively. To determine whether the direction of methylation 
change at these sites represented a significant enrichment a Fisher’s exact test 
was performed on each brain region, demonstrating a significant enrichment in 
the STG (P=0.003; Odds Ratio=2.743) and a trend for enrichment in the CER 
(P=0.137; Odds Ratio=1.623). 
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Figure 5.2: Composite boxplots to show sex-associated DMPs identified in both CER and STG, which survived Bonferroni 
correction in our mixed model, 8722bp (left) and 9055bp (right). 
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Genomic 
Position 
(bp) 
Gene Complex Effect 
Size MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
62 D-LOOP NCR N.S N.S N.S N.S 0.147 4.580E-03 
316 D-LOOP NCR -1.003 7.478E-03 N.S N.S N.S N.S 
498 D-LOOP NCR -7.345 0.010 N.S N.S N.S N.S 
499 D-LOOP NCR 1.307 1.370E-04 1.098 0.011 1.516 0.011 
526 D-LOOP NCR N.S N.S N.S N.S -0.559 0.040 
545 D-LOOP NCR -3.002 2.531E-03 -3.133 0.011 N.S N.S 
739 MT-RNR1 rRNA N.S N.S N.S N.S -0.408 0.031 
785 MT-RNR1 rRNA N.S N.S 0.936 0.012 N.S N.S 
809 MT-RNR1 rRNA N.S N.S N.S N.S -0.446 0.039 
900 MT-RNR1 rRNA N.S N.S N.S N.S -0.489 0.020 
932 MT-RNR1 rRNA N.S N.S N.S N.S -0.901 0.025 
1023 MT-RNR1 rRNA -0.926 0.011 N.S N.S N.S N.S 
1024 MT-RNR1 rRNA -0.251 5.312E-03 N.S N.S -0.446 0.028 
1146 MT-RNR1 rRNA N.S N.S N.S N.S -0.594 0.039 
1177 MT-RNR1 rRNA -0.645 9.298E-03 N.S N.S -1.217 6.000E-03 
1217 MT-RNR1 rRNA -0.214 0.033 -0.254 0.030 N.S N.S 
1262 MT-RNR1 rRNA -1.009 1.406E-03 N.S N.S -1.484 0.025 
Table 5.3: Nominally significant DMPs associated with sex. In total 131 DMPs were nominally associated with sex in our 
multi-level model, 97 in STG and 32 in CER. Hypermethylation in females is indicated by a negative effect size value. 
Abbreviations: C1 (Complex I), C2 (Complex II), C3 (Complex III), C4 (Complex IV), C5 (Complex V), NCR (non-coding 
region), rRNA (ribosomal RNA), tRNA (transfer RNA), STG (superior temporal gyrus), CER (CER), MM (mixed model), N.S. 
(Not significant). Bold indicates DMPs present in both tissues. 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
1389 MT-RNR1 rRNA -0.105 0.049 -0.165 0.047 N.S N.S 
1473 MT-RNR1 rRNA -0.877 2.567E-03 -1.103 0.026 N.S N.S 
1475 MT-RNR1 rRNA N.S N.S -0.523 0.045 N.S N.S 
1489 MT-RNR1 rRNA -0.179 0.028 N.S N.S N.S N.S 
1561 MT-RNR1 rRNA -0.784 9.879E-03 N.S N.S -1.042 0.020 
1916 Mt-RNR2 rRNA -0.192 8.703E-03 -0.174 0.026 N.S N.S 
2566 Mt-RNR2 rRNA 0.342 0.049 N.S N.S 0.651 0.044 
2643 Mt-RNR2 rRNA N.S N.S N.S N.S -0.608 0.023 
2491 Mt-RNR2 rRNA -1.040 0.016 N.S N.S N.S N.S 
2809 Mt-RNR2 rRNA 0.640 0.021 N.S N.S 0.894 0.038 
2810 Mt-RNR2 rRNA -0.260 0.040 N.S N.S N.S N.S 
2878 Mt-RNR2 rRNA -0.206 0.010 N.S N.S N.S N.S 
2943 Mt-RNR2 rRNA -0.258 0.022 N.S N.S N.S N.S 
3035 Mt-RNR2 rRNA N.S N.S N.S N.S 0.888 9.000E-03 
3047 Mt-RNR2 rRNA N.S N.S N.S N.S -0.345 0.045 
3254 MT-TL1 tRNA -0.620 0.040 N.S N.S N.S N.S 
3351 MT-ND1 C1 -0.718 0.029 N.S N.S -1.238 0.029 
3407 MT-ND1 C1 N.S N.S N.S N.S -0.151 0.029 
3436 MT-ND1 C1 N.S N.S N.S N.S -0.448 0.021 
3453 MT-ND1 C1 N.S N.S N.S N.S -0.414 0.05 
3531 MT-ND1 C1 -0.775 2.996E-03 N.S N.S N.S N.S 
3699 MT-ND1 C1 -0.446 1.764E-03 N.S N.S N.S N.S 
3922 MT-ND1 C1 N.S N.S N.S N.S -0.213 0.034 
3946 MT-ND1 C1 -0.215 0.020 N.S N.S N.S N.S 
3952 MT-ND1 C1 -0.176 0.045 N.S N.S -0.363 0.027 
4051 MT-ND1 C1 -0.134 9.467E-03 N.S N.S -0.204 0.031 
4127 MT-ND1 C1 N.S N.S N.S N.S -0.096 0.044 
4141 MT-ND1 C1 -1.231 0.041 N.S N.S N.S N.S 
4152 MT-ND1 C1 -0.778 0.047 N.S N.S N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
4153 MT-ND1 C1 -0.227 8.578E-03 N.S N.S -0.335 5.000E-03 
4375 MT-TQ tRNA -0.916 0.017 N.S N.S N.S N.S 
4426 MT-TM tRNA -0.491 0.029 N.S N.S -0.962 0.047 
4463 MT-TM tRNA -0.501 0.036 N.S N.S -0.519 0.007 
4490 MT-ND2 C1 N.S N.S 0.491 0.027 N.S N.S 
4531 MT-ND2 C1 N.S N.S N.S N.S N.S N.S 
4995 MT-ND2 C1 N.S N.S N.S N.S -0.601 0.034 
5164 MT-ND2 C1 N.S N.S N.S N.S -0.192 0.025 
5237 MT-ND2 C1 -0.210 3.134E-03 N.S N.S -0.303 0.012 
5271 MT-ND2 C1 N.S N.S N.S N.S -0.267 0.039 
5399 MT-ND2 C1 N.S N.S N.S N.S -1.557 0.023 
5737 N NA N.S N.S N.S N.S -0.534 0.016 
5743 N NCR N.S N.S N.S N.S -0.805 0.025 
5910 MT-CO1 C4 -0.167 0.033 N.S N.S -0.289 0.02 
5913 MT-CO1 C4 N.S N.S N.S N.S -0.25 0.042 
5972 MT-CO1 C4 N.S N.S -0.727 0.023 N.S N.S 
6020 MT-CO1 C4 -0.390 0.031 N.S N.S N.S N.S 
6069 MT-CO1 C4 -0.140 0.046 N.S N.S N.S N.S 
6128 MT-CO1 C4 -0.620 0.033 N.S N.S N.S N.S 
6164 MT-CO1 C4 -0.702 0.043 N.S N.S -1.461 0.032 
6181 MT-CO1 C4 -0.642 0.046 N.S N.S N.S N.S 
6190 MT-CO1 C4 -0.196 2.639E-03 N.S N.S -0.246 0.047 
6464 MT-CO1 C4 N.S N.S -0.42 2.33E-03 N.S N.S 
6563 MT-CO1 C4 -0.603 0.014 N.S N.S N.S N.S 
6572 MT-CO1 C4 -0.656 0.018 N.S N.S -1.191 0.032 
6824 MT-CO1 C4 -0.426 0.019 N.S N.S N.S N.S 
6876 MT-CO1 C4 -0.172 0.016 N.S N.S -0.212 4.67E-03 
7007 MT-CO1 C4 -0.679 0.013 N.S N.S N.S N.S 
7012 MT-CO1 C4 -0.643 0.033 -0.562 3.95E-03 N.S N.S 
7019 MT-CO1 C4 -1.176 1.343E-04 -1.612 7.13E-03 N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
7161 MT-CO1 C4 N.S N.S N.S N.S -0.381 0.02 
7332 MT-CO1 C4 N.S N.S N.S N.S -0.213 0.048 
7599 MT-CO2 C4 -0.925 0.044 -1.148 0.029 N.S N.S 
7757 MT-CO2 C4 N.S N.S -0.251 0.049 N.S N.S 
7792 MT-CO2 C4 -0.923 4.513E-03 -0.882 4.89E-03 N.S N.S 
7813 MT-CO2 C4 -0.827 0.015 N.S N.S N.S N.S 
7849 MT-CO2 C4 N.S N.S N.S N.S 0.551 0.016 
7859 MT-CO2 C4 N.S N.S N.S N.S -0.143 0.021 
7910 MT-CO2 C4 -0.108 0.016 N.S N.S N.S N.S 
7928 MT-CO2 C4 -0.228 6.582E-03 -0.229 1.45E-03 N.S N.S 
7978 MT-CO2 C4 -0.663 3.750E-03 N.S N.S N.S N.S 
7979 MT-CO2 C4 N.S N.S N.S N.S -0.346 0.012 
8036 MT-CO2 C4 N.S N.S -0.558 0.041 N.S N.S 
8140 MT-CO2 C4 0.495 0.032 N.S N.S N.S N.S 
8213 MT-CO2 C4 N.S N.S N.S N.S -0.237 8.85E-03 
8387 MT-ATP8 C5 N.S N.S N.S N.S -0.439 0.019 
8584 MT-ATP6 C5 -0.727 0.046 N.S N.S N.S N.S 
8722 MT-ATP6 C5 -1.547 7.560E-06 -1.649 1.04E-03 -1.446 4.20E-03 
8879 MT-ATP6 C5 -0.179 0.011 N.S N.S N.S N.S 
8958 MT-ATP6 C5 -1.089 9.311E-03 N.S N.S -1.729 0.012 
9009 MT-ATP6 C5 -0.875 5.939E-04 N.S N.S -1.045 0.038 
9010 MT-ATP6 C5 N.S N.S N.S N.S -0.153 0.033 
9055 MT-ATP6 C5 0.519 7.934E-05 0.571 7.78E-03 0.467 6.38E-03 
9195 MT-ATP6 C5 N.S N.S N.S N.S -0.985 0.047 
9381 MT-CO3 C4 -0.736 0.019 -1.163 0.021 N.S N.S 
9384 MT-CO3 C4 -0.174 0.048 N.S N.S N.S N.S 
9449 MT-CO3 C4 -0.575 0.022 N.S N.S N.S N.S 
9488 MT-CO3 C4 -0.704 0.048 N.S N.S N.S N.S 
9774 MT-CO3 C4 -0.148 7.120E-03 N.S N.S -0.272 0.016 
9786 MT-CO3 C4 -0.295 0.020 N.S N.S N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
9828 MT-CO3 C4 -0.161 0.012 N.S N.S -0.231 3.00E-03 
10067 MT-ND3 C1 N.S N.S N.S N.S -0.949 0.038 
10142 MT-ND3 C1 -0.976 8.609E-03 N.S N.S -1.275 0.04 
10143 MT-ND3 C1 -0.288 7.821E-03 N.S N.S -0.477 0.035 
10176 MT-ND3 C1 -0.345 0.021 N.S N.S N.S N.S 
10197 MT-ND3 C1 -0.213 0.033 N.S N.S N.S N.S 
10200 MT-ND3 C1 -0.750 0.038 N.S N.S -1.396 0.043 
10202 MT-ND3 C1 -0.639 6.312E-03 N.S N.S N.S N.S 
10203 MT-ND3 C1 N.S N.S N.S N.S -0.451 0.020 
10436 MT-TR tRNA -1.690 0.015 N.S N.S N.S N.S 
10586 MT-ND4L C1 -0.277 0.011 N.S N.S N.S N.S 
11126 MT-ND4 C1 -0.185 0.011 N.S N.S -0.324 2.00E-03 
11389 MT-ND4 C1 -0.576 0.038 N.S N.S N.S N.S 
11422 MT-ND4 C1 -0.689 0.032 N.S N.S N.S N.S 
11690 MT-ND4 C1 -0.243 2.970E-03 N.S N.S -0.39 0.024 
11693 MT-ND4 C1 N.S N.S N.S N.S -0.23 0.047 
11716 MT-ND4 C1 0.461 0.038 N.S N.S N.S N.S 
11914 MT-ND4 C1 0.384 0.013 N.S N.S N.S N.S 
12053 MT-ND4 C1 -1.502 4.841E-03 N.S N.S N.S N.S 
12054 MT-ND4 C1 -0.159 0.011 N.S N.S -0.265 0.033 
12192 MT-TH tRNA -0.152 0.047 N.S N.S N.S N.S 
12207 MT-TS2 tRNA -0.254 0.024 -0.207 0.029 N.S N.S 
12456 MT-ND5 C1 -1.363 0.040 N.S N.S N.S N.S 
12457 MT-ND5 C1 -0.125 0.029 N.S N.S N.S N.S 
12528 MT-ND5 C1 N.S N.S N.S N.S N.S N.S 
12813 MT-ND5 C1 N.S N.S N.S N.S -0.423 0.034 
12814 MT-ND5 C1 -0.187 6.048E-03 N.S N.S -0.303 0.049 
12868 MT-ND5 C1 -0.230 0.043 N.S N.S -0.499 0.047 
12871 MT-ND5 C1 -0.148 0.045 N.S N.S -0.279 0.047 
13121 MT-ND5 C1 N.S N.S N.S N.S -0.349 0.048 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
13210 MT-ND5 C1 -0.268 6.665E-04 N.S N.S -0.38 0.01 
13288 MT-ND5 C1 -0.216 0.037 N.S N.S N.S N.S 
13322 MT-ND5 C1 -0.461 0.043 N.S N.S N.S N.S 
13336 MT-ND5 C1 -0.244 0.045 N.S N.S N.S N.S 
13406 MT-ND5 C1 N.S N.S N.S N.S -0.119 0.041 
13530 MT-ND5 C1 N.S N.S N.S N.S -0.846 0.037 
13551 MT-ND5 C1 -0.714 0.024 N.S N.S -0.945 0.035 
13596 MT-ND5 C1 -0.556 0.050 N.S N.S N.S N.S 
13597 MT-ND5 C1 -0.207 1.857E-03 N.S N.S -0.271 0.033 
13610 MT-ND5 C1 -0.285 0.024 N.S N.S N.S N.S 
13643 MT-ND5 C1 -0.566 0.028 N.S N.S -0.814 0.047 
13703 MT-ND5 C1 -0.179 0.044 N.S N.S N.S N.S 
13758 MT-ND5 C1 -0.858 0.028 -1.098 7.63E-04 N.S N.S 
13915 MT-ND5 C1 -0.284 8.943E-04 N.S N.S -0.452 0.01 
13940 MT-ND5 C1 -0.214 0.023 N.S N.S N.S N.S 
14160 MT-ND6 C1 -0.345 0.022 N.S N.S -0.445 0.023 
14226 MT-ND6 C1 N.S N.S 0.168 0.039 N.S N.S 
14249 MT-ND6 C1 -0.326 1.939E-03 -0.214 0.023 -0.437 0.033 
14384 MT-ND6 C1 -0.234 0.013 N.S N.S N.S N.S 
14559 MT-ND6 C1 -3.281 2.507E-04 N.S N.S -4.35 0.002 
14568 MT-ND6 C1 -2.704 0.020 N.S N.S N.S N.S 
14697 MT-TE tRNA -0.833 0.038 N.S N.S N.S N.S 
14680 MT-TE tRNA N.S N.S N.S N.S -1.265 0.036 
14698 MT-TE tRNA N.S N.S N.S N.S -0.283 0.042 
14720 MT-TE tRNA -1.369 9.117E-03 N.S N.S -1.943 0.016 
14759 MT-CYB C3 -0.879 0.012 N.S N.S -1.115 0.046 
14831 MT-CYB C3 -0.187 0.017 N.S N.S N.S N.S 
14945 MT-CYB C3 0.089 0.045 0.147 0.037 N.S N.S 
14963 MT-CYB C3 N.S N.S N.S N.S N.S N.S 
14996 MT-CYB C3 N.S N.S N.S N.S -0.236 0.028 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size 
MM 
Significance 
Level (P) MM 
Effect 
Size CER 
Significance 
Level (P) 
CER 
Effect 
Size STG 
Significance 
Level (P) 
STG 
15005 MT-CYB C3 -0.171 0.042 N.S N.S N.S N.S 
15044 MT-CYB C3 N.S N.S -0.468 0.043 N.S N.S 
15045 MT-CYB C3 -0.218 0.027 N.S N.S -0.248 0.037 
15148 MT-CYB C3 -0.263 0.011 N.S N.S N.S N.S 
15199 MT-CYB C3 N.S N.S N.S N.S -0.726 0.049 
15391 MT-CYB C3 N.S N.S N.S N.S -0.956 0.046 
15431 MT-CYB C3 -0.225 7.557E-03 N.S N.S -0.304 0.042 
15500 MT-CYB C3 -0.238 0.024 N.S N.S N.S N.S 
15590 MT-CYB C3 -0.473 0.050 N.S N.S -1.099 0.030 
15591 MT-CYB C3 -0.275 9.043E-03 N.S N.S -0.45 9.39E-03 
15595 MT-CYB C3 -0.986 4.346E-03 N.S N.S N.S N.S 
15616 MT-CYB C3 -0.663 0.013 N.S N.S N.S N.S 
15761 MT-CYB C3 -0.374 2.732E-04 -0.491 1.15E-03 -0.257 0.028 
15811 MT-CYB C3 -1.576 2.328E-03 -1.471 0.027 N.S N.S 
15812 MT-CYB C3 N.S N.S 0.09 0.037 N.S N.S 
16083 D-LOOP NCR -1.498 0.022 N.S N.S N.S N.S 
16129 D-LOOP NCR N.S N.S N.S N.S -0.515 9.44E-03 
16329 D-LOOP NCR -0.159 0.048 N.S N.S -0.303 0.012 
16495 D-LOOP NCR 0.547 7.115E-03 N.S N.S 0.765 0.025 
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5.4.4. MtDNA Methylation Varies Significantly between Different Anatomical 
Regions of the Brain 
Given that we have recently identified tissue-specific DMRs in mtDNA across 
different brain regions using MeDIP-Seq (Chapter 3) (64), we were interested in 
investigating whether differences in mtDNA could be identified at single cytosine 
resolution between anatomically distinct brain regions. In our multi-level model, 
we identified 80 nominally significant (P<0.05) differences in mtDNA 
methylation across the genome that were associated with tissue type, of which 
57 were found to be hypermethylated in CER relative to STG (Table 5.4).  
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Table 5.4: Nominally significant DMPs associated with tissue type. In total 
80 tissue specific DMPs were identified between STG and CER, shown here in 
order of significance. Positive effect sizes represent hypermethylation in the 
CER compared to the superior temporal gyrus. Abbreviations: C1 (Complex I), 
C2 (Complex II), C3 (Complex III), C4 (Complex IV), C5 (Complex V), NCR 
(non-coding region), rRNA (ribosomal RNA), tRNA (transfer RNA). 
 
Genomic 
Position (bp) Gene Complex 
Effect 
Size 
Significance Level 
(P) 
14846 MT-CYB C3 0.233 2.159E-04 
6563 MT-CO1 C4 -0.996 2.242E-04 
14945 MT-CYB C3 0.188 2.514E-04 
3699 MT-ND1 C1 -0.503 3.343E-04 
13198 MT-ND5 C1 0.110 1.465E-03 
4712 MT-ND2 C1 1.631 1.902E-03 
1216 MT-RNR1 rRNA -0.828 2.154E-03 
5756 N NCR 0.325 2.423E-03 
8580 MT-ATP6 C5 1.350 2.809E-03 
9673 MT-CO3 C4 0.209 3.283E-03 
6824 MT-CO1 C4 0.424 3.554E-03 
10670 MT-ND4L C1 -0.575 3.751E-03 
6015 MT-CO1 C4 0.434 4.413E-03 
10202 MT-ND3 C1 0.639 4.651E-03 
12735 MT-ND5 C1 0.965 4.685E-03 
9776 MT-CO3 C4 0.558 4.959E-03 
16454 D-LOOP NCR 0.657 5.208E-03 
2718 MT-RNR2 rRNA 0.781 5.426E-03 
13669 MT-ND5 C1 0.229 5.518E-03 
3406 MT-ND1 C1 -0.732 6.134E-03 
11717 MT-ND4 C1 0.260 6.446E-03 
1537 MT-RNR1 rRNA -0.845 6.464E-03 
10536 MT-ND4L C1 -1.696 6.720E-03 
1314 MT-RNR1 rRNA 1.056 7.333E-03 
9773 MT-CO3 C4 0.651 7.361E-03 
9294 MT-CO3 C4 -0.233 8.445E-03 
12876 MT-ND5 C1 -0.505 9.341E-03 
6020 MT-CO1 C4 0.323 0.010 
7859 MT-CO2 C4 0.152 0.011 
15590 MT-CYB C3 0.629 0.011 
13524 MT-ND5 C1 0.498 0.012 
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Genomic 
Position (bp) Gene Complex 
Effect 
Size 
Significance Level 
(P) 
11163 MT-ND4 C1 0.134 0.012 
1488 MT-RNR1 rRNA -1.085 0.013 
12813 MT-ND5 C1 0.371 0.014 
3453 MT-ND1 C1 -0.553 0.014 
4996 MT-ND2 C1 0.208 0.015 
6329 MT-CO1 C4 0.497 0.015 
8114 MT-CO2 C4 0.290 0.015 
2809 MT-RNR2 rRNA 0.657 0.016 
6456 MT-CO1 C4 0.184 0.017 
6075 MT-CO1 C4 0.099 0.018 
6016 MT-CO1 C4 0.086 0.020 
1226 MT-RNR1 rRNA -0.435 0.020 
33 D-LOOP NCR -0.840 0.021 
6053 MT-CO1 C4 0.429 0.021 
1597 MT-RNR1 rRNA -0.637 0.021 
9828 MT-CO3 C4 0.122 0.021 
6128 MT-CO1 C4 0.392 0.022 
8544 MT-ATP8 C5 0.553 0.023 
3094 MT-RNR2 rRNA 0.601 0.023 
740 MT-RNR1 rRNA -0.161 0.026 
9752 MT-CO3 C4 0.498 0.026 
3889 MT-ND1 C1 -0.637 0.027 
120 D-LOOP NCR 0.647 0.028 
3435 MT-ND1 C1 -0.464 0.028 
15045 MT-CYB C3 0.199 0.029 
187 D-LOOP NCR 0.140 0.030 
11184 MT-ND4 C1 0.099 0.030 
11861 MT-ND4 C1 0.135 0.031 
15005 MT-CYB C3 0.139 0.032 
6808 MT-CO1 C4 -0.104 0.032 
2566 MT-RNR2 rRNA 0.340 0.031 
7130 MT-CO1 C4 -0.446 0.035 
412 D-LOOP NCR 0.199 0.037 
15147 MT-CYB C3 -0.460 0.038 
900 MT-RNR1 rRNA 0.393 0.039 
3127 MT-RNR2 rRNA 0.521 0.039 
1323 MT-RNR1 rRNA 0.184 0.039 
8722 MT-ATP6 C5 -0.286 0.039 
1302 MT-RNR1 rRNA 0.461 0.040 
11004 MT-ND4 C1 0.169 0.040 
5353 MT-ND2 C1 0.184 0.041 
10736 MT-ND4L C1 0.812 0.043 
5053 MT-ND2 C1 -1.278 0.043 
13579 MT-ND5 C1 0.119 0.044 
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Genomic 
Position (bp) Gene Complex 
Effect 
Size 
Significance Level 
(P) 
3946 MT-ND1 C1 0.137 0.045 
15059 MT-CYB C3 0.141 0.045 
8958 MT-ATP6 C5 -0.739 0.047 
3172 MT-RNR2 rRNA 1.149 0.049 
14681 MT-TE tRNA 0.184 0.049 
 
5.4.5. MtDNA Methylation has a Tendency to Increase with Age Across the 
Mitochondrial Genome 
Given that alterations in mitochondrial function have been associated with age, 
as reviewed by Amigo et al. (258), we were interested to investigate whether 
age may alter mtDNA methylation patterns. Our initial multilevel model identified 
128 nominally significant probes associated with age, 119 of which were 
positively correlated with increasing age. Using our post-hoc linear regression 
models defined earlier for CER and STG, we tested this association in both 
tissues separately. Despite the small age range of the samples (77-87, 
mean=82, S.D.=3.46), we were able to identify 59 and 71 nominally significant 
DMPs for age in CER and STG respectively (Table 5.5). There was a positive 
association with age for 40 nominally significant DMPs in CER and 69 nominally 
significant DMPs in STG. In total, only two DMPs were found to be nominally 
significant, with the same direction of methylation change (both 
hypermethylated) in both tissues: 1597bp (MT-RNR1) and 4463bp (MT-TM) 
(Figure 5.3). Given that, for the majority of age-associated DMPs we observed 
hypermethylation with increasing age, we performed a Fisher’s exact test for 
enrichment on each individual tissue. This identified a significant enrichment for 
hypermethylated DMPs in association with increasing age in both the STG 
(P=5.074E-05; Odds Ratio = 8.439) and the CER (P=0.010; Odds Ratio=1.992).  
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Table 5.5: Nominally significant DMPs associated with age. DMPs were identified initially in the multi-level model, also 
shown are results from subsequent post-hoc linear regressions within each tissue seperately. Shown is the direction of effect 
and significance level for each DMP identified in the multi-level model and individual tissue regressions. Positive effect sizes 
show methylation levels positively correlating with age. Probes highlighted in bold indicate consistent DMPs in both 
significance and direction of effect in both CER and STG. Abbreviations: C1 (Complex I), C2 (Complex II), C3 (Complex III), 
C4 (Complex IV), C5 (Complex V), NCR (non-coding region), rRNA (ribosomal RNA), tRNA (transfer RNA), STG (superior 
temporal gyrus), CER (CER), MM (mixed model), N.S. (Not significant) 
Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
62 D-LOOP NCR N.S N.S N.S N.S 0.011 0.044 
80 D-LOOP NCR N.S N.S -0.094 0.043 N.S N.S 
97 D-LOOP NCR N.S N.S N.S N.S 0.040 0.013 
186 D-LOOP NCR -0.263 0.036 N.S N.S N.S N.S 
412 D-LOOP NCR 0.056 1.327E-03 N.S N.S 0.085 2.000E-03 
498 D-LOOP NCR -0.863 0.034 N.S N.S N.S N.S 
525 D-LOOP NCR N.S N.S N.S N.S 0.443 0.032 
545 D-LOOP NCR 0.345 0.011 0.393 0.023 N.S N.S 
739 MT-RNR1 rRNA 0.143 1.223E-03 N.S N.S 0.124 0.003 
808 MT-RNR1 rRNA 0.110 3.033E-03 N.S N.S 0.129 0.014 
900 MT-RNR1 rRNA 0.073 0.018 N.S N.S 0.095 9.31E-03 
932 MT-RNR1 rRNA 0.085 0.036 N.S N.S 0.173 0.012 
935 MT-RNR1 rRNA N.S N.S N.S N.S 0.13 0.041 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
1134 MT-RNR1 rRNA 0.049 4.091E-03 0.049 0.044 N.S N.S 
1146 MT-RNR1 rRNA N.S N.S N.S N.S 0.122 0.016 
1217 MT-RNR1 rRNA N.S N.S -0.038 0.033 N.S N.S 
1226 MT-RNR1 rRNA 0.120 0.030 N.S N.S N.S N.S 
1227 MT-RNR1 rRNA 0.035 0.011 N.S N.S N.S N.S 
1323 MT-RNR1 rRNA -0.033 0.026 N.S N.S N.S N.S 
1561 MT-RNR1 rRNA 0.142 4.348E-03 N.S N.S 0.173 0.015 
1597 MT-RNR1 rRNA 0.226 2.396E-04 0.234 0.045 0.217 0.030 
1750 Mt-RNR2 rRNA N.S N.S -0.091 6.779E-03 N.S N.S 
1916 Mt-RNR2 rRNA -0.025 0.021 -0.033 0.013 N.S N.S 
2202 Mt-RNR2 rRNA 0.315 0.030 N.S N.S N.S N.S 
2203 Mt-RNR2 rRNA 0.045 0.034 N.S N.S N.S N.S 
2566 Mt-RNR2 rRNA -0.054 0.046 N.S N.S N.S N.S 
2824 Mt-RNR2 rRNA 0.114 0.019 N.S N.S N.S N.S 
2878 Mt-RNR2 rRNA 0.025 0.034 N.S N.S N.S N.S 
2988 Mt-RNR2 rRNA N.S N.S N.S N.S -0.173 8.29E-03 
3078 Mt-RNR2 rRNA -0.369 0.011 N.S N.S N.S N.S 
3079 Mt-RNR2 rRNA 0.063 0.016 N.S N.S N.S N.S 
3247 MT-TL1 tRNA 0.231 0.034 N.S N.S N.S N.S 
3248 MT-TL1 tRNA 0.038 0.032 N.S N.S N.S N.S 
3254 MT-TL1 tRNA 0.168 2.662E-03 0.227 0.045 N.S N.S 
3351 MT-ND1 C1 0.103 0.039 N.S N.S N.S N.S 
3352 MT-ND1 C1 0.041 1.101E-03 0.039 0.030 N.S N.S 
3376 MT-ND1 C1 0.041 0.025 N.S N.S 0.063 0.022 
3407 MT-ND1 C1 N.S N.S N.S N.S 0.024 0.026 
3453 MT-ND1 C1 N.S N.S -0.143 0.039 N.S N.S 
3460 MT-ND1 C1 0.052 0.013 N.S N.S 0.085 0.034 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
3496 MT-ND1 C1 N.S N.S -0.047 0.026 N.S N.S 
3526 MT-ND1 C1 0.036 9.772E-03 N.S N.S N.S N.S 
3699 MT-ND1 C1 0.044 0.020 N.S N.S N.S N.S 
3954 MT-ND1 C1 0.125 0.012 0.172 0.048 N.S N.S 
3955 MT-ND1 C1 0.034 8.938E-03 N.S N.S N.S N.S 
3967 MT-ND1 C1 0.025 0.024 0.027 8.626E-04 N.S N.S 
4127 MT-ND1 C1 N.S N.S N.S N.S 0.038 1.82E-03 
4141 MT-ND1 C1 0.288 6.403E-03 0.316 0.026 N.S N.S 
4439 MT-TM tRNA 0.162 2.134E-03 N.S N.S N.S N.S 
4463 MT-TM tRNA 0.167 2.359E-04 0.234 0.019 0.101 3.08E-03 
4490 MT-ND2 C1 0.122 4.461E-03 0.141 3.000E-03 N.S N.S 
4540 MT-ND2 C1 0.093 0.047 N.S N.S N.S N.S 
5054 MT-ND2 C1 0.037 0.013 N.S N.S N.S N.S 
4848 MT-ND2 C1 N.S N.S N.S N.S 0.057 0.039 
5111 MT-ND2 C1 0.460 2.107E-03 N.S N.S 0.759 0.027 
5146 MT-ND2 C1 0.204 0.043 N.S N.S N.S N.S 
5163 MT-ND2 C1 0.329 6.088E-03 0.368 0.045 N.S N.S 
5164 MT-ND2 C1 N.S N.S N.S N.S 0.036 0.013 
5237 MT-ND2 C1 0.020 0.040 N.S N.S 0.041 0.018 
5244 MT-ND2 C1 0.036 0.012 N.S N.S N.S N.S 
5271 MT-ND2 C1 0.021 0.040 N.S N.S 0.039 0.045 
5459 MT-ND2 C1 0.351 0.034 0.687 0.046 N.S N.S 
5470 MT-ND2 C1 0.274 0.030 0.492 0.035 N.S N.S 
5737 N NCR N.S N.S N.S N.S 0.074 0.023 
5768 MT-TC tRNA N.S N.S N.S N.S 0.066 0.03 
5972 MT-CO1 C4 N.S N.S -0.118 0.020 N.S N.S 
5973 MT-CO1 C4 0.022 0.013 N.S N.S 0.035 0.040 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
6016 MT-CO1 C4 0.012 0.033 N.S N.S N.S N.S 
6020 MT-CO1 C4 0.062 0.027 N.S N.S N.S N.S 
6165 MT-CO1 C4 0.031 0.020 0.046 0.039 N.S N.S 
6263 MT-CO1 C4 N.S N.S 0.100 0.039 N.S N.S 
6464 MT-CO1 C4 0.132 7.709E-03 N.S N.S N.S N.S 
6564 MT-CO1 C4 N.S N.S 0.140 1.204E-04 N.S N.S 
6572 MT-CO1 C4 0.098 0.021 0.147 0.022 N.S N.S 
6689 MT-CO1 C4 0.217 3.436E-03 N.S N.S 0.249 0.034 
6808 MT-CO1 C4 0.015 0.049 N.S N.S N.S N.S 
6824 MT-CO1 C4 0.067 0.018 N.S N.S N.S N.S 
6852 MT-CO1 C4 0.040 0.031 N.S N.S N.S N.S 
6855 MT-CO1 C4 0.022 0.047 N.S N.S N.S N.S 
6876 MT-CO1 C4 N.S N.S N.S N.S 0.024 0.014 
7012 MT-CO1 C4 0.126 0.012 0.178 2.534E-04 N.S N.S 
7160 MT-CO1 C4 0.092 7.440E-03 N.S N.S N.S N.S 
7161 MT-CO1 C4 N.S N.S N.S N.S 0.050 0.035 
7218 MT-CO1 C4 N.S N.S -0.175 0.010 N.S N.S 
7427 MT-CO1 C4 0.097 0.048 N.S N.S N.S N.S 
7462 MT-TS1 tRNA 0.088 0.032 0.121 0.037 N.S N.S 
7600 MT-CO2 C4 0.035 7.255E-03 N.S N.S N.S N.S 
7775 MT-CO2 C4 N.S N.S N.S N.S 0.015 0.019 
7849 MT-CO2 C4 -0.089 0.038 N.S N.S -0.108 6.92E-03 
7859 MT-CO2 C4 N.S N.S N.S N.S 0.022 0.023 
7928 MT-CO2 C4 0.031 0.012 0.030 3.000E-03 N.S N.S 
7978 MT-CO2 C4 0.077 0.020 N.S N.S N.S N.S 
7979 MT-CO2 C4 N.S N.S N.S N.S 0.045 0.020 
7997 MT-CO2 C4 0.015 0.048 N.S N.S N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
8036 MT-CO2 C4 0.103 3.611E-04 0.109 0.020 N.S N.S 
8113 MT-CO2 C4 0.083 0.033 N.S N.S N.S N.S 
8117 MT-CO2 C4 0.096 0.024 N.S N.S N.S N.S 
8140 MT-CO2 C4 N.S N.S 0.105 0.042 N.S N.S 
8141 MT-CO2 C4 N.S N.S N.S N.S 0.027 0.033 
8147 MT-CO2 C4 0.158 0.033 N.S N.S N.S N.S 
8151 MT-CO2 C4 0.083 0.022 N.S N.S N.S N.S 
8165 MT-CO2 C4 0.032 0.037 N.S N.S N.S N.S 
8165 MT-CO2 C4 N.S N.S N.S N.S 0.054 0.032 
8545 MT-ATP8 C5 0.033 0.018 N.S N.S 0.058 0.022 
8580 MT-ATP6 C5 0.156 0.027 N.S N.S 0.265 0.015 
8648 MT-ATP6 C5 0.025 0.047 N.S N.S N.S N.S 
8722 MT-ATP6 C5 -0.065 0.018 -0.095 0.033 N.S N.S 
8879 MT-ATP6 C5 0.025 0.019 N.S N.S N.S N.S 
8959 MT-ATP6 C5 N.S N.S -0.026 0.025 N.S N.S 
9010 MT-ATP6 C5 N.S N.S N.S N.S 0.032 0.013 
9328 MT-CO3 C4 N.S N.S N.S N.S 0.085 0.043 
9393 MT-CO3 C4 N.S N.S N.S N.S 0.090 0.033 
9445 MT-CO3 C4 N.S N.S 0.032 0.040 N.S N.S 
9449 MT-CO3 C4 0.077 0.044 N.S N.S N.S N.S 
9774 MT-CO3 C4 N.S N.S 0.021 2.434E-03 N.S N.S 
9777 MT-CO3 C4 0.035 0.044 N.S N.S N.S N.S 
9918 MT-TG tRNA 0.025 0.011 N.S N.S N.S N.S 
10067 MT-ND3 C1 0.135 0.014 N.S N.S N.S N.S 
10182 MT-ND3 C1 0.030 0.046 N.S N.S N.S N.S 
10202 MT-ND3 C1 0.099 6.257E-03 N.S N.S N.S N.S 
10203 MT-ND3 C1 0.040 0.044 N.S N.S 0.062 0.029 
                                                                                                  
166 
 
Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
10436 MT-TR tRNA -0.232 0.026 -0.492 0.015 N.S N.S 
10676 MT-ND4L C1 0.179 1.136E-03 0.258 8.800E-03 N.S N.S 
10677 MT-ND4L C1 0.022 0.038 N.S N.S N.S N.S 
10684 MT-ND4L C1 0.111 0.037 0.221 0.019 N.S N.S 
10934 MT-ND4 C1 0.068 0.040 N.S N.S N.S N.S 
11162 MT-ND4 C1 0.024 7.039E-03 N.S N.S 0.126 0.016 
11184 MT-ND4 C1 0.023 0.033 N.S N.S 0.034 0.033 
11192 MT-ND4 C1 N.S N.S N.S N.S 0.034 0.036 
11389 MT-ND4 C1 N.S N.S N.S N.S 0.138 0.032 
11455 MT-ND4 C1 0.093 0.021 N.S N.S 0.143 4.601E-03 
11492 MT-ND4 C1 N.S N.S N.S N.S 0.225 0.037 
11611 MT-ND4 C1 N.S N.S N.S N.S 0.033 0.029 
11647 MT-ND4 C1 N.S N.S N.S N.S N.S N.S 
11648 MT-ND4 C1 0.079 0.027 -0.028 1.194E-03 N.S N.S 
11689 MT-ND4 C1 0.129 2.981E-03 N.S N.S N.S N.S 
11852 MT-ND4 C1 N.S N.S N.S N.S N.S N.S 
11913 MT-ND4 C1 0.161 0.012 N.S N.S N.S N.S 
12054 MT-ND4 C1 0.021 0.023 N.S N.S N.S N.S 
12124 MT-ND4 C1 N.S N.S 0.334 0.018 N.S N.S 
12192 MT-TH tRNA 0.049 6.945E-04 0.056 5.77E-03 N.S N.S 
12207 MT-TS2 tRNA N.S N.S -0.045 9.06E-03 0.059 0.028 
12405 MT-ND5 C1 0.320 0.042 N.S N.S N.S N.S 
12774 MT-ND5 C1 0.116 0.044 N.S N.S N.S N.S 
12813 MT-ND5 C1 0.051 0.028 N.S N.S N.S N.S 
12817 MT-ND5 C1 N.S N.S N.S N.S 0.057 0.028 
12863 MT-ND5 C1 0.024 0.027 N.S N.S N.S N.S 
12870 MT-ND5 C1 0.065 0.046 0.096 0.010 N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
12876 MT-ND5 C1 0.065 0.028 N.S N.S N.S N.S 
12888 MT-ND5 C1 0.061 0.048 0.079 0.043 N.S N.S 
13210 MT-ND5 C1 0.019 0.046 N.S N.S 0.041 0.032 
13530 MT-ND5 C1 N.S N.S N.S N.S 0.127 0.040 
13668 MT-ND5 C1 N.S N.S N.S N.S 0.145 0.014 
13758 MT-ND5 C1 N.S N.S -0.107 4.263E-03 0.218 0.041 
13810 MT-ND5 C1 N.S N.S -0.045 0.037 N.S N.S 
13939 MT-ND5 C1 N.S N.S N.S N.S 0.301 0.045 
13967 MT-ND5 C1 0.193 0.025 N.S N.S 0.279 0.036 
13968 MT-ND5 C1 N.S N.S N.S N.S 0.034 0.038 
14159 MT-ND6 C1 0.528 0.035 1.009 0.010 N.S N.S 
14225 MT-ND6 C1 0.460 8.214E-04 N.S N.S 0.698 6.60E-03 
14226 MT-ND6 C1 0.027 0.026 N.S N.S N.S N.S 
14268 MT-ND6 C1 N.S N.S 0.026 0.019 N.S N.S 
14383 MT-ND6 C1 0.258 8.788E-04 N.S N.S 0.397 0.018 
14458 MT-ND6 C1 0.218 0.017 0.344 0.031 N.S N.S 
14459 MT-ND6 C1 0.234 0.027 N.S N.S N.S N.S 
14568 MT-ND6 C1 0.379 0.029 N.S N.S N.S N.S 
14698 MT-TE tRNA 0.029 7.440E-03 0.024 0.023 N.S N.S 
14804 MT-CYB C3 N.S N.S N.S N.S 0.047 0.048 
14929 MT-CYB C3 0.078 0.027 0.107 0.046 N.S N.S 
14958 MT-CYB C3 0.026 0.042 N.S N.S N.S N.S 
14963 MT-CYB C3 N.S N.S -0.013 0.010 N.S N.S 
14996 MT-CYB C3 0.023 0.024 0.041 1.191E-03 N.S N.S 
15040 MT-CYB C3 N.S N.S N.S N.S 0.091 0.034 
15045 MT-CYB C3 N.S N.S N.S N.S 0.048 0.019 
15092 MT-CYB C3 0.042 0.013 0.047 0.043 N.S N.S 
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Genomic 
Position 
(bp) 
Gene Complex Effect Size MM 
Significance 
level (P 
Value) MM 
Effect 
Size CER 
Significance 
level (P 
Value) CER 
Effect 
Size STG 
Significance 
level (P Value) 
STG 
15199 MT-CYB C3 N.S N.S N.S N.S 0.118 0.043 
15275 MT-CYB C3 0.073 0.020 N.S N.S 0.113 0.039 
15391 MT-CYB C3 0.170 0.017 N.S N.S 0.169 0.031 
15437 MT-CYB C3 N.S N.S -0.038 0.033 N.S N.S 
15557 MT-CYB C3 0.040 0.011 N.S N.S N.S N.S 
15590 MT-CYB C3 0.084 0.027 0.090 0.035 N.S N.S 
15591 MT-CYB C3 N.S N.S N.S N.S 0.057 0.018 
15595 MT-CYB C3 0.094 0.040 N.S N.S N.S N.S 
15596 MT-CYB C3 0.025 8.795E-03 N.S N.S 0.046 0.010 
15761 MT-CYB C3 N.S N.S -0.030 0.030 N.S N.S 
15811 MT-CYB C3 N.S N.S 0.194 0.043 N.S N.S 
15812 MT-CYB C3 N.S N.S -0.028 3.611E-03 N.S N.S 
15927 MT-TT tRNA N.S N.S N.S N.S 0.070 0.045 
16083 D-LOOP NCR 0.208 0.034 N.S N.S N.S N.S 
16095 D-LOOP NCR 0.212 0.010 N.S N.S N.S N.S 
16360 D-LOOP NCR N.S N.S 0.184 0.023 N.S N.S 
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Figure 5.3: DNA methylation levels for significant DMPs associated with age present 
in both STG and CER. Shown are DNA methylation levels for the two age-associated 
DMPs that were present in the STG (A) and CER (B), which resided at 4463bp (purple: 
R=0.720), and 1597bp (green: R=0.557). 
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5.4.6. Conservation of Methylation Levels across the Mitochondrial Genome 
Speculation over the validity of mtDNA methylation has been rife in the field of 
mitochondrial epigenetics, with studies indicating mtDNA methylation levels are 
non-biologically across specific regions of the genome (70). We were therefore 
interested to see how much variability could be observed between mtDNA 
methylation across the genome. We identified a conserved pattern of mtDNA 
methylation across the genome. By measuring the standard deviation at each 
site, we looked to determine the variation in methylation amongst individuals. In 
total, 496 sites had a standard deviation less than 0.5%, whilst only 104 sites 
were identified with a standard deviation greater than 1.0%. As such, a 
relatively conserved pattern of mtDNA methylation between individuals was 
identified across the mitochondrial genome (Figure 5.4).  
 
By looking at methylation levels across each locus and each individual, we 
identified a total of 576 sites (approximately 4.68% of total number of sites in 
the cohort) that had a mtDNA methylation level greater than 5%. To determine 
whether these increases were associated with age, sex or tissue type, a 
Fisher’s exact test for enrichment was performed for each. However, no 
significant enrichment for relatively high levels of methylation being associated 
to any of the co-variates in this study could be identified in this study.   
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Figure 5.4: Genome-wide plots of DNA methylation. The average level of methylation at each site was calculated for each 
sex and tissue. Shown are average DNA methylation levels across ChrM for (A) Males in the CER, (B) Males in STG, (C) 
Females in CER and (D) Females in STG. A separate plot for each sex and tissue was then created to show the average 
percentage of DNA methylation. 
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5.5. Discussion 
Here, we present the first genome-wide map of mtDNA methylation, at single 
nucleotide resolution, in mitochondria isolated from post-mortem human brain 
tissue. Previous studies have investigated changes across the mitochondrial 
epigenome using publicly available data (63,70,252). However, these studies 
have been limited by low sequencing depth, the use of non-isolated mtDNA, 
and in the case of MeDIP-Seq, relatively low resolution. Hong et al., used 
publicly available BS-Seq data to show that mtDNA methylation does not exist 
at biologically relevant levels (<1%). However, an ability to determine this 
conclusively, given the multi-copy nature of the mitochondrial genome, as well 
as the relatively low sequencing depth derived from non-enriched BS-Seq, may 
have led to a gross underrepresentation of true mtDNA methylation levels. In 
our study, though average levels of mtDNA methylation across the 869 sites 
interrogated were low, (STG mean = 1.239%, CER mean = 1.230%), there was 
considerable variability in methylation across the genome of each individual. 
Interestingly, a site of the D-LOOP, 545bp, was found to have relatively high 
levels of mtDNA methylation, with an average of 15.3% and 14.6% methylation 
in the STG and CER respectively. This adds further evidence to a recent study 
that identified high levels of mtDNA methylation across the mitochondrial D-
LOOP (71), potentially highlighting a region of the mitochondrial genome which 
could have an important impact on the organelle’s function. 
 
Importantly, the enrichment process seemed to strongly affect the methylation 
levels of STG, whereas the methylation differences between enriched and non-
enriched CER samples were less obvious. It is important to note that this 
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analysis was only performed on a single sample for each tissue type and a 
more extensive analysis should be conducted in the future with more 
individuals. Despite this, given that a number of probes in both tissues were still 
affected, our results suggest that mtDNA enrichment prior to NGS library 
preparation could be very important to the study outcome. 
 
Establishing the extent to which confounders such as age, tissue type and sex 
play a role in ncDNA methylation studies has led to more robust and reliable 
analyses in epigenetic studies (191). However, previous studies into mtDNA 
methylation have not studied the genome-wide effect of these factors. Our 
preliminary analysis identified many nominally significant DMPs for all of the 
covariates, with five DMPs also passing a Benjamani-Hochberg correction for 
multiple testing when examining the effect of sex. Of these five, two also passed 
a more strict Bonferroni correction. The variation between these two results is 
likely due a reportedly high correlation that exists between nearby DNA 
methylation sites across the genome (259), suggesting that sites of DNA 
methylation are not truly independent, which is assumed by Bonferroni 
corrections. Furthermore, our post-hoc analysis in the separate tissues also 
demonstrated the same direction of effect for the sex-associated DMPs we 
identified within MT-ATP6 and D-LOOP. The small sample size of our study, as 
well as the lack of functional work carried out on these DMPs makes it difficult 
to ascertain the physiological relevance of the differences. However, their 
identification in the D-LOOP, a region known to regulate mitochondrial 
transcription and replication, could possibly effectuate changes in overall 
mitochondrial output. Additionally, the finding that within the STG, there is an 
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enrichment for hypermethylation in females and that in both STG and CER, 
there is an enrichment for hypermethylation with increasing age, highlights the 
need for carefully controlled epidemiological studies in the future. 
 
Age related changes have also been identified in other mtDNA methylation 
studies (74,260). Hypomethylation in ncDNA has been frequently attributed to 
increasing age (261) and age-associated hypermethylation has therefore been 
suggested to play a role in age–related disorders (262). As such, it is of real 
interest to investigate why mtDNA methylation tends to increase across the 
genome with age. If it is to be assumed that mtDNA methylation exists at a 
relatively low level across the mitochondrial genome, then increases in mtDNA 
methylation could be a sign of dysregulation within the mitochondria. It is 
therefore possible that this general increase across the genome could be 
attributed to the increase in mitochondrial dysfunction seen during ageing 
(176,263), potentially by altering regulation of mtDNA expression.  Despite this, 
few functional studies have investigated the effect of changes in mtDNA 
methylation, where mtDNA hypermethylation was shown to be associated with 
apoptosis in diabetic retinopathy (86). However, to date, no study has looked at 
the effect of multiple, site-specific mtDNA methylation changes occurring 
simultaneously. 
 
The ubiquitous nature of mitochondrial distribution throughout the body, except 
for red blood cells, highlights the importance of maintaining correct 
mitochondrial function throughout healthy ageing. Despite levels of mtDNA 
methylation being relatively low in this study in comparison to ncDNA 
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methylation, a recent study identified that those individuals with increased 
mtDNA methylation levels at a site within MT-RNR1 were associated with 
increased mortality risk when followed up nine years later (74). As such, low 
levels of mtDNA methylation could be due to the averaging effect of analysing 
the mitochondrial epigenome across mitochondria in multiple states and as 
such, underestimate true levels existing within mitochondria. 
Further, studies have also shown that mtDNA methylation changes at specific 
sites in the D-LOOP negatively correlate with changes in gene expression.  One 
study demonstrated that increases in D-LOOP methylation were associated with 
reduced MT-CYB, MT-ND6, and MT-CO2 transcript levels (86), whilst another 
showed that reduced D-LOOP methylation was associated with increased MT-
ND2 expression in colorectal cancer tumour tissue (75). Taken together, this 
suggests that mtDNA methylation does have a functional role within the 
organelle. Further, whilst previous studies have demonstrated that mtDNA 
methylation is typically very low, with values of approximately 0.5 – 1.0% (33); 
we have identified several cytosines with DNA methylation levels greater than 
10% across the mitochondrial genome.  
 
Our study does however, have several limitations. Most importantly, whilst age 
related hypermethylation changes were observed in this cohort, given the small 
sample size, most ages were only represented once. Furthermore, we only 
investigated a relatively narrow range of ages, with all individuals between the 
ages of 77 and 87 years. It is therefore possible that the effects of age on DNA 
methylation merely represent inter-individual differences. However, the 
enrichment for hypermethylated DMPs associated with increasing age make 
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this less likely. Our study also does not attempt to functionally characterise 
nominated DMPs, for example to look at the correlation between mtDNA 
methylation and gene expression levels. Our primary aim was instead to define 
a methodology capable of analysing mtDNA methylation at high resolution 
across the mitochondrial genome and, importantly, to provide strong evidence 
to support the existence of mtDNA methylation in the brain. 
 
5.6. Conclusion 
Our study provides the first genome-wide analysis of mtDNA methylation at 
single base resolution, providing a map of mtDNA methylation across human 
brain as well as identifying differences in mtDNA methylation between different 
tissue types, sex and age. This not only highlights a potential biological 
importance for mtDNA methylation but also highlights the need to control for 
these factors in future studies. Further, the identification of these traits, 
particularly the enrichments identified to be associated with age and sex, 
suggest that mtDNA methylation has potential functional relevance, giving 
evidence to its existence as an independent mark. Interestingly our data also 
alluded to a multitude of relatively highly methylated positions across the 
mitochondrial genome; however, there was no enrichment between these 
increased levels and each of the covariates analysed. Detecting these variable 
sites in a larger cohort may however, reveal clues to their biological relevance.
                                                                                                  
177 
 
Chapter 6. Interrogating the Role of MtDNA methylation in AD 
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6.1.  Aims 
1. To validate sex- and age-specific DMPs previously identified in Chapter 5. 
2. To determine whether altered mtDNA methylation patterns are seen in AD, 
using Braak stage as a measure of neuropathology. 
3. To determine whether altered nuclear-encoded mitochondrial gene DNA 
methylation is associated with AD, using Braak stage as a measure of 
neuropathology.  
4. To correlate mtDNA methylation differences associated with AD with 
nuclear-encoded mitochondrial gene methylation differences associated 
with AD in matched samples. 
 
6.2. Introduction 
The brain is an organ that represents only 2% of the average human’s body 
weight. However despite this, the brain accounts for approximately 20% of the 
body’s total oxygen output (264). This discrepancy between weight and 
consumption is largely due to the neuronal population and the requirement to 
maintain an environment critical for the establishment of regular and correct action 
potential firing (265). Given that mitochondria provide the main source of total 
cellular ATP, the requirement for the critical refinement and correct regulation of 
mitochondrial homeostasis is of upmost importance for the physiological health of 
the brain. 
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AD is a complex disease characterised by the accumulation of Aβ plaques, tangles 
of hyperphosphorylated tau, and mitochondrial dysfunction (266). The 
neuropathological spread of tangles throughout AD brain has been well 
documented; in the earliest stages of the disease these are largely isolated to the 
ECX and hippocampus, whilst by the end stages of the disease these have spread 
throughout the CTX (191). However, at present little is known about the exact 
molecular mechanisms that may be driving disease progression. 
 
In recent years, it has been hypothesised that AD has an epigenetic component 
(191). In 2014, the first EWAS in AD brain were published. These studies 
demonstrated robust and reproducible changes in ncDNA methylation at several 
loci in AD CTX (95,198), implicating a potential role for epigenetic mechanisms in 
disease aetiology. However, one caveat of these studies is that the platform used 
(Illumina Infinium 450K Methylation array) has no coverage of the mitochondrial 
genome. As such, no genome-wide study to date has investigated whether the 
mitochondrial dysfunction that is seen in AD may be driven by mitochondrial 
epigenetic changes.  
 
We have previously hypothesised that, given that mitochondrial dysfunction and 
epigenetic modifications have both been identified in AD (95,198,267), mtDNA 
methylation may have an important role in AD pathology (1). Furthermore, a recent 
study has identified epigenetic changes in two regions of the mitochondrial genome 
that are significantly associated with Braak stage, a standardised measure of 
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disease pathology in AD, using a candidate based gene approach (BS-
pyrosequencing) (200). Whilst this has added weight to our original hypothesis, a 
genome-wide, high resolution study of mtDNA methylation in AD has yet to be 
undertaken. In Chapter 5 we presented a new method for studying mtDNA 
methylation using targeted BS-Seq, which captures the mitochondrial methylome 
at single-base resolution. Whilst there was little variation in the methylation levels 
observed in our pilot study, an enrichment for hypermethylation in females for sex-
associated DMPs in the STG was observed, with a similar trend in the CER. 
Furthermore, we also identified an enrichment for hypermethylated DMPs 
associated with increasing age in both the STG and CER.  
 
Here, we looked to identify differences in mtDNA methylation in AD brain samples 
using the targeted BS-Seq method we previously developed in Chapter 5. 
Furthermore, given that previous studies have highlighted a complex interplay 
between the nucleus and mitochondria on a genetic and proteomic level 
(1,267,268), we also hypothesised that this may occur at an epigenetic level. We 
therefore analysed DNA methylation levels of nuclear-encoded mitochondrial 
genes, which encode for proteins that translocate into the mitochondria (herein 
referred to as nuclear-mitochondrial genes), using data generated on the same 
samples using the Illumina 450K array, to investigate this further. 
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6.3. Methods 
 
6.3.1. Sample Demographics for Mitochondrial Isolations 
200mg of ECX brain tissue was obtained from 96 donors archived in the LBB, for 
mitochondrial isolation. From a subset of these donors, we also had access to 
ncDNA methylation data generated on the Illumina 450K array (N=49). Samples 
were selected to have varying degrees of AD pathology (Braak Stage 0-VI) and all 
AD patients were over the age of 65 at diagnosis, see Table 6.1 for sample 
demographics.  
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Table 6.1: Sample demographics of samples used for mtDNA analysis in Chapter 6. Shown are Braak stage, 
age at death, sex, sequencing depth and mapping efficiency (from our study) and finally whether samples had 
available matched Illumina 450K array data. Data is only shown for samples that passed QC 
Individual Braak 
Stage 
Age 
(at death) 
Sex Sequencing 
Depth 
Mapping 
Efficiency (%) 
Illumina 450K array 
data available 
1 VI 73 Female 33084 81.10 Yes 
2 VI 83 Male 1780 79.90 Yes 
3 III 91 Male 1220 76.70 Yes 
4 V 88 Male 1089 79.00 No 
5 0 84 Male 1659 81.70 Yes 
6 VI 77 Male 242 59.50 Yes 
7 IV 81 Male 2110 84.80 Yes 
8 II 76 Female 2086 77.20 Yes 
9 V 85 Female 2034 79.90 Yes 
10 V 65 Male 1778 76.60 Yes 
11 VI 76 Male 2211 71.40 Yes 
12 IV 79 Male 2032 71.40 No 
13 V 85 Female 2239 84.60 Yes 
14 V 89 Female 3300 83.70 Yes 
15 V 88 Male 2397 83.00 Yes 
16 0 90 Male 701 66.70 Yes 
17 VI 65 Female 2271 81.50 Yes 
18 II 80 Male 2212 81.80 Yes 
19 0 66 Female 3097 81.40 Yes 
20 V 90 Female 1577 65.20 Yes 
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Individual Braak 
Stage 
Age 
(at death) 
Sex Sequencing 
Depth 
Mapping 
Efficiency (%) 
Illumina 450K array 
data available 
21 V/VI 70 Female 1642 83.20 Yes 
22 IV 79 Male 4157 76.60 Yes 
23 0 77 Female 17485 43.90 Yes 
24 V 89 Female 1860 79.70 Yes 
25 III 98 Female 1561 82.40 No 
26 VI 83 Male 1490 85.90 Yes 
27 IV 86 Male 3762 78.90 Yes 
28 VI 84 Male 1166 85.40 Yes 
29 II 90 Female 1550 79.50 Yes 
30 II 67 Female 3315 76.30 Yes 
31 0 80 Female 969 83.50 No 
32 II 89 Female 1151 79.60 Yes 
33 V 97 Female 2111 86.40 No 
34 V 97 Female 311 86.80 Yes 
35 VI 78 Male 624 85.90 Yes 
36 III 97 Male 3277 83.30 Yes 
37 II 82 Female 2168 84.10 No 
38 VI 80 Male 1892 81.60 Yes 
39 VI 85 Male 3602 81.60 Yes 
40 II 85 Female 4558 83.80 Yes 
41 I 55 Female 3583 84.50 No 
42 VI 87 Male 10291 78.30 Yes 
43 0 63 Male 2025 86.20 Yes 
44 I 67 Male 523 85.10 Yes 
45 V 89 Male 18057 63.70 Yes 
46 III 92 Female 3130 84.20 Yes 
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Individual Braak 
Stage 
Age 
(at death) 
Sex Sequencing 
Depth 
Mapping 
Efficiency (%) 
Illumina 450K array 
data available 
47 VI 72 Male 1438 81.20 No 
48 III 88 Female 832 82.40 Yes 
49 III 91 Female 755 84.10 No 
50 VI 74 Male 3392 82.20 Yes 
51 VI 81 Female 597 80.60 Yes 
52 0 69 Female 1073 78.00 Yes 
53 IV 92 Male 2071 79.70 Yes 
54 VI 78 Female 2242 75.70 Yes 
55 VI 85 Male 11332 79.10 Yes 
56 II 74 Male 1761 76.20 No 
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6.3.2. Mitochondrial Isolation 
Mitochondria were isolated from frozen, post-mortem brain tissue according to the 
protocol outlined in Section 2.3.4. MtDNA was further enriched through the use of a 
custom library designed to amplify the mitochondrial genome (Agilent 
Technologies, California, U.S.A.) as described in Section 2.3.6. 
 
6.3.3. Custom Capture of the Mitochondrial Epigenome 
To capture the mitochondrial epigenome, a custom library of RNA baits (Agilent, 
California, U.S.A.: Design ID 0687721) were designed to provide 100% coverage 
of the genome at 5X tiling density, as shown in Chapters 2 and 5. Isolated mtDNA 
extracted from frozen, post-mortem brain tissue was subjected to an adapted 
version of the Agilent 1μg Methyl-Seq protocol (see Section 2.3.6). After generating 
indexed libraries for each sample, samples were then pooled in equimolar 
concentrations and sequenced using the Illumina HiSeq 2500 by Exeter 
Sequencing Service (Exeter, U.K.), who returned 96 fastq file pairs. 
 
6.3.4. Analytical Workflow for MtDNA Methylation 
After sequencing, 100bp paired reads were de-multiplexed and following quality 
assessment using FastQC, reads were trimmed for adaptor content using 
TrimGalore (253). Using the same package, we also trimmed the first base pair 
from the 3’ end of both reads. Trimmed files were then aligned to human 
mitochondrial genome, rCRS, through Bismark, using Bowtie 1 (204). On average, 
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643,143 reads mapped per sample, providing an average sequencing depth of 
3439 times. The average mapping efficiency for each sample to the mitochondrial 
genome was 78.28% (S.D = 8.81). Mapped reads were then de-duplicated using 
the deduplicate_bismark function before CpG and non-CpG methylation was called 
by bismark_methylation_extractor. Given the variation in sequencing depth 
between samples, 40 samples were removed in sample QC. Reasons for removal 
of samples included low mapping efficiency (N=2), and in the remaining samples, 
over 30% of total sites receiving less than 15 calls for methylation/unmethylated 
cytosine. Further, of the 869 cytosines profiled, 601 were called in the majority 
(75%) of all remaining samples. Only these 601 cytosines were considered in later 
statistical analysis. Of note, samples that were primarily affected were of low yield 
after RNA-DNA hybridisation during the Agilent protocol, suggesting that the quality 
of DNA in these samples may have been reduced.  
 
All statistical analyses were carried out in R (v3.3.0) (254). Briefly, a linear 
regression was used to define the effect of each co-variate: age, sex and Braak 
stage, on mtDNA methylation. For this analysis, Braak stage was grouped into 
three bins, "low", "medium" and "high", corresponding to Braak stage 0-II, III-IV and 
V-VI respectively. This method was used to improve power and reduce the 
differences between group sizes in the analysis. Nominal significance was deemed 
P<0.05. To correct for multiple testing, a Bonferroni correction threshold was used 
(P=8.319E-05). 
 
                                                                                                  
187 
 
6.3.5. DNA Methylation Analysis of Nuclear-Mitochondrial Genes 
NcDNA methylation levels for ~485,000 loci across the human genome were 
available from ECX samples from two cohorts of individuals (Table 6.2) with 
varying degrees of AD pathology from other experiments performed within our 
laboratory (N=217 in total) (198,269). From this data, we focussed our analyses on 
nuclear-mitochondrial probes, which we defined as probes covering genes 
encoding for proteins that translocate into the mitochondria (N=13,170). These 
genes were identified as nuclear-mitochondrial genes in MitoCarta, a mitochondrial 
database (270). Probes corresponding to these gene names were then extracted 
from each sample file for later use. For each ECX cohort we performed a linear 
regression analysis on all nuclear-mitochondrial probes. These linear regressions 
looked to associate ncDNA methylation with Braak stage bins (as previously 
defined), whilst controlling for age, sex and cellular proportion (as estimated by the 
R package CETS (271)).  
 
Probes that were associated with Braak stage in both cohorts, with the same 
direction of effect, were used for a subsequent meta-analysis using metaphor, a 
package in R (272). From each regression analysis, the respective standard errors 
and methylation differences of these probes were extracted and used as 
parameters in the meta-analysis. This gave the overall effect size and significance 
level of each individual probe across the two cohorts. To correct for multiple 
testing, a Bonferroni correction for ncDNA was used (P=3.798E-06).  
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Table 6.2: Summary sample demographics for nuclear-mitochondrial gene 
analysis. 
 
Of the 56 mtDNA samples we analysed in our study (Table 6.1), a subset of 49 
had nuclear-mitochondrial probe methylation data available from the 450K array 
(269) (noted on Table 6.1). An analysis was carried out to determine the 
significance of correlations between ncDNA and mtDNA loci that were identified as 
being significantly differentially methylated with respect to Braak stage bins by 
creating a correlation matrix in R (v3.3.0) (254) and using it to plot a heatmap. To 
determine whether probes (or DMPs) in one genome were significantly correlated 
with more probes (or DMPs) in the other genome than expected by chance, the 
frequency and distribution of significant correlations for each was calculated. A 
Fisher’s exact test for enrichment was then performed, analysing the significance 
of multiple significant correlations within one locus, when compared to the total 
 
Braak stage 
Cohort 1 Cohort 2 
0-II III-IV V-VI 0-II III-IV V-VI 
Total Number 29 18 66 24 18 62 
Females/ Males 16/13 11/7 40/26 12/12 11/7 39/23 
Age (Mean +/- 
SD) 
77.62 +/- 
12.57 
88.50 +/- 
5.60 
85.41 
+/- 8.07 
80.33 +/- 
9.75 
88.50 +/- 
5.60 
85.59 +/- 
8.16 
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number of significant, and non-significant, correlations identified throughout the 
dataset. 
6.4. Results 
 
6.4.1. MtDNA Methylation Shows Sex-Specific Patterns 
We identified 23 nominally significant DMPs associated with sex (Table 6.3). In 
Chapter 5 we previously identified five sex-specific DMPs which survived 
Benjamani-Hochberg, of which two also survived Bonferroni correction. In the 
current study, only three of these five loci passed QC, with the two passing 
Bonferroni correction in Chapter 5 not passing our selection criteria. Of all sex-
specific DMPs identified in both STG and CER, only one, at 15,761bp (MT-CYB) 
was identified in the ECX. However, we also identified that three of the 23 DMPs 
that were nominally significantly differentially methylated in the ECX were also in 
the STG, but not CER. Our previous analysis in Chapter 5 also showed that there 
was a significant enrichment for hypermethylation in females for sex-associated 
DMPs in the STG. Of the 23 nominally significant sex-associated DMPs we 
identified in the current study, 22 were hypermethylated in females, with  a Fisher’s 
Exact test showing a significant enrichment of hypermethylation in females for sex-
associated DMPs (P = 1.891E-03; Odds Ratio = 10.390), again confirming that 
sex-associated DMPs tend to be hypermethylated in female CTX. 
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6.4.2. Conserved Patterns of MtDNA Methylation Exist between Cohorts 
In Chapter 5, we also showed a relatively conserved, low level of mtDNA 
methylation present across the mitochondrial genome, with methylation levels 
typically between 1-3%. Interestingly in the current study, which utilises a larger 
cohort, a similar pattern was also identified, with an average methylation level of 
0.95%. However, there were on average 10 sites within each individual that 
demonstrated relatively high levels (>5%) of mtDNA methylation. To test whether 
these relatively high levels of methylation were associated with any of the 
covariates used in our analysis, a Fishers exact test for enrichment was performed 
for each. However, the frequency of relatively high levels of mtDNA methylation 
was not enriched for associations with sex, age, or disease. 
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Table 6.3: Methylation differences and corresponding P values for sex-associated DMPs in ECX. Also shown 
are the methylation levels and P values for these loci in the STG and CER from the data generated in Chapter 5.  
Hypermethylation in males is indicated by a positive methylation value. DMPs that were present in more than one 
tissue are highlighted in bold. Effect sizes are determined as the percentage methylation differences between the two 
sexes. Abbreviations: Non-significant (N.S), Complex I (C1), Complex III (C3), Complex IV (C4), Complex V (C5), 
Non-coding regions (NCR). 
Genomic Information ECX STG CER 
Genomic 
Position (bp) 
Gene Complex 
Effect 
Size 
P Value 
Effect 
Size 
P Value 
Effect 
Size 
P Value 
1488 MT-RNR1 rRNA 1.579 0.045 0.251 N.S 0.034 N.S 
1489 MT-RNR1 rRNA -0.092 0.020 -0.264 N.S -0.095 N.S 
1562 MT-RNR1 rRNA -0.145 0.005 0.041 N.S -0.139 N.S 
3010 MT-RNR2 rRNA -0.144 0.030 -0.268 N.S -0.217 N.S 
3530 MT-ND1 C1 -2.159 0.001 0.432 N.S -0.220 N.S 
4996 MT-ND2 C1 -0.147 0.016 -0.134 N.S -0.067 N.S 
6021 MT-CO1 C4 -0.073 0.020 -0.225 0.054 0.092 N.S 
6164 MT-CO1 C4 -0.907 0.024 -1.461 0.032 0.057 N.S 
6618 MT-CO1 C4 -0.146 0.019 -0.090 N.S -0.134 N.S 
7161 MT-CO1 C4 -0.112 0.005 -0.381 0.020 0.048 N.S 
7332 MT-CO1 C4 -0.158 0.007 -0.213 0.048 0.177 N.S 
7814 MT-CO2 C4 -0.100 0.006 -0.088 N.S 0.050 N.S 
7850 MT-CO2 C4 -0.087 0.042 -0.208 N.S -0.049 N.S 
8114 MT-CO2 C4 -0.144 0.035 -0.359 N.S 0.072 N.S 
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Genomic Information ECX STG CER 
Genomic Gene Complex Effect P Value Effect P Value Effect P Value 
8879 MT-ATP6 C5 -0.079 0.043 -0.262 0.069 -0.096 N.S 
8959 MT-ATP6 C5 -0.144 0.000 -0.044 N.S 0.012 N.S 
9621 MT-CO3 C4 -0.152 0.013 -0.152 N.S 0.066 N.S 
11456 MT-ND4 C1 -0.094 0.011 -0.234 N.S -0.025 N.S 
13531 MT-ND5 C1 -0.079 0.036 -0.165 N.S 0.009 N.S 
15557 MT-CYB C3 -0.142 0.002 -0.191 N.S -0.106 N.S 
15761 MT-CYB C3 -0.120 0.017 -0.257 0.028 -0.491 0.001 
16566 D-LOOP NCR -0.840 0.048 0.263 N.S -0.562 N.S 
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6.4.3. MtDNA Methylation Changes are Associated with Age 
We identified 16 age-associated DMPs (Table 6.4). Of the 16 identified, nine were 
found to be positively correlated with age. As in Chapter 5, we ran a Fisher’s exact 
test, to test for enrichment for hypermethylation within age-associated DMPs.  
However, despite observing an enrichment for these in both the STG and CER in 
Chapter 5, we did not observe an enrichment in ECX. 
 
Table 6.4: Methylation differences and P values for age-associated DMPs in 
ECX. Positive effect sizes correspond to hypomethylation with increasing age. 
Effect sizes are determined as differences in percentage methylation per year 
increase in age. Abbreviations: C1 (Complex I), C3 (Complex III), C4 (Complex IV), 
NA (Not annotated), NCR (non-coding region), rRNA (ribosomal RNA). 
Genomic 
Position (bp) 
Gene Complex Effect Size P Value 
9673 MT-CO3 C4 0.006 7.00E-03 
1537 MT-RNR1 rRNA -0.100 9.00E-03 
5740 NA NA -0.063 9.00E-03 
1217 MT-RNR1 rRNA -0.008 0.01 
808 MT-RNR1 rRNA -0.048 0.012 
15355 MT-CYB C3 0.008 0.014 
13759 MT-ND5 C1 0.013 0.017 
499 D-LOOP NCR -0.047 0.017 
8007 MT-CO2 C4 0.006 0.019 
6016 MT-CO1 C4 0.004 0.020 
12888 MT-ND5 C1 -0.067 0.023 
13579 MT-ND5 C1 0.007 0.024 
10775 MT-ND4 C1 0.005 0.027 
9329 MT-CO3 C4 0.005 0.033 
7342 MT-CO1 C4 -0.008 0.046 
14846 MT-CYB C3 0.006 0.049 
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6.4.4. Site-Specific Changes in MtDNA Methylation are Associated with AD 
Pathology. 
In this study, we used binned Braak stages as a metric to quantify the different 
stages of AD neuropathology. We identified 29 nominally significant DMPs that 
were associated with Braak stage (Figure 6.1; Table 6.5). Of the 29 DMPs 
significantly associated with Braak stage, six corresponded to genes within 
complex I of the ETC, three within Complex III and ten within complex IV. Of the 
remainder, two were present in DMPs corresponding to tRNAs, four in rRNA and 
one within the non-coding region (NCR). Despite this, no enrichment was identified 
for significant DMPs in any ETC complex. The most significant DMP associated 
with Braak stage bins, (3531bp; MT-ND1; P=3.603E-03) can be seen in Figure 
6.1.   8.179E-05. of threshold significant bonferroniour  reach  not  did  this However,
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Figure 6.1: A Manhattan plot of the mitochondrial genome, showing 
association between DNA methylation and Braak stage. The blue line denotes 
nominal significance (P=0.05). The genomic position for each gene across the 
mitochondrial genome is denoted by a grey rectangular box. 
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Figure 6.2: DNA Methylation levels corrected for age and sex of the most significant 
DMP associated with Braak stage. After adjusting for age and sex, individuals were 
grouped according to Braak stage bins, low (N=17), Medium (N=11) and High (N=28). A DMP 
at 3531bp, residing in gene MT-ND1 showed significantly increased DNA methylation with 
Braak stage (P=3.603E-03). 
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Table 6.5: DNA Methylation and P values for Braak stage-associated DMPs in 
ECX. Positive effect sizes correspond to hypomethylation with increasing Braak 
stage. Effect sizes are determined as differences in methylation percentage per 
binned Braak stage. Abbreviations: C1 (Complex I), C2 (Complex II), C3 (Complex 
III), C4 (Complex IV), C5 (Complex V), NA (not annotated), NCR (non-coding 
region), rRNA (ribosomal RNA), tRNA (transfer RNA). 
 
 
 
 
 
 
 
 
 
 
 
 
Genomic 
Position (bp) 
Gene Complex Effect Size P Value 
5740 NA NA 0.787 4.00E-03 
1415 MT-RNR1 rRNA -0.081 4.11E-03 
3531 MT-ND1 C1 0.227 5.08E-03 
10775 MT-ND4 C1 -0.068 6.85E-03 
7928 MT-CO2 C4 -0.067 7.81E-03 
8059 MT-CO2 C4 0.456 0.013 
15392 MT-CYB C3 -0.079 0.015 
3248 MT-TL1 tRNA -0.104 0.017 
13726 MT-ND5 C1 0.094 0.017 
15041 MT-CYB C3 -0.057 0.017 
9611 MT-CO3 C4 -1.012 0.019 
9574 MT-CO3 C4 -0.819 0.022 
16454 D-LOOP NCR -0.605 0.025 
2642 Mt-RNR2 rRNA 0.464 0.032 
7419 MT-CO1 C4 0.111 0.036 
3495 MT-ND1 C1 -0.687 0.038 
7164 MT-CO1 C4 0.050 0.038 
9145 MT-ATP6 C5 -0.058 0.041 
3643 MT-ND1 C1 -0.062 0.042 
9921 MT-TG tRNA 0.043 0.043 
12951 MT-ND5 C1 0.535 0.043 
15200 MT-CYB C3 -0.048 0.046 
786 MT-RNR1 rRNA -0.061 0.046 
9383 MT-CO3 C4 0.963 0.047 
14920 MT-CYB C3 0.617 0.047 
2844 Mt-RNR2 rRNA -0.056 0.048 
8164 MT-CO2 C4 0.413 0.048 
6564 MT-CO1 C4 -0.055 0.049 
6808 MT-CO1 C4 -0.059 0.049 
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6.4.5. Differentially Methylation Nuclear-Mitochondrial Genes are Associated with 
AD pathology 
We had access to nuclear-mitochondrial DNA methylation data (N=13,170 probes) 
from the ECX in two separate cohorts of individuals with varying degrees of AD 
neuropathology. Initially we looked to identify DNA methylation differences 
associated with Braak stage in each cohort separately, whilst controlling for age, 
sex and cellular proportions.  In total, we identified 714 nominally significant DMPs 
in cohort 1 and 635 in cohort 2(269)(269). Of these, 44 DMPs overlapped between 
cohorts with the same direction of effect and were taken forward for a meta-
analysis (Table 6.6). Of the 44 DMPs identified, one probe, which resided at 
Chr16: 89,598,950 (cg03169557), located within the Spastic Paraplegia 7 (SPG7) 
gene, was found to pass Bonferroni correction for multiple testing (P=2.430E-06 
(Figure 6.3)  
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Figure 6.3: DNA methylation residuals after correcting for age, sex and cell 
proportion, of SPG7 the most significant Braak-associated DMP in a nuclear-
mitochondrial gene. Shown are data for (A) cohort 1 (N=113) and (B) cohort 2 
(N=104).  
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Table 6.6: Methylation differences and P values for nuclear-mitochondrial DMPs associated with Braak-stage 
in meta-analysis of ECX. Shown are the effect size and P Values for linear regressions in each ECX cohort 
separately, in addition to overall P value from meta-analysis. Positive effect sizes denote hypomethylation with 
increasing Braak stage. Effect sizes are determined as differences in methylation percentage per binned Braak stage 
Data is ordered by most significant P values in the meta-analysis.  
Probe Gene 
Meta-analysis Cohort 1 Cohort 2 
Methylation 
Difference 
(%) 
P Value 
Methylation 
Difference 
(%) 
P Value 
Methylation 
Difference 
(%) 
P Value 
cg03169557 SPG7 0.300 2.43E-06 0.200 9.40E-05 0.800 1.18E-03 
cg05242371 DMPK -0.600 1.86E-05 -0.400 0.022 -0.800 1.599E-04 
cg14025831 PANK2 0.500 2.58E-05 0.400 7.15E-04 0.600 0.016 
cg22656126 WDR81 0.600 8.91E-05 0.500 1.52E-03 0.800 0.024 
cg24547396 COMT -0.400 1.01E-04 -0.400 9.77E-04 -0.300 0.045 
cg26182964 ECHS1 -0.400 1.12E-04 -0.400 4.27E-03 -0.500 0.012 
cg20140950 RDH13 -0.300 2.41E-04 -0.300 5.29E-03 -0.500 0.015 
cg01200965 HK2 0.300 2.45E-04 0.200 2.38E-03 0.400 0.047 
cg22011804 FASTK -0.500 3.61E-04 -0.500 6.94E-03 -0.500 0.026 
cg12615866 MRPL1 0.200 3.66E-04 0.200 0.027 0.200 6.73E-03 
cg05191825 ISCU 0.100 3.93E-04 0.100 0.020 0.100 9.62E-03 
cg07837729 MACROD1 0.100 4.86E-04 0.100 0.022 0.100 0.011 
cg03611265 HEBP1 0.700 4.94E-04 0.600 0.034 0.800 6.46E-03 
cg27490193 HINT2 0.100 5.07E-04 0.100 7.92E-03 0.100 0.029 
cg20938103 COX8C -0.400 5.54E-04 -0.300 5.76E-03 -0.700 0.027 
cg02996269 PPA2 -0.200 6.19E-04 -0.300 0.015 -0.200 0.018 
cg03462975 HSD17B8 -0.300 6.96E-04 -0.300 0.022 -0.200 0.015 
                                                                                                  
201 
 
Probe Gene 
Meta-analysis Cohort 1 Cohort 2 
Methylation 
Difference 
(%) 
P Value 
Methylation 
Difference 
(%) 
P Value 
Methylation 
Difference 
(%) 
P Value 
cg08889044 SERHL2 -0.200 8.32E-04 -0.200 0.016 -0.200 0.025 
cg01192051 POLG 0.500 8.58E-04 0.500 0.029 0.700 0.012 
cg19191600 C6orf136 -0.300 8.76E-04 -0.300 9.69E-03 -0.400 0.043 
cg27249304 TYSND1 -0.200 9.25E-04 -0.100 0.019 -0.200 0.024 
cg15558129 LYPLAL1 -0.200 9.51E-04 -0.200 0.025 -0.200 0.019 
cg01972394 ALDH4A1 -0.200 1.12E-03 -0.300 0.010 -0.200 0.042 
cg26215887 SLC25A28 0.100 1.18E-03 0.100 0.033 0.200 0.01 
cg22920873 C7orf55 0.200 1.28E-03 0.200 0.041 0.200 0.016 
cg06538141 COX4I2 -0.200 1.34E-03 -0.200 0.021 -0.500 7.20E-03 
cg15466587 MRPS14 0.200 1.48E-03 0.100 0.018 0.200 0.034 
cg15035364 PMPCB -0.100 1.57E-03 -0.100 0.022 -0.100 0.035 
cg25110782 SHMT2 -0.300 1.87E-03 -0.300 0.022 -0.300 0.041 
cg07274998 OAT -0.200 1.92E-03 -0.200 0.04 -0.200 0.023 
cg25934700 SELO 0.200 2.26E-03 0.100 0.012 0.400 0.031 
cg19371708 GRPEL1 0.100 2.34E-03 0.100 0.028 0.100 0.037 
cg23407809 WDR81 0.300 2.55E-03 0.200 0.032 0.400 0.027 
cg03090204 ACSF3 -0.200 2.87E-03 -0.200 0.026 -0.400 0.026 
cg26070540 COX4I2 -0.400 3.17E-03 -0.400 0.05 -0.600 0.027 
cg24266622 SLC25A14 0.300 3.18E-03 0.200 0.041 0.600 0.012 
cg14192396 ALDH18A1 0.100 3.52E-03 0.000 0.035 0.100 0.049 
cg09038794 MOCS1 0.100 3.64E-03 0.100 0.034 0.100 0.049 
cg17518978 FARS2 -0.300 4.07E-03 -0.200 0.023 -0.600 0.041 
cg01531949 IDH3A 0.100 5.68E-03 0.100 0.049 0.100 0.049 
cg13716849 SARDH 0.300 6.33E-03 0.200 0.039 0.600 0.031 
cg06161915 SND1 0.200 7.09E-03 0.100 0.031 0.500 0.029 
cg17886330 ALDH4A1 -0.200 7.10E-03 -0.200 0.044 -0.500 0.031 
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6.4.6. Nuclear and MtDNA Methylation Patterns are Correlated in Braak-
Associated Loci 
Given that the mitochondrion and nucleus have been shown to have a complex 
interplay at the genomic and proteomic level, with many nuclear genes encoding 
for proteins responsible for the correct regulation of mitochondrial functioning, we 
were interested in examining whether there was a correlation between methylation 
differences within the nuclear and mitochondrial genomes. To this end, we used a 
correlation matrix to investigate the relationship between the 44 nuclear-
mitochondrial Braak-associated probes we identified in our meta-analysis (Table 
6.6) and the 29 mtDNA Braak-associated mitochondrial DMPs (Table 6.5). In total, 
this identified 55 nominally significant correlations between these mtDNA DMPs 
and ncDNA loci (Figure 6.4; Table 6.7). To determine whether any probes or 
DMPs were enriched for significant correlations with the other genome, Fisher’s 
exact tests for enrichment were performed (see Section 5.3.5). This identified two 
mitochondrial DMPs that were enriched for significant correlations with nuclear-
mitochondrial DMPs: 3495bp (MT-ND1; P=5.825E-05; Odds Ratio = 6.609), and 
7164bp (MT-CO1; P=0.037; Odds Ratio = 3.027). Further, two nuclear-
mitochondrial DMPs were identified as being enriched for significant correlations 
with mitochondrial DMPs: cg20938103 (Cytochrome C Oxidase Subunit 8C 
(COX8C); P=0.041, Odds Ratio = 3.463) and cg25110782 (Serine 
Hydroxymethyltransferase 2 (SHMT2); P=0.041, Odds Ratio = 3.463). 
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Figure 6.4: Correlations were calculated between each mitochondrial DMP and each nuclear-mitochondria 
DMP associated with Braak stage and plotted as a heatmap. Probes in the nuclear genome (x-axis) are ordered 
alphabetically whilst DMPs encoded by the mitochondrial genome (y-axis) are ordered by genomic location. To show 
the strength of correlations a colour scale was used, with dark red corresponding to strongly negative correlations 
and dark blue being associated with strongly positive correlations. 
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Mitochondrial 
DMP (bp) 
Mitochondrial 
Gene 
Nuclear Probe 
Correlated 
Nuclear 
Gene 
Correlation (r) P Value 
9921 MT-TG cg20140950 RDH13 -0.507 3.243E-04 
10775 MT-ND4 cg20938103 COX8C -0.490 5.470E-04 
6564 MT-CO1 cg20938103 COX8C -0.457 1.427E-03 
3495 MT-ND1 cg15466587 MRPS14 0.480 2.664E-03 
7164 MT-CO1 cg25110782 SHMT2 0.428 3.000E-03 
15392 MT-CYB cg19191600 C6orf136 -0.420 3.670E-03 
3495 MT-ND1 cg07274998 OAT -0.463 3.895E-03 
3643 MT-ND1 cg23407809 WDR81 0.413 4.310E-03 
12951 MT-ND5 cg22011804 FASTK 0.441 6.310E-03 
15041 MT-CYB cg09038794 MOCS1 -0.393 6.900E-03 
3495 MT-ND1 cg27249304 TYSND1 -0.426 8.510E-03 
3531 MT-ND1 cg05191825 ISCU 0.376 0.010 
5740 NA cg14912396 ALDH18A1 0.392 0.010 
3248 MT-TL1 cg25110782 SHMT2 -0.370 0.011 
3495 MT-ND1 cg01200965 HK2 -0.401 0.012 
7164 MT-CO1 cg17518978 FARS2 0.358 0.015 
9145 MT-ATP6 cg19371708 GRPEL1 -0.357 0.015 
7164 MT-CO1 cg14025831 PANK2 0.352 0.016 
786 MT-RNR1 cg23407809 WDR81 0.231 0.017 
3495 MT-ND1 cg27490193 HINT2 0.387 0.018 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
Table 6.7: List of significant correlations between mitochondrial DMPs and nuclear-mitochondrial DMPs 
that are significantly associated with Braak stage. Data is ordered by P value. 
                                                                                                  
205 
 
Mitochondrial 
DMP (bp) 
Mitochondrial 
Gene 
Nuclear Probe 
Correlated 
Nuclear 
Gene 
Correlation (r) P Value 
6564 MT-CO1 cg03462975 HSD17B8 0.348 0.018 
9921 MT-TG cg03169557 SPG7 0.347 0.018 
14920 MT-CYB cg14192396 ALDH18A1 0.388 0.018 
2844 MT-RNR2 cg19191600 C6orf136 -0.341 0.020 
9145 MT-ATP6 cg25110782 SHMT2 -0.343 0.020 
14920 MT-CYB cg20938103 COX8C -0.382 0.020 
8059 MT-CO2 cg05191825 ISCU -0.393 0.021 
16454 D-LOOP cg05242371 DMPK 0.362 0.022 
7164 MT-CO1 cg24266622 SLC25A14 0.334 0.023 
9574 MT-CO3 cg26182964 ECHS1 0.364 0.023 
10775 MT-ND4 cg07837729 MACROD1 -0.330 0.025 
3531 MT-ND1 cg03462975 HSD17B8 -0.330 0.026 
3643 MT-ND1 cg20140950 RDH13 0.329 0.026 
2642 MT-RNR2 cg22920873 C7orf55 0.336 0.027 
1415 MT-RNR1 cg01200965 HK2 -0.325 0.028 
15041 MT-CYB cg06161915 SND1 0.324 0.028 
3495 MT-ND1 cg17886330 ALDHA4 -0.360 0.029 
2642 MT-RNR2 cg03611265 HEBP1 -0.333 0.029 
2642 MT-RNR2 cg20938103 COX8C 0.331 0.030 
15200 MT-CYB cg22920873 C7orf55 0.321 0.030 
14920 MT-CYB cg25110782 SHMT2 0.353 0.032 
8164 MT-CO2 cg22920873 C7orf55 0.323 0.033 
3531 MT-ND1 cg14025831 PANK2 0.314 0.034 
3531 MT-ND1 cg12615866 MRPL1 -0.312 0.035 
3495 MT-ND1 cg25934700 SELO -0.345 0.037 
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Mitochondrial 
DMP (bp) 
Mitochondrial 
Gene 
Nuclear Probe 
Correlated 
Nuclear 
Gene 
Correlation (r) P Value 
3495 MT-ND1 cg05191825 ISCU 0.166 0.038 
7928 MT-CO2 cg22011804 FASTK -0.307 0.038 
3495 MT-ND1 cg24547396 COMT -0.337 0.041 
3643 MT-ND1 cg01192051 POLG -0.303 0.041 
2642 MT-RNR2 cg12615866 MRPL1 -0.312 0.042 
10775 MT-ND4 cg03169557 SPG7 -0.297 0.045 
15200 MT-CYB cg19191600 C6orf136 -0.296 0.046 
13726 MT-ND5 cg15558129 LYPLAL1 0.294 0.047 
1415 MT-RNR1 cg25934700 SELO -0.294 0.048 
7164 MT-CO1 cg14192396 ALDH18A1 0.294 0.048 
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6.5. Discussion 
The two major aims of this study were to validate existing findings identified in 
Chapter 5 and to identify differences in mtDNA methylation associated with AD 
neuropathology (Braak stage). The strongest associations between mtDNA 
methylation in Chapter 5 were seen with respect to sex. Unfortunately, due to the 
strict selection criteria for mitochondrial probes included in the current study, the 
two probes that passed Bonferroni correction in our initial mixed model, 8722bp 
and 9055bp (Chapter 5), were removed during QC. Despite this, we again 
demonstrated a significant enrichment for sex-associated DMPs to be 
hypermethylated in females compared to males in CTX.  
 
In Chapter 5, we also identified an enrichment for hypermethylated DMPs 
associated with increasing age. We failed to identify a similar enrichment in the 
current study. However, it is important to note that in the present study, we had the 
added covariate of Braak stage in our regression analysis, which given that AD is 
an age-related disorder, will also be associated with age. Whilst linear regression 
models can help to better define the role of covariates in determining mtDNA 
methylation, it remains impossible to account for all variance. As such, the lack of 
validation for the age-specific DMPs identified in Chapter 5 may be due to the use 
of a more complex model. To better understand the role of ageing on mtDNA 
methylation status, it would be important to conduct future studies on healthy non-
demented control donors, over a wider range of ages than those investigated in the 
current study. The ideal experiment would utilise longitudinal samples from the 
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same individuals to determine mtDNA methylation changes over time. However, 
this is not possible when using post-mortem human tissue from an inaccessible 
tissue such as the brain. An alternative experiment may seek to examine 
longitudinal changes in mtDNA methylation with age, using genetically identical 
mice. 
 
Of the 29 mitochondrial Braak-associated DMPs identified, six corresponded to 
genes within Complex I of the ETC. A further ten corresponded to genes within 
Complex IV of the ETC. Taken together, these findings could indicate 
dysregulation within the ETC at the methylome level. However despite this, no 
enrichment for genes within any ETC complex was identified, which could be due 
to the fact that a large proportion of the assay consists of methylated cytosines 
within ETC complexes. Interestingly, previous studies have identified that 
mutations in genes within Complex I of the ETC lead not only to decreases in 
OXPHOS efficiency (273) but also to an increase in free radical production (274). 
Both of these changes have been routinely observed in AD (275) and associated 
with AD pathology (276). A recent study identified that mtDNA methylation 
differences were also associated with Braak stage in AD patients within both the D-
LOOP and MT-ND1 (200). This pyrosequencing study identified an increase in D-
LOOP methylation and a decrease in methylation in MT-ND1 at multiple sites 
across both regions. Whilst Blanch and colleagues did indeed identify three DMPs 
within MT-ND1 and one within D-LOOP, only 3495bp (MT-ND1) and 16,454bp (D-
LOOP) identified in our study were in the same direction as the general pattern of 
methylation observed in their study.  
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Given that robust and reproducible DNA methylation changes in the nuclear 
genome have previously been identified in several EWAS of AD using the 450K 
array (198,242,243,277,278), we were interested to determine whether we could 
identify differential DNA methylation in nuclear-mitochondrial genes. A meta-
analysis of two cohorts (94,279) identified 44 DMPs with respect to AD 
neuropathology. Interestingly one DMP, SPG7, reached Bonferroni significance 
and has been previously shown to be associated with AD from a published EWAS 
in AD prefrontal CTX (95). SPG7 is the only gene to have been associated with 
spastic paraplegia 7, which has been shown to present with a number of 
neurological factors such as white-matter damage in the frontal lobe (280); ALS, a 
chronic, neurodegenerative disease (281); and in several models of cerebellar 
ischemia (282,283). Importantly, downregulation of this gene has been associated 
with the opening of the mPTP, leading to subsequent Ca2+ retention and 
mitochondrial dysfunction (34), all of which have been identified in AD (284). 
 
Our final analysis aimed to better understand the relationship between methylation 
patterns in the mitochondrial and nuclear genomes. By investigating the frequency 
of significant correlations between Braak-associated DMPs we identified in both 
genomes we identified four DMPs (two mtDNA and two ncDNA), which were 
significantly enriched for correlations to the other genome. Within the mitochondrial 
genome, both 3495bp (MT-ND1) and 7164bp (MT-CO1) were enriched for 
significant correlations, whilst in the nuclear genome cg20938103 (COX8C) and 
cg25110782 (SHMT2) had more significant correlations with mtDNA DMPs than 
expected by chance. The functional relevance of this cross-talk between the 
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genomes warrants further investigation. However, it is worth noting that six of nine 
nuclear-mitochondrial probes correlated to 3495bp (MT-ND1) shared an inverse 
relationship, which could suggest a compensatory mechanism, by which changes 
in the levels of mtDNA methylation could potentially lead to changes in expression 
and protein translation could invoke a compensatory reaction in nuclear-
mitochondrial genes. Whilst the relationships between these two methylomes at 
this time can only be hypothesised, the data remains intriguing and studies should 
seek to investigate this potential complex interplay further.  
 
6.6. Conclusions 
Despite a strict and conservative selection criterion for loci in the current study, we 
were first able to validate sex-specific trends of hypermethylation in females 
observed in Chapter 5. Importantly, our study has identified a number of novel 
mtDNA loci that were differentially methylated with respect to Braak stage. 
Functional exploration could provide new insights into this field. Finally, our study 
was the first to attempt to correlate differences between the nuclear and 
mitochondrial methylomes, pointing to the possibility of a new layer of complex 
regulation between the two and potentially, an additional way in which to regulate 
mitochondrial functionality. 
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Chapter 7. General Discussion 
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7.1. Introduction 
Throughout this chapter, I aim to summarise the key findings made throughout 
each chapter of the thesis and the limitations present within these studies. I will 
then look to discuss and address the limitations when studying the field of mtDNA 
methylation, with emphasis on how my research has aimed to tackle some of these 
issues. Finally, I will discuss my opinion on the future perspectives for the field in 
an attempt to outline what studies could allow for its further development. 
 
7.2. Key Findings from the Thesis 
 
7.2.1. Chapter 3: Investigating the use of Publicly Available Data for the 
Determination of MtDNA Methylation Patterns Across Different Tissue Types. 
In our study, we aimed to provide an in-silico pipeline to control for the presence of 
NUMTs in publicly available genome-wide methylomic datasets from post-mortem 
brain tissue, to gain a better understanding of the mitochondrial epigenome in 
human brain. A number of different approaches have been used to define 
mitochondrial variants in whole-genome sequencing (285-288) and RNA-Seq data 
(289) given the high relative-abundance of reads that align to the mitochondrial 
genome. However, the method we employ in Chapter 3, despite being more 
computationally intensive and somewhat slower than these previous approaches, 
is likely to yield the most true representation of mtDNA profiles. Indeed, similar 
approaches have been suggested for complementary analysis of mtDNA from 
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total-genome data using other sequencing technologies, as reviewed by Ye et al., 
2014 (290); however our methodology is the first to be implemented on MeDIP-Seq 
data. Although MeDIP-Seq data has been employed to interrogate the 
mitochondrial epigenome in a variety of cell lines and tissues (63), the pipeline 
used in this study may not have adequately addressed the homology between the 
nuclear and mitochondrial genomes. That study aligned reads derived from whole-
genome data and aligned directly to the mitochondrial genome (63). Whilst the 
study does attempt to address this limitation, via simultaneous modelling to the 
nuclear genome, forcing reads derived from whole-genome data into a targeted 
sequence could lead to a mixed nuclear-mitochondrial profile of mtDNA 
methylation being established.  
 
One caveat of the method employed in Chapter 3 is that it removes any regions of 
the mitochondrial genome that share a high sequence homology to regions of the 
nuclear genome, meaning we were only able to examine a truncated sequence. 
However, our study did identify a relatively conserved pattern of mtDNA 
methylation between samples. This pattern of conservation was also seen in 
previous studies (63). 
 
Our study also demonstrated that mtDNA methylation patterns were able to 
separate tissues based on their Euclidean distance, a measure of the variation 
between all samples. Furthermore, we were able to identify eight DMRs that were 
significantly differentially methylated after Bonferroni correction between total CTX 
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and CER. When taken together, our findings show tissue-specific differences in 
mtDNA methylation, and suggest that these could be influenced by brain-specific 
cell populations. Overall, our findings highlight that the mitochondrial epigenome 
warrants further investigation and that, ideally, such studies should be undertaken 
in isolated mtDNA in order to prevent the need to truncate the consensus 
sequence. 
 
7.2.2. Chapter 4: A Comparison of MtDNA Isolation Methods in Post-Mortem 
Archived Human Brain Tissue: Applications for Studies of Mitochondrial Genetics 
in Brain Disorders. 
Our study represents an important step in developing a protocol to better 
interrogate the mitochondrial epigenome in the absence of NUMTs. Currently, most 
available mtDNA isolation techniques have been optimised on fresh tissue or cell 
lines (291,292), and have not been tested in frozen post-mortem brain tissue. 
Further, another common isolation methodology employs the use of long-range 
PCR to amplify the mitochondrial genome prior to sequence analysis (292). 
However, this method cannot be used prior to bisulfite treatment, as PCR 
abolishes the DNA methylation signature. As such, a method to specifically isolate 
mtDNA from frozen post-mortem tissue, which could then be used for downstream 
(epi)genomic analyses, was of upmost importance.  
 
In Chapter 4, we compared different methodologies to enrich for mtDNA relative to 
ncDNA. Interestingly, one method (Method B), which utilised the exonuclease 
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RecJf to preferentially cleave linear DNA (ncDNA), gave a lesser enrichment than 
the standard phenol: chloroform DNA extraction technique. One possible 
explanation for this could be that potential nicks introduced into mtDNA via the 
freeze-thawing process may have linearised the genome. Our study found that an 
antibody based enrichment technique from Miltenyi Biotec (Method E), significantly 
enriched for mtDNA compared to all other techniques tested.  This method used an 
anti-TOM-22 antibody conjugated to magnetic microbeads to capture mitochondria, 
from which we later extracted DNA. Interestingly, this is in contrast to a previous 
study, which showed similar enrichments between Method E and the use of Percoll 
(Method A) (293). However, that study was carried out on cultured human cells. 
Method A relies on the establishment of a density gradient for adequate 
enrichment of mitochondria. Whilst mitochondria in cell lines and fresh tissue are 
likely to have similar weights and conformations, the shock of freeze-thawing tissue 
can lead to degradation of mitochondria and may therefore increase the size of the 
mitochondrial fraction, resulting in more nuclear contaminants being extracted from 
a less distinct band.  Method E is dependant not on the physical properties of 
mitochondria, but on the organelle’s protein content. TOM-22 is a protein 
expressed on the OMM, as such our findings could be explained by the specificity 
of this antibody, which is independent of tissue quality. 
 
In summary, in Chapter 4, we therefore identified a methodology that is both fast 
and reliable for the enrichment of mtDNA from archived, post-mortem brain tissue, 
providing a basis for further studies into the field of mitochondrial epigenetics.  
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7.2.3. Chapter 5: A Genome-wide Interrogation of MtDNA Methylation via NGS 
In Chapter 3 we identified mtDNA DMRs between CTX and CER. However, one 
caveat of this approach is that the antibody enrichment and fragment based library 
preparation makes it impossible to examine mtDNA methylation differences at 
single nucleotide resolution. Therefore, in Chapter 5 we employed an adapted 
NGS methodology from Agilent to identify specific patterns of mtDNA methylation 
across the mitochondrial epigenome in mtDNA isolated using the anti-TOM22 
antibody method we selected in Chapter 4.  
 
Our primary analysis identified that mtDNA methylation exists with a distinct 
prevalence towards non-CpG sites. This corroborates a previous study which 
shows that mtDNA methylation in the mitochondrial D-LOOP also has a striking 
prevalence towards non-CpG methylation (256). Of interest, this pattern of 
methylation is of stark contrast to that primarily exhibited in mammalian nuclear 
genomes (294-296), where only a small percentage of DNA methylation sites are 
found in this context and as such, the pattern of mtDNA methylation shares more 
similarity to that of a prokaryote (256), which is corroborated by our findings.  
 
Our analysis focused on identifying DMPs associated with tissue type, sex and 
age. Sexual dimorphism of mitochondrial output has previously been identified 
(297) and has also been associated with neuronal cell death (298). Despite these 
studies being limited to nuclear-mitochondrial genes, they do give evidence to 
support a sex-specificity for mitochondrial function. Interestingly our study 
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highlighted five DMPs remaining significantly associated with sex after Benjamani-
Hochberg correction. Further, two DMPs, at 9055bp and 8722bp, also passed a 
more strict Bonferroni correction for multiple testing. Two of these DMPs were 
identified within MT-ATP6, a gene encoding for a mitochondrial protein within 
Complex V of the ETC. This complex is critical for sustainability of the proton 
gradient required for ATP generation (299). Whilst the functional consequences of 
these differences have yet to be determined, it remains plausible that they could 
contribute towards some of the sex-specific variability observed in mitochondrial 
outputs. 
 
An interesting observation in ncDNA epigenetics is the association of epigenetic 
modifications with ageing. In general, global levels of ncDNA methylation show 
hypomethylation with increasing age (300-303). However, EWAS has 
demonstrated that these age-associated ncDNA methylation changes are loci-
specific, with multiple CpGs showing hypermethylation with increasing age 
(304,305). Furthermore, in both EWAS of age the ratio of hyper- to hypomethylated 
probes is relatively close to one. In Chapter 5, we showed an enrichment for age-
associated DMPs to be hypermethylated with increasing age in both the STG and 
CER, suggesting that mtDNA methylation is dissimilar to ncDNA methylation in this 
respect.  
 
Our findings also disputes previous research that has suggested that mtDNA 
methylation exists at low, biologically irrelevant levels (70). Whilst in Chapter 5 we 
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report that in general, mtDNA methylation levels were low (1-3%), we found that an 
average of 4.68% of all loci in our cohort displayed DNA methylation levels greater 
than 5%. The average sequencing depth of our study was of an order of magnitude 
greater than the previous study by Hong and colleagues and, as such, is more 
likely to represent average methylation levels in a multi-copy, heteroplasmic 
genome. Importantly, we also identified one locus within the mitochondrial D-LOOP 
with average DNA methylation levels of 15.3% and 14.6% methylation in the STG 
and CER respectively. Interestingly, this region has been strongly implicated in 
mitochondrial transcription and replication (306-308). As such, relatively high levels 
of mtDNA methylation at this site could have strong functional implications for 
mitochondrial biogenesis.  
 
Our method was able to specifically and significantly enrich for mtDNA in the 
absence of NUMTs. To demonstrate this, we sequenced matched samples that 
were enriched for mtDNA and their respective ncDNA using our mtDNA isolation 
method (Method E- Chapter 3), prior to library preparation. We then calculated the 
average loci-wise mean and standard error of each methylated cytosine to 
determine the potential variability at each site. By comparing this to methylation 
levels of matched, ncDNA samples, we were able to infer whether the enrichment 
affected DNA methylation levels. Loci with DNA methylation levels greater than the 
standard error for that tissue type were said to be affected by the enrichment. In 
total, only 167 of 870 probes were unaffected by the enrichment for STG. However, 
679 of 870 probes were unaffected by the enrichment process in CER. Whilst the 
sample size makes drawing clear conclusions from this analysis difficult, it does 
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suggest that enriching for mtDNA prior to sequencing can affect DNA methylation 
levels observed. 
 
In summary, this study identified a number of DMPs associated with tissue, sex 
and age. As such, our study highlights the importance of controlling for these 
factors in future epidemiological studies and also potentially implicates mtDNA 
methylation as a functional epigenetic mark. Further, we were able to develop and 
optimise a custom, targeted BS-Seq method for the mitochondrial epigenome, 
providing the basis for more detailed investigations into mtDNA methylation in 
future studies. 
 
7.2.4. Chapter 6: Interrogating the Role of MtDNA Methylation in AD 
Given that AD is characterised by mitochondrial dysfunction, we hypothesised that 
this may be driven by epigenetic processes. In the final data Chapter we aimed to 
use the methods developed in Chapters 4 and 5 to investigate mtDNA methylation 
differences associated with AD neuropathology, as well as validating sex and age 
associated DMPs identified in Chapter 5. In addition, we investigated DNA 
methylation differences in AD in nuclear-encoded genes encoding proteins that are 
imported into the mitochondria.  
 
Initially we sought to identify sex-associated DMPs and compare these to those we 
identified in Chapter 5. Initially, we sought to identify sex-associated DMPs and 
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compare these to those we identified in Chapter 5. However, only one, at 15,761bp 
(MT-CYB) was replicated in all three regions. Unfortunately, the majority of studies 
investigating MT-CYB have focussed on its role in disease (309-311) and as such, 
sex-specific variation within this gene has yet to be thoroughly investigated. 
However, a further three were found to be in common between ECX and STG, as 
well as a further two which were significant in ECX and trended towards 
significance in STG. We were unable to find any common sex-associated DMPs 
between ECX and CER. This suggests that sex-specific DMPs may also be tissue-
specific, with the two cortical brain regions (ECX and STG) sharing more sex-
associated DMPs than ECX and CER. It is worth noting however, that we did find 
more sex-associated DMPs in common between the STG and CER than between 
ECX and STG; however, this is possibly due to the STG and CER being isolated 
and analysed at the same time (i.e. within Chapter 5), whilst the ECX analysis 
(Chapter 6) was independent, and thus samples were isolated and analysed at a 
different time.  
 
Our primary aim in Chapter 6 was to identify mtDNA methylation differences 
associated with AD neuropathology, as defined by Braak stage. We identified 29 
nominally significant, disease-associated DMPs. Interestingly, many of these 
DMPs occurred in genes encoding for ETC proteins, however no enrichment for 
DMPs in any ETC complex was identified. The deregulation of OXPHOS and 
generation of ROS has been tightly linked to mitochondrial dysfunction and AD 
(267,312). However to date, no study has identified the molecular mechanisms 
driving this phenomenon. It would be important to investigate the consequence of 
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disease-associated mtDNA methylation differences we identified, on mitochondrial 
function.  
 
Our meta-analysis aimed to investigate DNA methylation differences in nuclear-
encoded mitochondrial genes and identified 44 nominally significant DMPs that 
were consistently differentially methylated in both cohorts. Of these, one DMP 
residing in SPG7 was Bonferroni significant. This DMP has been previously 
identified as an EWAS locus in AD in a cohort of 708 prefrontal CTX samples (95). 
Our findings further highlight the robustness of this DMP in AD, by identifying it in a 
cohort of 217 ECX samples from independent donors. SPG7 is the only gene to 
have been associated with spastic paraplegia 7, which not only presents with 
limbic deterioration but also a number of neurological factors such as white-matter 
damage in the frontal lobe (280). Further, genetic and transcriptomic variation 
within SPG7 have also been associated with ALS, a chronic, neurodegenerative 
disease (281), as well as in spastic ataxia (313), and has also been found  to play 
a role in various models of cerebellar ischemia (282,283). SPG7 downregulation 
has been shown to lead to the establishment of the mPTP (283). Interestingly, the 
establishment of the mPTP leads to Ca2+ retention and mitochondrial 
depolarisation and has been associated with AD pathogenesis in previous studies, 
as reviewed in Qi, et al., 2016 (284). 
 
Finally in Chapter 6 we investigated the relationship between the 44 nuclear-
encoded Braak-associated DMPs and the 29 mitochondrial-encoded Braak-
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associated DMPs. In total we identified 55 nominally significant correlations 
between the two genomes. Further, we identified four DMPs (two mitochondrial, 
two nuclear) that were enriched for significant correlations within the other genome. 
This final analysis therefore provides a potential new mechanism for the complex 
interplay between the two genomes and should be further investigated to better 
understand the molecular mechanisms in place to aid correct mitochondrial 
functioning. Negative correlations between DMPs within the two genomes could 
indicate a potential compensatory mechanism, whereby changes in the methylation 
profile of specific loci in one genome could lead to an alteration of ETC complex 
function, resulting in changes to the methylation profiles of other loci in the other 
genome. However, this assumes that mtDNA methylation has an effect on gene 
expression. Whilst a recent study has shown that changes in mtDNA methylation at 
the mitochondrial promoter regions are associated with differences in the 
expression of a number of mitochondrial genes (314), a thorough genome-wide 
investigation into mtDNA methylation and gene expression has yet to be 
undertaken. Therefore, understanding the potential complex relationship between 
the two genomes at the epigenetic level requires careful consideration. 
 
7.3. General Discussion and Future Perspectives 
Despite identifying nominally significant differences associated with all covariates 
analysed in Chapters 5 and 6, the effect sizes seen in both studies are relatively 
small and elucidating their functional consequence could prove very difficult. It is 
important to note however that this could be due to the high levels of heterogeneity 
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taken from a tissue sample. The multi-copy nature of mitochondria ensures that, 
not only does mtDNA show a great level of heteroplasmy across tissues, but also 
that it may occur within a single cell (315). As such, a detailed investigation into the 
actual level of mtDNA methylation at the single-cell level would significantly 
advance the field.  
 
The development of single cell techniques for the investigation of genetic 
heteroplasmy within mitochondria has aided in elucidating our understanding of 
such variation within the organelle (316,317). For example Jayaprakash et al., 
(2015) developed a technique, MSeek, to isolate and sequence mtDNA from cells 
at different timepoints, allowing for the accurate determination of heteroplasmy 
levels under different conditions. This has served to improve our understanding of 
the role of mitochondrial replication in maintaining levels of heteroplasmic variants 
(317) and could aid in more precisely determining mitochondrial variants within 
cells causing mitochondrial dysfunction. To determine the functional effect of 
mtDNA methylation within a cell at a high precision would be of great benefit to the 
field, however at present, there is no methodology capable of accurately 
processing such low levels of mtDNA for epigenetic sequencing. 
 
To determine the role mtDNA methylation may play on the governance of changes 
to mitochondrial gene expression, ROS levels and ETC activity is of upmost 
importance for future studies and would aid in determining whether mtDNA 
methylation may contribute to disease. One way in which this could addressed is 
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through the use of a cybrid cell line (see Section 1.5.4). Briefly, native mtDNA is 
knocked down within a cell line and patient mtDNA with a (genetic) variant of 
interest is inserted. This allows for a control cell line with the same ncDNA as the 
cell line with the inserted mtDNA. As such, variation in mitochondrial output would 
be driven by the mitochondrial variant (318). To date, this has only been performed 
to establish the effects of mt-SNPs (319), however it remains possible to utilise this 
methodology to explore the functional effects of mtDNA methylation. By treating 
cells with 5-aza, a commonly used DNA methylation inhibitor (320-322) or SAM, a 
substrate used to increase DNA methylation (323), parent cell mtDNA methylation 
could be abolished or increased. Whilst delineating the specific effects of mtDNA 
methylation in the parent cells would be difficult, given that ncDNA methylation 
would also be affected, transferring mtDNA with altered methylation profiles into a 
cybrid cell line could help to answer key questions in the field of mitochondrial 
epigenetics. One caveat of this approach is that it would only investigate global 
alterations in mtDNA methylation levels, and would not be able to distinguish the 
functional effects of site-specific mtDNA methylation changes.  
 
Adaptations on the original CRISPR-Cas9 genetic editing technology have allowed 
for site specific epigenetic modifications (324). Traditionally, the CRISPR-Cas9 
construct employs a synthetic guide RNA to recognise and target the sequence of 
interest. Cas9 is then directed towards this sequence, cutting the DNA and 
allowing for targeted, site-specific genetic alterations (325). To allow for the 
addition of specific epigenetic modifications to the target site, the cleavage sites of 
Cas9 are deactivated, producing a dCas9 variant that binds to the target sequence 
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without cutting DNA (324). Further, by addition of a mitochondrial specific targeting 
sequence to the original CRISPR construct, specific mtDNA alterations can be 
achieved (326). It is therefore possible that a coupling of these two adaptations 
could create a construct that would specifically target specific loci in the 
mitochondrial epigenome. By tethering DNMT or TET proteins to this mitochondrial 
dCas9, mtDNA methylation could therefore be increased or decreased respectively 
at target sites.  
 
In Chapter 6 we identified a number of significant correlations between disease-
associated DMPs encoded by the nuclear and mitochondrial genomes. However, 
the potential importance of these correlations has yet to be elucidated. For 
example, inverse correlations could represent a compensatory mechanism, 
whereas positive correlations could indicate the development of a positive 
feedback loop. However, it is important to note that these differences were 
identified in a small cohort and none passed any testing for multiple corrections, 
nor have they been validated by subsequent experiments. Despite this, with the 
development of technologies such as CRISPR-Cas9 epigenetic editing, it would 
remain of significant interest to determine whether ncDNA methylation differences 
can lead to specific alterations in the mitochondrial methylome and whether these 
changes may in turn, effect mitochondrial output.  
 
A major limitation of this study is the pre-enrichment methodology we chose to 
employ. Our adapted mitochondrial isolation method, utilised throughout the course 
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of this thesis, showed significant enrichments for mtDNA. However, we showed in 
Chapter 5 that mtDNA methylation varied in matched samples that were and were 
not enriched for mtDNA prior to capture. This raises two important questions. First, 
how similar is the methylome of pure mtDNA to the methylome of mitochondria 
isolated using the anti-TOM22 antibody approach? Second, if mitochondria were 
isolated from matched samples using different isolation methodologies that 
achieved a similar purity, would the mtDNA methylome of these matched samples 
be similar; does the enrichment methodology we employ throughout this thesis 
have any unexplored biases and would a different methodology yield different 
methylation profiles? Both questions would be important to address in the future to 
provide further evidence to support the reproducibility of our experimental design. 
 
Despite these limitations, it is important to note the stage in which the field of 
mtDNA epigenetics was prior to these studies, being restricted to candidate based 
gene approaches to explore small sections of the mtDNA epigenetic variation in 
disease (1,221). The development of EWAS has led to a significant improvement in 
our understanding of the complex role that ncDNA epigenetics plays in health and 
disease, as reviewed by Flanagan., 2015 (327). It is therefore possible that the 
development of this mitochondrial epigenome-wide pipeline could similarly aid the 
field of mitochondrial epigenetics.   
 
Our studies have now provided a strong basis for the future exploration of mtDNA 
methylation in any number of clinical phenotypes or experimental settings, with 
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many questions still remaining to be answered. The most important of which are 
first, whether variation in mtDNA methylation has an effect on mitochondrial 
function and second, whether in certain phenotypes, for example in those that are 
characterised by high  levels of mitochondrial dysfunction, the effect sizes seen 
may be greater than those identified in Chapters 5 and 6. Experimental design 
remains critical to answering these questions and coupling a discovery based 
approach such as the one defined throughout the course of this thesis, with a 
target validation methodology such as the dCas9 approach suggested could aid in 
the elucidation of a previously ill-defined layer of epigenetic regulation. 
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 2 
Matthew Devall, Jonathan Mill and Katie Lunnon 3 
 4 
Keywords: 5 
Alzheimer’s disease, AD, dementia, mitochondria, epigenetics, DNA methylation, mtDNA, 6 
heteroplasmy, 5-methylcytosine, 5-hydroxymethylcytosine 7 
SUMMARY  8 
Considerable evidence suggests that mitochondrial dysfunction occurs early in Alzheimer’s 9 
disease, both in affected brain regions and in leukocytes, potentially precipitating 10 
neurodegeneration through increased oxidative stress. Epigenetic processes are emerging 11 
as a dynamic mechanism through which environmental signals may contribute to cellular 12 
changes, leading to neuropathology and disease. Until recently little attention was given 13 
to the mitochondrial epigenome itself, as preliminary studies indicated an absence of DNA 14 
modifications. However, recent research has demonstrated that epigenetic changes to the 15 
mitochondrial genome do occur, potentially playing an important role in several disorders 16 
characterized by mitochondrial dysfunction. This review explores the potential role of 17 
mitochondrial epigenetic dysfunction in Alzheimer’s disease etiology and discusses some 18 
technical issues pertinent to the study of these processes. 19 
 20 
 21 
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 22 
 23 
Alzheimer’s disease (AD) is a chronic, currently incurable, neurodegenerative disorder, 24 
accounting for more than 60% of dementia cases, with current estimates predicting more 25 
than 135 million dementia cases worldwide by 2050 [1]. The classic neuropathological 26 
hallmarks associated with AD include the formation of amyloid beta (Aβ) plaques and 27 
neurofibrillary tangles. These are suggested to play a role in the further development of 28 
other characteristics of the disease, such as disruption of calcium homeostasis, loss of 29 
connectivity, the generation of reactive oxidative species (ROS) and altered plasticity, 30 
ultimately leading to neurodegeneration [2-6]. Mitochondrial dysfunction is a consistent 31 
feature of AD pathology in both the brain and white blood cells [7-10] although the 32 
molecular mechanism(s) mediating this phenomena are yet to be fully elucidated. 33 
 34 
Mitochondrial dysfunction: a prominent feature of AD 35 
Being the site of ATP generation, mitochondria provide the cell with the energy required to 36 
properly function; as such they are often described as ‘the powerhouse of the cell’. 37 
Mitochondria are cylindrical organelles containing ~16.6kb of DNA (mtDNA) [11], which is 38 
separate to the nuclear genome and inherited in a maternal, non-Mendelian fashion. The 39 
mitochondrial genome consists of 37 genes, 13 of which encode for polypeptides required 40 
for the electron transport chain (ETC) (Figure 1), in addition to two ribosomal RNAs and 22 41 
transfer RNAs. The mitochondria play a vital role in a variety of key biological functions, 42 
including apoptosis via caspase dependent and independent mechanisms [12], the 43 
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regulation of calcium homeostasis [13, 14] and the production of ROS [15]. For these 44 
reasons, mitochondrial dysfunction has been implicated in the pathogenesis associated with 45 
AD [16, 17] and forms the basis of the mitochondrial cascade hypothesis [18]. Proposed by 46 
Swerdlow et al, this hypothesis states that an individual’s genetic code will determine their 47 
basal mitochondrial function and that, throughout ageing, this function will decline due to a 48 
combination of genetic and environmental factors, determining an individual’s time of 49 
disease onset [18].  50 
 51 
Mitochondrial-encoded ETC gene expression has been shown to be altered in both early and 52 
late stages of AD, with decreased expression of complex I and increased expression of 53 
complexes III and IV [7]. Increased expression of mitochondrial-encoded ETC complex genes 54 
has also been associated with aging, with increased expression of complexes I, III, IV and V 55 
in  12- and 18-month wild-type mice compared to 2-month mice, which was accompanied 56 
by increased oxidative damage [19]. However decreased expression of these genes was 57 
seen in older, 24-month old mice. Further evidence for a role of mitochondria in AD 58 
pathogenesis comes from a study demonstrating increased levels of mitochondrial gene 59 
expression and oxidative damage in a transgenic Amyloid Precursor Protein (APP) mutant 60 
mouse model of AD [20]. In addition, various components of the mitochondrial permeability 61 
transition pore (mPTP), which acts as a voltage-dependent channel regulating mitochondrial 62 
membrane permeability, have been shown to interact with Aβ in various murine models of 63 
AD. For example, one recent study found that, in APP transgenic mice, Aβ acts to upregulate 64 
VDAC1, a component of the mPTP, leading to mPTP blockade. [21]. Interestingly, this study 65 
also reports that VDAC1 may interact with hyperphosphorylated tau, suggesting another 66 
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mechanism of mitochondrial dysfunction. An earlier study found that Aβ present in 67 
mitochondria interacts with CypD, another component of the mPTP, in cortical samples 68 
from post-mortem AD patients and mAPP transgenic mice [22]. In the mouse model, this 69 
was shown to lead to increased ROS production and neuronal cell death. Taken together, 70 
this illustrates how mitochondrial-encoded gene expression is altered in AD, a variety of 71 
mechanisms by which Aβ interacts with mitochondria in AD, and how mitochondrial 72 
dysfunction can lead to changes associated with AD, thus highlighting the need for 73 
continued research into the field. 74 
 75 
Epigenetics and AD 76 
Given the high heritability estimates for AD [23], considerable effort has focussed on 77 
understanding the role of genetic variation in disease etiology, although more recently it has 78 
been hypothesized that epigenetic dysfunction may also be important [24]. A number of 79 
studies have shown reduced global levels of the DNA modifications 5-methylcytosine (5-mC) 80 
and 5-hydroxymethylcytosine (5-hmC) in AD brain [25-28] with only a handful of studies 81 
have looked at changes occurring at specific loci (reviewed in [24]). Recent methodological 82 
advances in microarray and genomic sequencing technologies have enabled researchers to 83 
undertake epigenome-wide association studies (EWAS) in AD brain, identifying several 84 
consistent differentially methylated regions (DMRs) associated with disease [29-31]. Many 85 
of these DMRs are tissue-specific, restricted to regions of the brain associated with AD 86 
pathology, and correlate strongly with quantitative measures of neuropathology.  As such, a 87 
strong case is being built for a role of epigenetics in the etiology of AD. 88 
 89 
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Epigenetic regulation of the mitochondrial genome 90 
Although hypotheses about the importance of mtDNA modifications are by no means 91 
recent, research in this area has been marred by contradictory results since the 1970s [32-92 
35]. The confirmation in 2011 of both 5-mC and 5-hmC occurring in mtDNA prompted a 93 
resurgence of interest in mitochondrial epigenomics [36]. The mitochondrial epigenome has 94 
some notable differences compared to the nuclear epigenome, and an overview of the 95 
mitochondrial genome, including its CpG sites, can be seen in Figure 1. Unlike the nuclear 96 
genome, the mitochondrial genome does not contain classical CpG islands [36], and is not 97 
associated with chromatin; instead it is structurally organised by nucleoids [37, 38]. As a 98 
result, mtDNA is not associated with histone proteins and relies on transcription factors 99 
such as mitochondrial transcription factor A (TFAM) to mediate compaction [39]. Histone 100 
modifications do not therefore play a direct role in regulating mitochondrial gene 101 
expression, highlighting the potential importance of DNA modifications in the regulation of 102 
mitochondrial function [40]. Evidence suggests that mtDNA methylation largely influences 103 
mtDNA structure and replication and is affected by factors which influence nucleoid 104 
compaction and DNA methyltransferase (DNMT) binding [41]. It has been shown that 105 
different areas of mtDNA are packaged differently and that a depletion of the nucleoid 106 
protein ATAD3 can reduce mtDNA methylation, resulting in an open circular state 107 
mitochondrial genome, although evidence for an effect of TFAM on mtDNA methylation was 108 
inconclusive [41]. 109 
 110 
DNMTs are a family of enzymes that catalyse the removal of a methyl group from methyl 111 
donors such as S-adenosylmethionine (SAM) for addition to the 5-position of cytosine. 112 
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Recently, a DNMT isoform, mitochondrial DNMT1 (mtDNMT1), has been found to contain a 113 
mitochondrial targeting sequence allowing it to bind to the D-loop of the mitochondrial 114 
genome, which contains the promoter sites for both the light and heavy strand of mtDNA 115 
and can therefore influence mitochondrial gene expression by altering transcriptional 116 
activity [36]. Furthermore, it has been suggested that the presence of these 117 
methyltransferases in mitochondria may be tissue-specific. Although Shock et al, did not 118 
observe mitochondrial localization of DNMT3a in the two cell lines they investigated, a later 119 
paper has found that DNMT3a is present, and in higher levels than mtDNMT1, in the 120 
mitochondria of motor neurons [42]. This study also demonstrated significantly higher 121 
global levels of both mitochondrial DNMT3a and 5-mC in Amyotrophic Lateral Sclerosis (ALS) 122 
motor neurons in vivo, suggesting a potential role for mtDNA methylation in motor neurons. 123 
DNMT1 and DNMT3b have also been observed in the mitochondria, with their inactivation 124 
reducing methylation at CpG sites [43].  125 
 126 
Recently, it has been debated whether 5-hmC is just an intermediary product of the 127 
demethylation process of 5-mC to cytosine or could represent an independent epigenetic 128 
mark [44]. Growing evidence now suggests that 5-hmC could be a mark in its own right, 129 
produced from the conversion of 5-mC by TET1, TET2 and TET3 [45], with both TET1 and 130 
TET2 being present in the mitochondria [43]. Taken together with the presence of 5-hmC in 131 
the mitochondrial D-Loop [36], this strengthens the evidence suggesting that demethylation 132 
pathways are not only important in nuclear epigenetics, but may also play a role in the 133 
mitochondria. Furthermore, recent evidence suggests that 5-mC and 5-hmC exist stably 134 
within mtDNA at cytosines not preceding a guanine base, suggesting a role for non-CpG 135 
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methylation in mtDNA [46]. Further, CpG and non-CpG methylation has been observed in 136 
the mitochondrial D-loop at conserved regions associated with DNA-RNA hybrid formation 137 
during transcription, suggesting that DNA methylation in mitochondria shares similarities 138 
with plants and fungi and that this methylation may play a role in regulating  mtDNA 139 
transcription and replication in a cell type-specific fashion [43]. 140 
 141 
MtDNA modifications in disease 142 
Despite little being known about the physiological impact of variation in mtDNA 143 
methylation, some recent studies have shown that it may be associated with a variety of 144 
diseases. The majority of studies have focussed on diseases where mitochondrial 145 
dysfunction is known to be prevalent, for example in cancer, which has been previously 146 
linked with mitochondrial dysfunction [47] and more recently in Down’s Syndrome, where 147 
mitochondrial abnormalities have also been reported [48]. Particularly, for the purpose of 148 
this review, mitochondrial dysfunction and mtDNA methylation aberrations in Down's 149 
syndrome cells (see Table 1) are interesting given that these patients have an increased 150 
likelihood of presenting with AD-like phenotypes throughout aging [49, 50] due to 151 
possessing an extra copy of  APP. An overview of studies of mtDNA epigenetics in disease is 152 
given in Table 1. 153 
 154 
MtDNA modifications: evidence for a role in AD and aging  155 
Until recently the role of mtDNA modifications in AD has been largely ignored, despite the 156 
evidence that mitochondrial dysfunction is involved in AD [18] and that ncDNA methylation 157 
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differences are associated with the disease [29-31]. At a global level, an initial dot blot study 158 
showed some evidence for increased mitochondrial 5-hmC in AD superior temporal gyrus 159 
tissue, although definitive conclusions could not be drawn given the small number of 160 
samples used [51]. Mitochondrial DNA modifications in the brain have been shown to be 161 
associated with aging, with global mtDNA 5-hmC levels reduced in the frontal cortex of aged 162 
mice and specifically decreased 5-hmC levels being found in the regulatory D-Loop, as well 163 
as in two genes encoding ETC complex I polypeptides (MT-ND2 and MT-ND5) [52]. Aging 164 
was not only found to be associated with overall decreased mtDNA 5-hmc levels but also 165 
with increased cortical expression of the mitochondrial ETC genes MT-ND2, MT-ND4, MT-166 
ND4L, MT-ND5, and MT-ND6 [52]. A post-mortem study of frontal cortex described 167 
differential mtDNA gene expression of these genes, and other mitochondrial-encoded 168 
genes, in both early and late-stage AD. [7] Taken together, these findings illustrate that 169 
alterations in mitochondrial-encoded genes do occur with aging and in age-related diseases, 170 
yet without further studies, the exact role of mtDNA methylation on mitochondrial gene 171 
expression in these instances remains uncertain. 172 
  173 
Two genomes are better than one: interactions between the nuclear and mitochondrial 174 
genomes 175 
As research into the field of mitochondrial epigenetics gains momentum, studies have 176 
focused on a potential trans-acting role of mtDNA in the epigenetic regulation of ncDNA, 177 
whereby covalent modifications across the mtDNA genome may affect not only the 178 
expression of a gene in cis, but also have trans-acting effects on the transcription of genes in 179 
the nuclear genome. Evidence for this is provided by cybrid models, which combine the 180 
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nuclear genome of one source with the mitochondrial genome of another in an attempt to 181 
determine the functional role of the mtDNA. Using Restriction Landmark Genomic Scanning 182 
(RLGS) and Rho0 cells, a form of cybrid cell line designed for investigating mtDNA depletion, 183 
one study found that mtDNA depletion significantly altered DNA methylation at CpG islands 184 
in nuclear encoded genes [53], indicating that there are functional interactions between the 185 
two genomes. Re-introduction of wild-type mtDNA restored DNA methylation levels, at 186 
some RLGS spots, suggesting that, at least for some genes, mitochondria may play a role in 187 
nuclear DNA methylation. This is corroborated by a recent study demonstrating that 188 
mitochondrial haplotype variation can affect ncDNA methylation, with mtDNA haplotype J 189 
exhibiting higher global DNA methylation levels, reduced ATP, and overexpression of the 190 
nuclear gene methionine adenosyltransferase I, alpha (MAT1A), which is required for SAM 191 
production thus regulating methylation patterns in the nuclear genome [54]. Therefore 192 
genetic variations in mtDNA are capable of influencing epigenetic modifications in both the 193 
mitochondrial and nuclear genomes. As such, it is possible that mitochondrial dysfunction in 194 
AD could lead to alterations in mtDNA methylation, affecting nuclear gene expression.  195 
 196 
The mitochondria comprises approximately 1500 proteins, however of these, only 13 are 197 
encoded by the mitochondrial genome; the remainder are encoded by the nuclear genome 198 
and imported into the mitochondria. A recent study found that >600 of these genes have 199 
tissue-specific differentially methylated regions, ultimately leading to changes in 200 
mitochondrial function dependent upon tissue type [55]. This suggests that there is an 201 
additional level of complexity to consider in the study of mitochondrial epigenetics, 202 
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whereby epigenetic changes in one genome may affect transcriptional control in another in 203 
a tissue-specific manner.  204 
 205 
Interrogating the mitochondrial epigenome: technical caveats 206 
Despite the potential importance of mitochondrial DNA modifications in AD, there are a 207 
number of technical challenges specific to interrogating the mitochondrial epigenome that 208 
have hampered widespread studies to date. These issues can be broadly summarized as 209 
encompassing genetic issues and specificity issues, which are outlined briefly with potential 210 
solutions in Table 2.  211 
1. Genetic issues 212 
1.1. Nuclear pseudogenes  213 
By far the greatest concern when analyzing mtDNA methylation arises from regions of 214 
homology between the mitochondrial genome and nuclear mitochondrial pseudogenes 215 
(NUMTs).  These genes are nuclear paralogs of mtDNA which have been translocated and 216 
inserted into the nuclear genome during evolution of both genomes [56]. This phenomena 217 
has been shown to be evolutionarily conserved across many species including cats [57], 218 
mice, chimpanzees, rhesus macaques [58] and hominins [59].  These insertions were 219 
thought to typically occur in non-coding regions; however, more evolutionary recent 220 
translocations have actually been shown to prefer integration into coding regions, thus 221 
leading to potential alterations in gene function with implications for disease [60]. NUMTs 222 
are generally small and typically comprise ~0.1% of the nuclear genome [61]. However in 223 
humans, it has been shown that some NUMTs can be as large as 14.7kb, representing a 224 
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significant portion of the ~16.6kb human mitochondrial genome [62]. As such, the presence 225 
of NUMTs can cause major issues in genomic analyses using pre-sequencing enrichment 226 
methods such as custom capture or long-range PCR as the likelihood of NUMT co-227 
amplification, or even preferential amplification, increases due to the strong sequence 228 
similarity between the two segments of genome [63]. As such, this sequence similarity can 229 
lead to the misclassification of NUMTs as mtDNA during analysis, and has led to a number of 230 
publications wrongly describing NUMTS as mtDNA [64, 65]. NUMT misclassification has also 231 
been observed in AD genetic studies whereby amplification of the NUMT sequence has led 232 
to false heteroplasmies (see below) being reported [66, 67]. One potential solution is to 233 
separate mitochondria prior to DNA extraction in an attempt to reduce the risk of 234 
contaminating the mitochondrial and nuclear genomes. However, despite extensive 235 
research being dedicated to mtDNA analysis, existing methods for mitochondrial isolation 236 
and mtDNA extraction via the use of fractional precipitation or gradient ultracentrifugation 237 
remain time consuming and labour intensive [68] and often leave residual nuclear DNA 238 
contamination following mitochondrial isolation [69].  239 
1.2.  Variation in mtDNA: haplogroups and genetic and epigenetic 240 
heteroplasmy  241 
Each mitochondrion contains between 2-10 copies of mtDNA. However, not all mtDNA in 242 
each mitochondrion share the same DNA sequence. Indeed, mutations in some copies of 243 
mtDNA mean that the cell itself may be made up of a mixture of different sequences. This 244 
phenomenon is known as mitochondrial heteroplasmy and has been linked to various 245 
mitochondrial diseases, [70]. It is a potential confounder in studies of mitochondrial 246 
diseases, because inter- and intra-individual heteroplasmic variation can confuse the 247 
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association between a haplogroup with its corresponding phenotype.  The importance of 248 
this issue, in the context of this review, is highlighted by a recent study demonstrating that 249 
mitochondrial heteroplasmy alters DNA methylation across the nuclear-encoded 250 
mitochondrial genes TFAM and POLMRT [71]. Finally, if mtDNA methylation is altered across 251 
different mtDNA in the same mitochondrion, it could create an epigenetic mosaic within the 252 
mitochondrion, the cell and across the tissue, whereby each copy of mtDNA may possess its 253 
own methylation profile. If this ‘methylomic heteroplasmy’ were to occur it could be very 254 
difficult to tease apart the effects of such a mosaic in functional studies. 255 
 256 
On a larger scale, mutations in mtDNA can be used to help group cohorts or "haplogroups". 257 
Throughout evolution, mutations in mtDNA may be conserved and passed on through 258 
maternal inheritance, thus allowing for the tracing of common ancestral lineage by 259 
comparing haplogroups. Numerous studies have identified both contributory and protective 260 
effects of different haplogroups in AD. For example, haplogroup K reduces the risk of 261 
developing sporadic AD in Apolipoprotein ε4 (APOε4) carriers in an Italian population [72] 262 
but not in the Polish population [73]. This presents an additional potential caveat in 263 
mitochondrial epigenetics, as mitochondrial haplogroups have been found to affect global 264 
levels of DNA methylation [54]. As such, extra care should be taken to account for 265 
haplogroup variability in AD mitochondrial epigenetic studies.   266 
2. Specificity and technical issues 267 
The brain is a complex, heterogeneous organ with numerous functionally-distinct sub-268 
regions, each with their own different composition of cell types. Unsurprisingly, there are 269 
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clear tissue-specific epigenetic differences across brain regions [74, 75]. There is an added 270 
level of complexity with respect to the mitochondrial epigenome because each 271 
mitochondrion contain between 2-10 copies of mtDNA and each cell contains varying levels 272 
of mitochondria; therefore the amount of mtDNA copies in each cell can vary between 100-273 
10,000 dependent upon cell type. In neurodegenerative diseases such as AD, the issue 274 
becomes more complicated in that the disease itself is characterized by the loss of neuronal 275 
cells and the activation of glia, a process that has been associated with changes in 276 
mitochondrial morphology and fission [76, 77]. A recent study using laser capture 277 
microdissection demonstrated that alterations in mitochondrial 5-hmC are seen with age in 278 
dissected mouse cerebellar purkinje cells, which was not evident in whole cerebellar tissue 279 
[52], demonstrating the importance of cell-specific analyses in heterogeneous tissue, 280 
particularly when investigating functional impact. 281 
 282 
Currently, the most common method of measuring DNA methylation is via the conversion of 283 
DNA with sodium bisulfite followed by subsequent sequence analysis. However, these 284 
approaches are unable to distinguish between 5-mC and 5-hmC [78], an important 285 
limitation given recent studies confirmed the presence of 5-hmC in mitochondria in brain 286 
tissue [52]. Studies have found that although both DNA modifications are present in the 287 
mitochondria, they occur at much lower levels compared to in ncDNA [36, 51], and thus 288 
methods used for quantification may need to be more sensitive. Furthermore, variation in 289 
mitochondrial copy number may lead to the dilution of signals and reduce detection if the 290 
tissue is largely heterogeneous. Importantly, the mitochondrial genome is not interrogated 291 
using tools such as the Illumina Infinium 450K methylation array, the current gold standard 292 
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for methylomic analyses in large numbers of samples; thus methods for detecting mtDNA 293 
modifications across the entire mitochondrial genome are largely restricted to antibody-294 
based enrichment, such as MeDIP-Seq, which may be less sensitive for detecting low levels 295 
of modified cytosine and does not interrogate methylation levels at single base resolution 296 
[79]. 297 
 298 
Future Perspective: the potential for biomarkers in AD 299 
Two important goals of research into the etiology of AD are a) a fast, non-invasive, 300 
inexpensive and reliable biomarker and b) an effective treatment that targets the underlying 301 
neuropathology. A potential utility for DNA methylation biomarkers has been proposed for 302 
diseases in which traditional biomarkers are either too expensive, invasive, unspecific or  303 
insensitive for clinical purposes [80]. Epigenetic modifications have been widely studied in a 304 
variety of different cancers and other conditions such as preeclampsia to check for their 305 
suitability as prognostic and/or diagnostic biomarkers [81-83]. Differential methylation of 306 
mtDNA has yet to be examined with respect to its potential utility as an AD biomarker, but 307 
certainly warrants further investigation. 308 
 309 
Conclusion 310 
With mitochondrial epigenetics only recently emerging as a focus for biomedical research, 311 
the role of the mitochondrial epigenome in AD has yet to receive much attention. However, 312 
it is possible that deregulation of the mitochondrial methylome may lead to aberrant 313 
changes in many of the intricately controlled processes that it helps to govern, such as 314 
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apoptosis, which may play a key role in pathogenesis. Furthermore, as mitochondrial 315 
dysfunction occurs early in AD pathogenesis, it is plausible that alterations in the 316 
mitochondrial methylome may play a major role in the onset and development of the 317 
disease. Despite the field presenting numerous challenges the links between mitochondrial 318 
epigenetics and AD provide good bounds for future research directions. 319 
 320 
EXECUTIVE SUMMARY 321 
Mitochondrial dysfunction: a prominent feature of AD 322 
 The mitochondrial genome plays a vital role in a variety of key biological functions, 323 
including apoptosis via caspase dependant and independent mechanisms, regulating 324 
calcium homeostasis and production of ROS. 325 
 Mitochondrial dysfunction is reported to occur in both the brain and blood of AD 326 
patients. 327 
EWAS and AD 328 
 Studies focussing on global levels of 5-mC and 5-hmC have found a reduction in 329 
levels of both marks in AD brain.  330 
 Three recent EWAS studies have found differential methylation at specific loci in AD 331 
brain. 332 
Epigenetic regulation of the mitochondria genome 333 
 Despite early controversial results, both 5-mC and 5-hmC have been recently 334 
reported in mitochondria.  335 
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 MtDNA is not tightly wrapped by histones and is instead condensed by nucleoids, 336 
suggesting methylation could play an important role in gene regulation. 337 
 DNMT1 can bind to the D-Loop of the mitochondrial genome and can influence gene 338 
expression. 339 
 MtDNA methylation occurs at both CpG sites and non-CpG site in the mitochondrial 340 
genome. 341 
MtDNA methylation: a key player in AD? 342 
 Very few empirical studies have examined the role of mtDNA methylation in brain.  343 
 Decreased mtDNA 5-hmC levels and increased expression of some mitochondrial-344 
encoded genes has been seen in the pre-frontal cortex of aged mice. 345 
Technical caveats 346 
 NUMT misclassification has been observed in AD genetic studies whereby 347 
amplification of the NUMT sequence has led to false heteroplasmies being reported. 348 
 MtDNA methylation could be altered in different mitochondria, creating a 349 
methylomic heteroplasmy. 350 
 MtDNA methylation patterns could be cell-specific and is an important consideration 351 
when investigating heterogeneous tissues such as brain.  352 
 353 
 354 
 355 
 356 
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 357 
Figure 1: The structure of the mitochondrial genome showing genes encoded by the 358 
mitochondria. 3358 mtDNA genetic variants are shown in red and black lines highlight the 359 
predicted CpG sites relative to mutations that define the mitochondrial haplogroup. PH and 360 
PL represent the heavy and light strand promoter regions and OH and OL represent the 361 
origins of heavy-strand and light-strand replication respectively.  Image taken from [84]. 362 
 363 
 364 
 365 
 366 
 367 
 368 
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Table 1: An overview of current studies of mitochondrial epigenetics in disease. 369 
Abbreviations: Quantitative Real-Time PCR (qRT-PCR), mitochondrial DNA (mtDNA), simple 370 
steatosis (SS), non-alcoholic steatohepatitis (NASH), S-adenosylmethionine (SAM) , Liquid 371 
chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS), Liquid 372 
chromatography mass spectrometry (LC-MS), Immunofluorescence (IF), Amyotrophic lateral 373 
sclerosis (ALS). 374 
 375 
 376 
Research Question Techniques Main Findings Reference 
The effect of different environmental 
exposures (metal-rich particulate 
matter, air benzene levels and traffic 
derived elemental carbon levels) on 
mitochondria 
Pyrosequencing  
qRT-PCR  
Increased exposure to particulate matter increases MT-
RNR1 and MT-TF gene methylation 
 
Increased MT-RNR1 methylation is associated with a 
significant increase in mtDNA copy number. 
[85] 
The effect of mtDNA methylation in 
the mitochondrial D-Loop on gene 
expression in colorectal cancer cells. 
Methylation-
specific PCR  
 
Western blotting  
An increased level of demethylated sites in the D-Loop of 
tumour cells is strongly associated with increased MT-
ND2 expression and mtDNA copy number. 
[47] 
The effect of methylation in the D-
Loop, MT-ND6 and MT-CO1 on 
disease progression in simple 
steatosis (SS) and non-alcoholic 
steatohepatitis (NASH) 
Methylation-
specific PCR  
 
qRT-PCR  
Increased MT-ND6 methylation and decreased MT-ND6 
protein levels in NASH compared to SS. Physical activity 
reduced MT-ND6 methylation in NASH. 
 
[86] 
The effect of decreased S-
adenosylmethionine (SAM) on 
mtDNA methylation in Down’s 
Syndrome lymphoblastoid cells 
LC-ESI-MS 
 
LC-MS/MS 
Decreased SAM availability in Down's syndrome 
lymphoblastoid cells reduces methyl uptake to 
mitochondria and leads to mtDNA hypomethylation. 
[87] 
The tissue specificity of DNMTs and 
5-mC in the mitochondria in relation 
to ALS models. 
IF  
 
Pyrosequencing  
Increased methylation at six cytosine sites in the 16S 
rRNA gene in the spinal cord of an ALS mouse cell line.  
 
Reduced levels of mtDNMT3a protein in skeletal muscle 
and spinal cord early in disease. 
 
 
  
[88] 
The effect of mtDNA methylation on 
mtDNA copy number in gastric 
cancer. 
qRT-PCR 
 
Pyrosequencing 
 
Reduced mtDNA copy number levels in late 
clinicopathological stages. 
 
Demethylation of mtDNA increases mtDNA copy number. 
 [89] 
19 
 
Table 2: A summary of the major issues and potential solutions in the field of mitochondrial epigenetics. Abbreviations: nuclear 
mitochondrial pseudogenes (NUMTs), fluorescence-activated cell sorting (FACS), laser capture microdissection (LCM). 
Caveat Potential Issues Potential Solutions 
Genetic Issues 
 
Wrongful Incorrect determination of 
pseudogenes as mtDNA affects the validity of 
results. 
1.   Isolate mitochondria before mtDNA extraction to avoid nuclear contamination 
2.  Specific primers designed with the consideration of NUMT amplification [90]. 
3.  BLAST search to identify known NUMTs 
Genetic mutations in mtDNA may have specific 
associated methylation signatures. 
Haplogroup and heteroplasmy studies should consider mtDNA methylation as a potential 
variable 
Cell Specificity and 
Technical Issues 
Different brain regions have differential 
methylation patterns and different cell 
population compositions. 
1. Larger samples sizes in specific brain subregions will improve statistical significance 
2. FACS or LCM to separate cell types such as glia and neurons prior to analysis. 
Reduced methylation levels in mitochondria 
and variation in mtDNA copy number may 
increase noise and dilute signals. 
Comparative analysis of techniques for their suitability to mitochondrial methylation studies 
should be considered. 
Bisulfite based methodologies cannot 
distinguish between 5-mC and 5-hmC. 
Using oxidative bisulfite-sequencing allows for the distinction of 5-mC and 5-hmC at single base 
resolution[91]. 
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REFERENCE ANNOTATIONS 
 Bellizzi et al., 2013 –reported both 5-mC and 5-hmC in mtDNA at both CpG and non-
CpG sites. The study also found that inactivation of DNMT1, DNMT3a and DNMT3b 
reduced CpG methylation levels markedly, but failed to impact non-CpG methylation 
to the same extent. As such, this study poses the question as to whether DNMT 
activity is important for mitochondrial methylation, or whether other factors may 
also be important. 
 Chestnut et al., 2011 – found that DNMT3a was localized in the mitochondria of 
motor neurons, potentially indicating tissue-specific localization of this 
methyltransferase. This study also found 5-mC in mitochondria in vivo, suggesting 
that mitochondrial methylation may play a role in motor neurons. 
 Dzitoyeva et al., 2012- found that the global levels of 5-hmC in mtDNA show an age-
associated decrease in murine frontal cortex and that this was inversely correlated 
with the expression of some mitochondrial genes, suggesting a potential role of 
mtDNA methylation in aging.  
 Lunnon et al., 2014 – used Illumina Infinium 450K methylation beadarray to 
demonstrate DNA methylation changes in AD cortex. 
 Manczak et al., 2004 –investigated expression levels of mitochondrial-encoded ETC 
genes in AD, reporting decreased expression of complex I and increased expression 
of complex III and IV in early and late-stage disease. 
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 Shock et al., 2011 – reported 5-mC and 5-hmC in mtDNA, leading to a resurgence of 
interest in the field of mitochondrial epigenetics. This paper also identified an 
isoform of DNMT1, mtDNMT1, in the mitochondria. 
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Abstract 
The field of mitochondrial epigenetics has received increased attention in recent years and changes 
in mitochondrial DNA (mtDNA) methylation has been implicated in a number of diseases, including 
neurodegenerative diseases such as amyotrophic lateral sclerosis. However, current publications 
have been limited by the use of global or targeted methods of measuring DNA methylation. In this 
review, we discuss current findings in mitochondrial epigenetics as well as its potential role as a 
regulator of mitochondria within the brain. Finally, we summarize the current technologies best 
suited to capturing mtDNA methylation, and how a move towards whole epigenome sequencing of 
mtDNA may help to advance our current understanding of the field. 
 
 
 
Highlights 
• Variation in nuclear DNA methylation has been associated with neuropsychiatric and 
neurodegenerative diseases.  
• The mitochondrial genome has been shown to be subject to regulation by DNA methylation.  
• A potential role for alterations in mitochondrial DNA methylation in brain disorders has not 
yet been investigated. 
• Next generation sequencing allows for an interrogation of the mitochondrial epigenome at 
single base resolution. 
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Introduction 
There is a resurgence of interest in the field of mitochondrial epigenetics, as mitochondrial 
dysfunction has been implicated in a variety of complex diseases including cancer [1, 2], amyotrophic 
lateral sclerosis [3, 4], and Alzheimer’s disease (AD) [5]. Unlike modifications to nuclear DNA 
(ncDNA), which are now recognized as a mechanism through which the environment can influence 
biological processes and contribute to the development of a range of different disease phenotypes 
[6-8], mtDNA methylation has only recently started to be investigated for its role in health and 
disease.  
Despite this recent interest, few studies of mtDNA methylation have extended past global studies of 
mtDNA methylation using immunocytochemical techniques or the investigation of single candidate 
genes within the mitochondrial genome [9]. Throughout the course of this review we consider the 
caveats of studying epigenetic variation in mitochondria, which are particularly pertinent for studies 
of brain disorders given that changes in cell type composition and mtDNA copy number variation, 
which occur frequently in neurodegenerative diseases [10, 11], could have profound effects on the 
interpretation of findings in the field of mitochondrial epigenetics. Finally we consider how recent 
advances in genomic technologies could be applied to allow accurate and quantifiable 
measurements of the mitochondrial epigenome in the brain. 
 
The Role of Mitochondria in the Brain 
Mitochondria are the “powerhouse” of the cell and their dynamic nature allows for the organelle to 
be moved to areas of high ATP demand, for example cortical neurons require approximately 4.7 
billion ATP per second to ensure continuous function [12]. Mitochondria are also implicated in many 
other important neurophysiological functions, for example synaptic mitochondria are believed to be 
involved in the regulation of neurotransmission by buffering extra intracellular Ca2+ [13], making the 
mitochondria a vital organelle in the establishment of Ca2+ homeostasis. Further, mitochondrial 
morphology and dynamics vary between synaptically immature and mature cortical neurons, with 
shorter mitochondrial lengths being observed in immature neurons allowing for increased 
movement and greater ability to meet the high energy demands of immature neurons, providing a 
key role for this organelle in neuronal development [14]. However, despite being the major site of 
reactive oxygen species (ROS) production, the mitochondria lack protective histones and defective 
mtDNA repair has been suggested to play a role in a number of neurodegenerative diseases [15]. As 
a by-product of ATP generation, ROS accumulation in areas of high ATP demand, such as post-
mitotic neuronal cells, has been associated with neuronal loss [16]. Mutations in mitochondrial-
encoded genes have been shown to cause a number of maternally heritable, monogenic diseases. 
Most notably, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes 
(MELAS) syndrome, a disease affecting multiple organs which can lead to the development of a 
number of syndromes, ranging from muscular weakness, fatigue and stroke-like episodes to 
dementia, epilepsy and diabetes in later stages [17]. As such, mtDNA variants have been shown to 
be an important driver of mitochondrial dysfunction and can have significant neuropathological 
effects [18].  
 
MtDNA methylation and regulation of the mitochondria  
The diverse range of mitochondrial functions coupled with their importance in the governance of 
cellular energy demands means that the expression of mitochondrial proteins requires sophisticated 
levels of fine-tuning. Although ~99% of mitochondrial proteins are encoded by the nuclear genome, 
the 16.569 Kb mitochondrial genome contains a total of 37 genes: 22 tRNAs, two rRNAs and 13 
genes that encode for polypeptides along the electron transport chain (ETC) [19]. Within the nuclear 
genome, epigenetic processes mediate the reversible regulation of gene expression, occurring 
independently of DNA sequence, acting principally through chemical modifications to DNA and 
nucleosomal histone proteins. Epigenetic mechanisms orchestrate a diverse range of important 
neurobiological and cognitive processes in the brain and epigenetic modifications to the nuclear 
genome have been widely hypothesized to play a role in many neurological disorders, including 
Alzheimer’s disease (AD) [11, 20, 21]. Given that mitochondrial dysfunction is a prominent feature of 
AD, we recently hypothesized that epigenetic modifications to the mitochondrial genome could be 
important in disease progression and pathology [5].  
Despite rapid progress in the field of nuclear epigenetics, the field of mitochondrial epigenetics has 
received little attention since initial, but contradictory studies in the field were published in the 
1970’s [22-24].  These controversies continue, with one recent report concluding an absence of 
biologically significant levels of mtDNA methylation in four regions of mtDNA analyzed in human 
HEK293 cells and publically available data [25]. However, given the low sequencing depth of mtDNA 
in the publically available data used in this study (94x), and that multiple copies of the mtDNA 
genome are present in any given cell, it is possible that the true extent of mtDNA methylation was 
not determined. In contrary to this finding, both 5-methylcytosine (5-mC) and 5-
hydroxymethylcystosine (5-hmC) have been identified in mammalian mitochondria from cell lines 
[26]. Further 5-mC has been found to co-localise in motor neurons with the mitochondrial marker 
superoxide dismutase 2 (SOD2).[4]. In addition, the identification of DNA methyltransferase 3a, 
(DNMT3a), an enzyme that plays an important role in catalyzing the transfer of the methyl moiety 
from the methyl donor protein S-adenoysl methionine (SAM), in mitochondria isolated from a 
mouse motor neuron cell line [4], and in mitochondria isolated from mouse brain and spinal cord 
[26], suggests potential tissue-specific mtDNA methylation. As the mitochondrial genome lacks 
protective histones, mtDNA instead being packaged via nucleoid proteins [27], post-translational 
histone modifications will not have a direct role on mitochondrial function. MtDNA methylation, on 
the other hand, may play an important role in regulating mitochondrial function, either 
independently, or via a complex mechanism involving nuclear-mitochondrial crosstalk [5]. Recent 
studies have suggested that mtDNA may have patterns of DNA methylation similar to that of plant 
and fungi, with methylation of cytosines adjacent to adenosine and thymine, in addition to the 
traditional CpG dinucleotide [28]. Since we recently suggested that mtDNA methylation could play a 
role in AD and other disorders characterized by mitochondrial dysfunction [5], further studies have 
been published to support our hypothesis. For instance, one study assessed mtDNA methylation in 
platelets in subjects with cardiovascular disease across seven genes using pyrosequencing and 
identified four genes with significantly increased levels of mtDNA methylation compared to controls 
[9]. In particular one gene, MT-C01, demonstrated >18% difference between groups. Another study 
showed differences in DNA methylation of the D-Loop and MT-RNR1 were concordant with 
methylation differences in the subtelomeric region D4Z4 in umbilical cord blood as well as the fetal 
and maternal side of the placenta, suggesting a potentially common epigenetic signature in these 
tissues [29]. The same group also recently demonstrated a positive correlation between airborne 
particulate matter exposure and placental mtDNA methylation in the D-Loop and MT-RNR1 using 
targeted bisulfite-pyrosequencing [30]. This study also showed that increased mtDNA methylation is 
accompanied by a reduction in mtDNA content, a potential marker of mitophagy, potentially 
indicating that alterations in mtDNA methylation of the D-Loop, a region highly involved in mtDNA 
transcription and replication, may lead to changes in mitochondrial biogenesis.   
The role of mtDNA genetic variation on underlying mitochondrial function has become increasingly 
studied in recent years. MtDNA haplogroups and genetic variation have been found to have 
pronounced effects on mitochondrial functions, leading to altered ETC functions and ROS levels, 
which are associated with increased breast cancer risk [31]. However, given that a single 
mitochondrion can contain up to 10 copies of the mitochondrial genome [32], and as there are 
multiple mitochondria in any given cell, the extent of heteroplasmic mutations and their effect on 
mitochondrial function is far from clear [33]. Further, relatively few of the studies investigating 
mtDNA methylation have related identified changes to alterations in gene expression. One recent 
study showed significant hypermethylation of the D-Loop is negatively associated with expression of 
three mitochondrial-encoded genes (CYTB, ND6, COXII) in retinal microvessels derived from diabetic 
retinopathy donors [34]. However, the group failed to find significant differences in the methylation 
of CYTB and conclude that, given the importance of the D-Loop in replication and transcription of the 
mitochondrial genome, changes in D-Loop methylation may result in transcriptional changes across 
the mitochondrial genome and potentially contribute to the pathogenesis of diabetic retinopathy. 
However, a recent in vivo study showed D-loop methylation did not correlate with the expression of 
mitochondrial-encoded genes during inflammation [35]. Briefly, it was found that lipopolysaccharide 
(LPS)-mediated inflammation in mice led to significant changes in mtDNA transcript levels which 
were reversed upon treatment with α-Lipoic acid (LA), an agent with anti-inflammatory properties. 
However, despite these transcriptional changes, neither treatment altered D-Loop methylation. 
Taken together, these two studies suggest that mitochondrial transcription may be driven by mtDNA 
methylation of the D-Loop; however, this phenomenon is not the sole driver of mitochondrial gene 
expression. Further studies should potentially employ a more holistic approach to investigating the 
relationship of mtDNA methylation, gene expression and potential nuclear-encoded effectors of 
mtDNA transcription. Further, the use of whole-methylome sequencing of the mitochondria may aid 
in the elucidation of base-specific mtDNA methylation changes which may be important in gene 
expression.  
The Bi-directionality of mitoepigenetics 
Interestingly, a number of nuclear factors are also known to affect mitochondrial function. A recent 
study found DNA methylation levels in the nuclear-encoded, mitochondrial-specific transcription 
factor DNA polymerase gamma A (POLGA) inversely correlate with mtDNA copy number in 
pluripotent and multipotent cell types [36]. The removal of mtDNA [37] or changes in mtDNA 
haplogroups [38] have been found to be associated with differences in ncDNA methylation levels, 
suggesting an important interplay between the two genomes and a bi-directionality to 
mitoepigenetics [39].  
Cytoplasmic hybrids (cybrids) are an important cell type for studying mitochondrial function that 
contain identical nuclei to the parent cell, but different mtDNA, allowing for a controlled 
investigation into the role of mtDNA variants. One study found that cybrids with mtDNA derived 
from haplogroup J had consistently higher levels of global ncDNA methylation than haplogroup H, 
suggesting that mtDNA variants may play an important role in influencing ncDNA methylation [40]. 
This difference in DNA methylation was accompanied by significant decreases in the expression of 
six of the 11 nuclear-encoded genes assayed that are involved in DNA methylation and acetylation 
processes, as well as significant increases in the transcription of MAT2B and MBD4, both of which 
are important for DNA methylation. Given the importance of these two processes in epigenomic 
regulation, this further illustrates how mtDNA genetic variation can impact on the nuclear genome. 
Another recent study investigating the mitochondrial 3243A>G heteroplasmy, which causes several 
clinical phenotypes including MELAS, showed that changes in heteroplasmy levels led to large and 
widespread changes in mitochondrial and transcriptional regulation, including changes in transcripts 
involved in DNA methylation and histone acetylation. Interestingly, high levels of this heteroplasmic 
variant (50-90%) resulted in ncDNA gene expression patterns that are similar to those seen in AD, 
Parkinson’s disease and Huntington’s disease.  With alterations in ncDNA methylation in 
neurodegenerative disorders now well established [11, 41-44], future studies may aim to study 
mtDNA and ncDNA epigenomes in parallel to gain an understanding of the complete cellular 
epigenetic landscape.  
 
Other mitochondrial DNA modifications 
The majority of mtDNA methylation research has focussed on the DNA methylation mark 5-mC. 
However a number of other epigenetic marks such as 5-hmC, 5-formylcytosine (5-fC) and 5-
carboxylcytosine (5-caC) have also been identified. Despite this, functional roles of 5-caC and 5-fC 
have yet to be elucidated, however evidence suggests that they are involved in the Tet-mediated 
oxidation pathway, which converts 5-mC back to unmodified cytosine  [45]. In a recent study, 5-fC 
and 5-caC, but not 5-hmC were found to lead to modest blocks in DNA transcription when mediated 
by either T7 RNA polymerase (T7 RNAP), or by human RNA polymerase II in an in vitro transcription 
assay, which was also replicated in 2 human cell lines [46]. Interestingly, T7 RNAP shares a high 
degree of homology with mitochondrial polymerases, and given the identification of 5-hmC and Tet 
proteins in mitochondria [26, 47], this study hypothesized a mechanism by which mtDNA 
demethylation products may be important for the regulation of mtDNA transcription. However, at 
present, no study has investigated 5-fC and 5-caC levels in mtDNA and further investigation into the 
modulation of mtDNA methylation needs to be undertaken.   
 
Methodologies appropriate for epigenetic studies of mtDNA 
Given the growing interest in studying epigenetic changes in mtDNA in a range of pathologies, there 
are a number of important considerations pertinent to this field of research. First, tissue-specific 
effects of DNA methylation mean that profiling a disease-relevant tissue is likely to be critical. 
Further, different cell types will have varying levels of mtDNA copy number and different DNA 
methylation levels dependent upon cellular requirements and localized environments [5]. As such, 
studies investigating mtDNA methylation should consider mtDNA copy number as a potential 
confounder to subsequent analysis. This is a pertinent issue in mtDNA methylation analysis given 
that a number of studies have implicated an association between mtDNA methylation status and 
mtDNA copy number [48] and that tissue homogenates contain a number of different cell types, 
many with varying levels of mtDNA copy numbers. One potential way to solve this problem would be 
to first isolate different cell types from tissue homogenate using Fluorescence-activated cell sorting 
(FACS). However isolating sufficient levels of mitochondria from individual cell populations to yield 
sufficient mtDNA for methylation analyses seems unlikely with current technologies requiring high 
input amounts of DNA. 
Another important consideration is the most appropriate method for studying mtDNA methylation. 
A host of different platforms have been developed that are capable of assessing DNA methylation in 
the nuclear genome. However, given the relative nascence of the field of mtDNA epigenetics, the 
appropriateness of the wide range of genomic technologies available has never been reviewed for its 
utility in this field. Advances in genomic technologies has seen ncDNA methylation studies move 
from profiling DNA methylation at a handful of candidate CpG sites to epigenome-wide association 
studies (EWAS). However, the current workhorse for such studies, the Illumina 450K methylation 
array, and its successor the Illumina EPIC methylation array, provide no coverage of the 
mitochondrial genome. Given that mtDNA methylation is now becoming increasingly investigated, 
an understanding of the technologies available to assess genome-wide changes in mitochondrial 
methylation is of upmost importance. An overview of genomic technologies that could be utilised to 
measure mtDNA methylation is provided in Table 1. 
 
To capture an accurate and precise representation of potential mtDNA methylation changes, a 
technique should ideally be able to detect DNA modifications with low error rate and at single 
nucleotide resolution. This is more pertinent to studies of mtDNA epigenetics than in studies of 
ncDNA methylation given the low levels of mtDNA methylation identified in recent studies [30, 49]. 
Currently, the only published genome-wide study investigating mtDNA methylation utilized 
publically-available methylated DNA immunoprecipitation sequencing (MeDIP-Seq) data [50]. Whilst 
this study was able to identify spatio-temporal patterns of mtDNA methylation in a variety of cells 
and tissues, the coverage was relatively low (5x). Given sequencing and genomic biases, low levels of 
coverage may result in some bases not being sequenced adequately for analysis. Further, the 
resolution of MeDIP-Seq also remains a limitation. Despite high levels of concordance between 
MeDIP-Seq data, which averages the methylation values across a region, and other technologies that 
focus on single CpG sites [51], it is possible that a correlation may not be observed across every 
region of the mitochondrial genome. For example, averaging methylation in regions as small as 
100bp in the mitochondrial genome could include averaging methylation across many gene 
boundaries of tRNAs in some regions and could greatly mask the true methylation status of these 
genes. Although this study was able to utilize publically available data that had been generated to 
inexpensively assess ncDNA methylation, studies to specifically assess mtDNA methylation would 
ideally investigate DNA methylation at single base resolution. Whole genome-bisulfite sequencing 
(WGB-Seq) is another source of publically available data that could be exploited to investigate 
mtDNA methylation, however although this allows the interrogation of DNA methylation at single 
nucleotide resolution, data with an appropriate depth of sequencing is lacking due to the expense of 
sequencing the entire ~3,000 Mb human genome. An alternative, and more appropriate next 
generation sequencing (NGS), approach would specifically capture the entire mitochondrial genome 
prior to sequencing and due to its relatively small size would allow for inexpensive sequencing at 
single base resolution analysis. Currently, two custom capture methylation technologies are 
available from Agilent and Nimblegen, and coverage can be tailored to suit the researcher’s needs, 
allowing for the interrogation of epigenetic variability within the mitochondrial genome. Despite 
costing considerably less than WGB-Seq, a targeted capture of the mitochondrial genome is still 
relatively expensive and requires a higher input of DNA.   
 
Aside from cost versus coverage issues, sequencing the mitochondrial genome is associated with a 
number of unique caveats; most notably, the presence of nuclear mitochondria pseudogenes 
(NUMTs) in the nuclear genome. NUMTs are regions of the mitochondrial genome that, over an 
evolutionary period of time, have translocated to the nuclear genome and therefore share a high 
sequence homology with their mitochondrial paralogue. As such, failure to account for these regions 
has led to misinterpretations of genetic sequencing data [52, 53], and is one pitfall of using publically 
available data, although informatic approaches to account for these regions are being developed 
[50]. Ideally to avoid misinterpretation of data, mitochondria should be isolated from the tissue of 
choice prior to sequencing [5], and in epigenetic studies of brain disorders, this therefore requires 
the isolation of large quantities of mtDNA from small amounts of frozen post-mortem tissue [54].  
Finally, the dependence on NGS technologies on PCR amplification prior to sequencing leads to a 
potential PCR bias and over-representation of some sequences. Given the tissue-specific nature of 
mitochondrial heteroplasmy, it is possible that these amplifications could influence findings. As such, 
a move towards third generation sequencing systems such as the Pac-Bio RS II and Oxford’s 
Nanopore is an appealing prospect. Furthermore, despite both technologies being associated with a 
high individual base call error rate at present, the Pac-Bio’s long read based deep sequencing has 
been used to accurately map complex regions of the human genome [55] as well as mitochondrial 
genomes in other species [56-58] [59]. Interestingly, given that both technologies use native DNA, 
both technologies provide the possibility of simultaneous genetic and epigenetic analysis, including a 
range of DNA modifications [60-64]. The circular consensus reads of PacBio RS II could provide an 
interesting platform for the simultaneous identification of the four major epigenetic marks in real 
time at a high coverage. However, isolation of high quality mtDNA from the range of frozen tissues 
commonly used in nuclear epigenetics could prove to be difficult and would require further 
investigation. The continual development of more accurate calling algorithms and likely future cost 
reductions may therefore lead to these third generation sequencing technologies being the optimal 
choice for providing specific, deep and targeted analysis of the mitochondrial (epi)genome. 
 
Conclusions 
Given the growing interest in studying mtDNA methylation in a range of brain disorders 
characterized by mitochondrial dysfunction, the advent of third generation sequencing technologies 
may allow for the accurate study of these small genomes in the near future. The circular consensus 
nature of Pac-Bio RS II potentially allows for the entire mitochondrial genome to be investigated 
from one long read, removing current NGS biases. However, this process would require isolation of 
intact mtDNA from a variety of potentially frozen and partially degraded tissues, which may prove 
challenging for researchers. Currently the use of NGS, particularly the more quantitative approaches 
of bisulfite-sequencing, may allow for the elucidation of mtDNA methylation and future studies 
should consider the utility of this approach versus candidate-based technologies such as 
pyrosequencing. 
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Abstract 22 
Given that many brain disorders are characterized by mitochondrial dysfunction, there is a growing 23 
interest in investigating genetic and epigenetic variation in mitochondrial DNA (mtDNA). One major 24 
caveat for such studies is the presence of nuclear-mitochondrial pseudogenes (NUMTs), which are 25 
regions of the mitochondrial genome that have been inserted into the nuclear genome over evolution 26 
and, if not accounted for, can confound genetic studies of mtDNA. Here we show the first systematic 27 
study to compare methods for isolating mtDNA from frozen post-mortem human brain tissue, and 28 
show that a commercial method from Miltenyi Biotech, which magnetically isolates mitochondria 29 
using antibodies raised against TOM22, gives a significant enrichment of mtDNA, and should be 30 
considered the method of choice for mtDNA studies in frozen brain tissue. 31 
 32 
 33 
 34 
 35 
 36 
Method Summary 37 
Here we compare five methods of isolating mitochondrial DNA (mtDNA) to standard phenol-38 
chloroform DNA extraction (that isolates nuclear DNA (ncDNA) and mtDNA) to determine the 39 
optimal method for enriching mtDNA from frozen post-mortem human brain tissue. 40 
 41 
 42 
 43 
 44 
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Main Text 45 
Mitochondria generate ATP, regulate calcium homeostasis [1, 2], mediate apoptosis [3], and produce 46 
reactive oxygen species (ROS). Mitochondrial dysfunction has been implicated in a number of 47 
diseases, including in the pathogenesis of brain disorders such as Alzheimer’s disease [4-6]. 48 
Mitochondria are unique mammalian organelles in that they contain their own genome; the 49 
mitochondrial genome is ~16.6kb of circular DNA (mtDNA) [7], separate to the nuclear genome 50 
(ncDNA) and inherited in a maternal, non-Mendelian fashion. The mitochondrial genome comprises 51 
37 genes; 13 encode for electron transport chain polypeptides, two for rRNAs and 22 for tRNAs. 52 
Because of its role in ROS production, mtDNA has a higher mutation rate (10-17 fold) than ncDNA 53 
[8]. Mutations in mtDNA are relatively common, with at least one in 200 healthy humans harboring a 54 
potentially pathogenic mtDNA mutation [9]. Indeed more than 300 point mutations in mtDNA are 55 
associated with disease risk and pathology in MitoMAP [10]. Interestingly, as each mitochondrion 56 
contains 2-10 copies of mtDNA and there are multiple mitochondria in any given cell, somatic 57 
mutations result in a mosaic of different mtDNA sequences within a given tissue. This phenomenon is 58 
known as mitochondrial heteroplasmy and is linked to various mitochondrial diseases [11]. Such 59 
heterogeneity is a potential confounder in studies of mitochondrial diseases, because inter- and intra-60 
individual heteroplasmic variation can confuse the association between a haplogroup and its 61 
corresponding phenotype. Therefore, unlike studies of ncDNA variation, it is important to use the 62 
specific tissue of interest for etiological research. Another interesting feature of the mitochondria is 63 
that over evolution sequences of mtDNA have translocated to the nuclear genome. Traditional 64 
mitochondrial genetic research, and more recently studies of mitochondrial epigenetics, can be 65 
hampered by the presence of these nuclear-mitochondrial pseudogenes (NUMTs) as they share a high 66 
homology with their mitochondrial paralogs [12, 13]. Given the interest in studying mtDNA genetic 67 
and epigenetic changes in the pathology of brain diseases characterized by mitochondrial dysfunction, 68 
it is imperative that NUMTs are correctly accounted for [14]. 69 
The specific isolation of mitochondria prior to downstream processing is vital to fully exclude issues 70 
relating to NUMT contamination. For this purpose, a number of methods have been developed to 71 
4 
 
specifically isolate mtDNA, although few of these approaches have been specifically optimized for 72 
use on post-mortem tissue, a major resource in many epidemiological studies. In fact most studies 73 
investigating mtDNA use fresh animal tissue or cell lines. The insult of freezing tissue prior to 74 
isolation will potentially alter the effectiveness of these techniques and increase the risk of NUMT 75 
inclusion in downstream analysis. In this study we compared the effectiveness of five different 76 
mitochondrial isolation methods on post-mortem brain tissue using quantitative real-time PCR (qRT-77 
PCR), to determine the optimal method for the specific enrichment of mtDNA, which was 78 
subsequently validated by next generation sequencing (NGS). We tested protocols based on A) 79 
Percoll gradients, B) linear DNA digestion, C) differential centrifugation, D) rapid differential 80 
centrifugation using a commercial kit and E) magnetic isolation of mitochondria using anti-TOM22 81 
antibodies.  82 
Method A was a modification of the method by Sims and Anderson (3). 150mg of tissue was 83 
dissociated using the gentleMACS dissociator (Miltenyi Biotech:130-093-235) and a mitochondrial 84 
extraction kit (Miltenyi Biotech:130-097-340). After removal of the nuclear fraction, the supernatant 85 
was spun at 13,000xg for 30 minutes at 4°C to form a crude mitochondrial pellet. The pellet was 86 
homogenized in a 12% Percoll solution and added above two layers (26% and 40%) of Percoll 87 
solution. Samples were spun at 30,700xg for 5 minutes at 4°C with the lower band containing the 88 
enriched mitochondrial fraction. Each mitochondrial fraction was diluted in four volumes of isolation 89 
buffer and centrifuged at 16,700xg for 10 minutes at 4°C to form a loose mitochondrial fraction. The 90 
supernatant was discarded, and mtDNA extracted using a DNA Mini kit (Qiagen:51304). Method B 91 
was based on the method by Zhou et al [15] that digests linear DNA but leaves circular DNA intact. 92 
20ug genomic DNA (previously extracted using a phenol-chloroform protocol) was treated with 4μl 93 
lambda exonuclease (5 U/μl) (New England Biolabs:M0262S) and 12μl RecJf (30 U/μl) (New 94 
England Biolabs:M0264S) in 400μl 1x lambda exonuclease buffer (New England Biolabs:B0262S) at 95 
37
o
C for 16 hours. Samples were incubated at 65
o
C for 10 minutes to inactivate the enzymes and 96 
subsequently purified using a DNA Mini Kit (Qiagen:51304). Method C was based on the method by 97 
Clayton and Shadel [16]. 100mg brain tissue was homogenized in 1ml chilled homogenization buffer 98 
5 
 
(0.25M sucrose/10mM EDTA/30mM Tris-HCl, pH 7.5). The homogenate was centrifuged at 1,000xg 99 
for 15 minutes at 4
o
C and supernatant removed. The pellet was re-homogenized in 600μl chilled 100 
homogenization buffer and spun at 1,000xg for 10 minutes at 4
o
C. The supernatant was combined 101 
with the supernatant from the previous step and centrifuged at 12,000xg for 30 minutes at 4
o
C to 102 
pellet the mitochondria. MtDNA was extracted using a DNA Mini Kit (Qiagen:51304). Method D 103 
was a modification of the method by Clayton and Shadel [16] and purchased as a commercial kit 104 
(Promokine:PK-CA577-K280). 100mg of brain tissue was homogenized with the reagents provided, 105 
according to the manufacturer’s instructions. In Method E 200mg of tissue was dissociated using the 106 
gentleMACS dissociator and a mitochondrial extraction kit (Miltenyi Biotech:130-097-340) according 107 
to the manufacturer’s protocol, with the exception of using an increased quantity of extraction buffer 108 
(40μl Solution 1 and 1ml 1x Solution 2). After homogenization the sample was spun at 200xg for 30 109 
seconds and passed through a 70μm pre-separation filter (Miltenyi Biotec:130-095-823) and washed 110 
with Solution 3. The homogenate was spun at 500xg for 5 minutes at 4°C and the supernatant 111 
removed. The supernatant was magnetically labelled with 100μl anti-human TOM22 antibody-112 
microbeads (Miltenyi Biotech:130-094-532) for 1 hour at 4°C under continuous agitation. The eluate 113 
was added to a LS column (Miltenyi Biotech:130-042-401) and placed in a MACS separator 114 
(Miltenyi Biotech:130-042-302) and washed. Upon removing the column from the magnetic field the 115 
mitochondria were pelleted by centrifugation at 13,000xg for 2 minutes at 4°C, washed in 1ml 116 
Storage Buffer and centrifuged at 13,000xg for 2 minutes at 4°C. The supernatant was discarded and 117 
mtDNA extracted using a DNA Mini Kit (Qiagen:51304). We compared these approaches to DNA we 118 
had previously isolated [17] using a phenol-chloroform protocol, which isolates both ncDNA and 119 
mtDNA We assessed the purity of each method using qRT-PCR as previously described (6). Briefly, 120 
the number of copies of mtDNA relative to ncDNA was determined by dividing the calculated 121 
number of copies of mtDNA (MT-CYB assay) by the calculated number of copies of ncDNA (B2M 122 
assay). 123 
Our data showed that Method B (linear DNA digestion) gave the lowest purity (1,242 mtDNA 124 
copies/ncDNA copy), and Method E (magnetic-microbeads) the highest purity (14,654 mtDNA 125 
6 
 
copies/ncDNA copy) (Figure 1A; Table 1). Of particular interest to the study was the relative 126 
enrichment compared to a standard phenol-chloroform extraction (Figure 1B). The only method to 127 
show no enrichment was Method B (linear DNA digestion). All other techniques showed a positive 128 
enrichment of mtDNA compared to phenol-chloroform. Methods A (Percoll), C (differential 129 
centrifugation) and D (rapid differential centrifugation) all gave modest positive enrichments of 2.4-, 130 
1.7- and 2.9- fold respectively. Although giving one of the lowest yields (3.2µg), the optimal method 131 
for enrichment relative to ncDNA was Method E (magnetic-microbeads), which gave a 10.7-fold 132 
enrichment, and was the only method to show significantly more copies of mtDNA/ncDNA copy 133 
compared to phenol-chloroform extraction (P=1.88x10
-3
). Using this method we saw a significant 134 
enrichment of mtDNA/ncDNA compared to Methods A (P=0.019), B (P=6.97x10
-4
) and C 135 
(P=8.48x10
-3
). To validate our enrichment, two of the biological replicates from Method E were 136 
compared to a non-enriched standard from phenol-chloroform extraction using NGS. DNA samples 137 
were fragmented by sonication using a Bioruptor (Diagenode:UCD-200) to an average size of 138 
~240bp. Sequencing libraries were prepared using the NEXTflex Rapid DNA-Seq kit (Bioo 139 
Scientific) and ligated to pre-indexed adapters (NEXTflex-96 DNA Barcodes; Bioo Scientific). 140 
Adapter-ligated DNA was amplified for 10 cycles using Herculase II Fusion DNA Polymerase 141 
(Agilent Technologies) and NEXTflex PCR primer mix, then pooled for sequencing on an Illumina 142 
HiSeq2500 (100bp paired-end, rapid run mode). Raw reads were quality and adaptor trimmed using 143 
TrimGalore! (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) before being aligned 144 
to GRCH37. Only high quality (Phred <20) reads, uniquely mapping to the genome were considered 145 
and total read counts were taken. For the non-enriched standard 1.1% of reads mapped to the 146 
mitochondrial genome, compared to an average of 18.7% (16.2% and 21.2% respectively) of reads 147 
with Method E, demonstrating an average 16.8 fold enrichment.   148 
 149 
Despite Method E providing a greater enrichment than Method C (differential centrifugation) in 150 
mouse liver [18] and a similar enrichment to Percoll in an osteosarcoma cell line [19], higher levels of 151 
mitochondrial enrichment have previously been reported [20]. However, this method, like Method B 152 
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in our study, relies on the circular nature of the intact mitochondrial genome, which, whilst present in 153 
cell lines and blood, may be more degraded in frozen, archived brain. In the context of genomic 154 
studies of mtDNA, where the exclusion of NUMTs is imperative, the relative enrichment of mtDNA is 155 
of far greater importance than the yield. Thus, although we saw a lower yield with magnetic-156 
microbeads (Method E) compared to the majority of methods tested, we observed the greatest purity 157 
with this method. The reasons for the observed greater enrichment of mtDNA/ncDNA relative to 158 
Percoll (Method A) in our study compared to the analysis by Hornig-Do and colleagues potentially 159 
may include i) our use of qRT-PCR, which is more sensitive than western blot, ii) our use of frozen 160 
samples, rather than fresh samples and iii) the use of brain, rather than a cell line, as brain has high 161 
levels of mitochondria. To our knowledge our study represents the first to systematically compare and 162 
contrast methods for isolating mtDNA from small quantities of frozen, post-mortem human brain. Our 163 
findings suggest that magnetic-microbeads provide a significant enrichment of mtDNA compared to 164 
any other method tested. This may be due to a number of reasons, for example the automated 165 
homogenization of tissue in this protocol could provide a more consistent and gentle approach than 166 
other techniques and the use of magnetically labelled antibodies provides a specific capture of intact 167 
mitochondria, which may also contain less degraded mtDNA. We recommend that given the current 168 
interest in studying the mitochondrial genome in human brain, that the magnetic-microbead method 169 
from Miltenyi Biotech is used prior to DNA extraction to minimize the inclusion of NUMTs in 170 
downstream analyses. 171 
 172 
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Table 1. An overview of starting material for each isolation technique and resulting yield.  
 
Method A B C D E F 
Overview Percoll DNAse 
digestion 
Differential 
centrifugation 
Rapid differential 
centrifugation 
Magnetic microbeads 
(anti-TOM22) 
Phenol-chloroform 
Quantity of starting Material 150mg  
(tissue) 
20μg  
(DNA) 
100mg 
(tissue) 
100mg 
(tissue) 
200mg 
(tissue) 
100mg 
(tissue) 
Number of samples 4 6 4 3 5 5 
Average concentration (ng/µl) DNA collected (±SEM) 162.4 (11.6) 40.3 (10.1) 23.7 (8.0) 257 (138.4)  32.4 (7.0) N/A 
Average yield (µg) DNA collected (±SEM) 8.1 (0.58) 2.0 (0.50) 4.7 (1.60) 13.7 (6.35) 3.2 (0.70) N/A 
Average copies of mtDNA (±SEM) 41,530 
(15,468) 
12,092,501 
(7,742,804) 
28,886,594 
(12,405,939) 
403,381 
(194,557) 
5,321,960 
(1,246,724) 
459,264  
(751,075) 
Average copies of ncDNA (±SEM) 155 (85) 8,768 (3,731) 20,746 (11,256) 720 (449) 402 (86) 4,011 (585) 
Average ratio mtDNA/ncDNA (±SEM) 3,337 (1,988) 1,242 (309) 2,270 (960) 3,949 (3,424) 14,654 (2,922) 1,367 (35) 
Fold Enrichment mtDNA/ncDNA relative to phenol-
chloroform (P-value) 
2.44 (0.297) 0.91 (0.725) 1.66 (0.320) 2.89 (0.342) 10.72 (1.88x10-3) N/A 
In brief we compared five methods of isolating mtDNA in post-mortem human brain tissue; (A) discontinuous Percoll gradient, (B) DNase digestion of linear 
DNA, (C) differential centrifugation, (D) rapid (commercial) mitochondrial isolation via differential centrifugation (E) magnetic labelling and pull-down of 
mitochondria using an antibody to TOM22. We compared the yield and enrichment to a non-enriched standard (phenol-chloroform) using an unpaired two-
tailed t-test. 
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Figure 1: Enrichment of mtDNA relative to ncDNA. In total five methods (Percoll (A), DNase digestion (B), 
differential centrifugation (C), rapid differential centrifugation (D) and magnetic microbeads (E) were compared 
to a non-enriched standard (phenol-chloroform (F)). Shown is the ratio of mtDNA/ncDNA (±SEM) (Fig 1A) and 
the relative enrichment compared to phenol-chloroform (Fig 1B). *** = P<0.005 
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Regional differences in mitochondrial DNA
methylation in human post-mortem brain
tissue
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Abstract
Background: DNA methylation is an important epigenetic mechanism involved in gene regulation, with alterations
in DNA methylation in the nuclear genome being linked to numerous complex diseases. Mitochondrial DNA
methylation is a phenomenon that is receiving ever-increasing interest, particularly in diseases characterized by
mitochondrial dysfunction; however, most studies have been limited to the investigation of specific target regions.
Analyses spanning the entire mitochondrial genome have been limited, potentially due to the amount of input
DNA required. Further, mitochondrial genetic studies have been previously confounded by nuclear-mitochondrial
pseudogenes. Methylated DNA Immunoprecipitation Sequencing is a technique widely used to profile DNA
methylation across the nuclear genome; however, reads mapped to mitochondrial DNA are often discarded. Here,
we have developed an approach to control for nuclear-mitochondrial pseudogenes within Methylated DNA
Immunoprecipitation Sequencing data. We highlight the utility of this approach in identifying differences in
mitochondrial DNA methylation across regions of the human brain and pre-mortem blood.
Results: We were able to correlate mitochondrial DNA methylation patterns between the cortex, cerebellum and
blood. We identified 74 nominally significant differentially methylated regions (p < 0.05) in the mitochondrial
genome, between anatomically separate cortical regions and the cerebellum in matched samples (N = 3 matched
donors). Further analysis identified eight significant differentially methylated regions between the total cortex and
cerebellum after correcting for multiple testing. Using unsupervised hierarchical clustering analysis of the
mitochondrial DNA methylome, we were able to identify tissue-specific patterns of mitochondrial DNA methylation
between blood, cerebellum and cortex.
Conclusions: Our study represents a comprehensive analysis of the mitochondrial methylome using pre-existing
Methylated DNA Immunoprecipitation Sequencing data to identify brain region-specific patterns of mitochondrial
DNA methylation.
Keywords: 5-mC, 5-Methylcytosine, Blood, Brain, DNA methylation, Epigenetics, MeDIP-seq, Mitochondria, NUMTs
Introduction
Mitochondria are unique organelles in that they have their
own circular genome, approximately 16.6 kb in size [1].
Mitochondrial DNA (mtDNA) consists of 37 genes, 22 en-
coding for transfer RNAs (tRNAs), two for ribosomal
RNAs (rRNAs) and 13 encoding for proteins important in
the electron transport chain. Each of these 13 proteins are
directly involved in the regulation of cellular respiration,
generating the majority of ATP required for the process.
However, mitochondria have an array of other important
cellular roles such as calcium homeostasis [2] and neural
stem cell differentiation [3]. As such, abnormal mitochon-
drial function, dynamics and trafficking have been ass-
ociated with a number of brain disorders including
Alzheimer’s disease [4, 5], schizophrenia [6], bipolar dis-
order [7] and major depressive disorder [8].
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Epigenetic processes mediate the reversible regulation
of gene expression, occurring independently of DNA se-
quence variation, acting principally through chemical
modifications to DNA and nucleosomal histone proteins
and orchestrate a diverse range of important physio-
logical functions. DNA methylation is the best character-
ized and most stable epigenetic modification modulating
the transcription of mammalian genomes and, because it
can be robustly assessed using existing genomic DNA
resources, is the focus of most human epidemiological
epigenetic research to date [9]. The most widely used
method for epigenome-wide analysis of DNA methyla-
tion is the Illumina 450K methylation array, and a num-
ber of studies have recently shown differential DNA
methylation of the nuclear genome (ncDNA), between
different tissue types [10–12] and also in a range of com-
plex diseases, from brain disorders such as Alzheimer’s
disease [13–15] and schizophrenia [16, 17], to systemic
diseases such as type 2 diabetes [18] and Crohn’s disease
[19]. However, with no representation of the mitochon-
drial genome on this platform, as well as a lack of analysis
on other genome-wide platforms, the role of mtDNA
methylation has been largely neglected [20, 21].
Since the identification of 5-methylcytosine (5-mC) in
mitochondria, research into mtDNA methylation as an
independent and potentially relevant mark has received
more regular attention [22, 23]. However, most research
is either focussed on low resolution, global DNA methy-
lation, or candidate gene DNA methylation changes
using techniques such as bisulfite pyrosequencing [20].
These recent publications have indicated that differences
in mtDNA methylation are present in a variety of differ-
ent phenotypes [24–29] and may have potential utility as
a biomarker [30]. In addition, a recent study has
explored the use of Methylated DNA Immunoprecipita-
tion Sequencing (MeDIP-seq) to investigate changes in
mtDNA methylation across 39 cell lines and tissues from
publicly available data [31]. At present, genome-wide se-
quencing technologies have not yet been used to interro-
gate alterations in the mtDNA methylome across tissues
in the same individuals.
A high proportion of current, publicly available, genome-
wide DNA methylation data has been generated through
the use of MeDIP-seq, a method designed to interrogate
genome-wide changes in methylation at high throughput
and low cost [32]. However, given the presence of nuclear-
mitochondrial pseudogenes (NUMTs), regions of the nu-
clear genome that share a high sequence homology with
their mitochondrial paralogue [33, 34], mitochondrial reads
are often discarded from further analysis. The development
of bioinformatic pipelines to investigate regions of differen-
tial mtDNA methylation from whole genome data would
provide a novel way in which to interrogate the mtDNA
methylome in publicly available data. Here, we control for
the presence of NUMTs in a previously published MeDIP-
seq dataset, to investigate differential DNA methylation
across the mitochondrial genome in human post-mortem
brain samples.
Results
MtDNA methylation patterns are correlated between the
cortex, cerebellum and blood
To date, no study has investigated differences in mtDNA
methylation across different matched regions of human
brain and blood samples. Our sample (Table 1) consisted of
MeDIP-seq data from three individuals, free of any neuro-
pathology and neuropsychiatric disease, for five different
regions of the cortex (Brodmann areas (BA) 8, 9 and 10, su-
perior temporal gyrus (STG) and entorhinal cortex (ECX)),
the cerebellum (CER) and pre-mortem blood [35]. Given
that MeDIP-seq data has been generated from standardly
extracted total genomic DNA and thus contains a mixture
of ncDNA and mtDNA [36], we initially controlled for
regions of high sequence homology between the two
genomes within our data by realigning mtDNA reads to a
series of custom reference genomes using an in-house
pipeline (see the Methods section) to specifically analyze
mtDNA methylation (Fig. 1). Briefly, after an initial align-
ment to the GRCH37 reference genome using BWA,
uniquely mapped reads were extracted and aligned to a
custom GRCH37 reference genome not containing the
mitochondrial sequence. Reads that did not map to this
custom genome were found to share less homology with
the nuclear genome and were taken forward and realigned
once more to the full reference genome. Initially, we were
interested to investigate whether changes in mtDNA across
the mitochondrial genome were highly correlated between
different tissue types. Using principal component analysis
(PCA), we found that mtDNA methylation patterns are
highly correlated between different cortical regions (r >
0.99, p < 2.2E−16), with a slightly weaker correlation be-
tween the cerebellum and cortex (r > 0.97, p < 2.2E−16)
(Fig. 2). Due to the small number of blood samples avail-
able, deriving a significance level for the correlations be-
tween the cerebellum and blood could not be made.
Table 1 Demographic information
Individual Age at
death (years)
Age at bloods
sampled (years)
Post-mortem
delay (hours)
Gender
1 82 79 43 Female
2 92 N/A 17 Female
3 78 78 10 Male
MeDIP-seq data was available from post-mortem brain samples obtained from
three individuals free of any neuropathology and neuropsychiatric disease.
Data was available for five different regions of the cortex (Brodmann areas
(BA) 8, 9 and 10, superior temporal gyrus (STG), entorhinal cortex (ECX), the
cerebellum (CER) and pre-mortem blood (BLD). MeDIP-seq data was available
for all individuals from cortical and cerebellar samples; however, blood MeDIP-
seq data was not available for individual 2. Data is freely available to download
from http://epigenetics.iop.kcl.ac.uk/brain
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Instead, in an attempt to explore the similarity between
matched blood and cerebellum samples, the direction of
differential methylation with respect to the cortex was used.
Here, we found that 93.1% of the windows analyzed in the
cerebellum and blood had the same direction of methyla-
tion difference with respect to the cortex, further suggesting
a strong correlation between the two tissue types.
Differentially methylated regions of the mitochondrial
genome can be identified between anatomically distinct
cortical regions and the cerebellum
Having identified correlated mtDNA methylation pat-
terns across different brain regions, we were interested
to investigate whether we could identify differentially
methylated regions (DMRs) in the mitochondrial gen-
ome between different regions of the cortex and cerebel-
lum. To identify such tissue-specific DMRs within the
mitochondrial genome, paired t tests were performed
across matched cortical and cerebellum samples at
100 bp windows across the mitochondrial genome (see
the Methods section). In total, we identified 74 nomin-
ally significant DMRs (p < 0.05) between the five individ-
ual cortical regions and the cerebellum (Table 2; Fig. 3).
Of these DMRs, seven (Table 2, bold face) were found to
be present across all prefrontal cortex areas (BA8, BA9,
BA10). Furthermore, the direction of methylation
Fig. 1 Overview of the analysis pipeline
Fig. 2 MtDNA methylation patterns are correlated between the cortex, cerebellum and blood. Samples were ordered based upon the
similarity of their principal components, RPKM values, with r calculated for the correlations between each tissue. BLD blood, BA8
Brodmann area 8, BA9 Brodmann area 9, BA10 Brodmann area 10, CER cerebellum, CTX cortex, ECX entorhinal cortex, STG superior
temporal gyrus
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Table 2 List of DMRs identified between five anatomically discreet cortical regions and cerebellum
Start
(bp)
Stop
(bp)
Gene(s) BA8 BA9 BA10 EC STG
p value Δ RPKM p value Δ RPKM p value Δ RPKM p value Δ RPKM p value Δ RPKM
1 100 D-Loop - - - - - - - - - -
101 200 D-Loop - - - - - - - - - -
201 300 D-Loop - - - - - - - - - -
301 400 D-Loop - - - - - - - - - -
401 500 D-Loop - - - - - - - - - -
501 600 MT-TF - - - - - - - - - -
601 700 MT-TF/MT-RNR1 - - - - - - - - - -
701 800 MT-RNR1 - - - - - - 3.21E−02 79156 - -
801 900 MT-RNR1 4.31E−02 94246 2.93E−02 −43592 - - - - 1.79E−02 95257
901 1000 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1001 1100 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1101 1200 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1201 1300 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1301 1400 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1401 1500 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1501 1600 MT-RNR1 ND ND ND ND ND ND ND ND ND ND
1601 1700 MT-RNR1/MT-
TV/MT-RNR2
ND ND ND ND ND ND ND ND ND ND
1701 1800 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
1801 1900 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
1901 2000 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2001 2100 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2101 2200 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2201 2300 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2301 2400 MT-RNR2 2.54E−02 −97351 3.20E−02 −29509 4.31E−02 −82048 - - - -
2401 2500 MT-RNR2 8.90E−03 70950 - - - - - - - -
2501 2600 MT-RNR2 3.30E−03 51937 - - - - - - - -
2601 2700 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2701 2800 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
2801 2900 MT-RNR2 - - - - - - - - - -
2901 3000 MT-RNR2 - - - - - - - - - -
3001 3100 MT-RNR2 - - - - - - - - - -
3101 3200 MT-RNR2 ND ND ND ND ND ND ND ND ND ND
3201 3300 MT-RNR2/MT-TL - - - - - - 2.09E−02 242424 - -
3301 3400 MT-TL1/MT-ND1 - - - - - - - - - -
3401 3500 MT-ND1 - - 1.54E−02 864685 - - - - - -
3501 3600 MT-ND1 4.41E−02 1180914 - - 1.72E−02 226066 - - - -
3601 3700 MT-ND1 4.73E−02 1250436 4.52E−02 1228936 3.73E−02 1183681 - - - -
3701 3800 MT-ND1 - - - - 2.16E−02 20818 - - - -
3801 3900 MT-ND1 - - - - - - - - - -
3901 4000 MT-ND1 - - - - - - - - - -
4001 4100 MT-ND1 2.41E−02 −39498 1.55E−02 −38704 - - 4.68E−02 −49753 1.56E−02 243767
4101 4200 MT-ND1 ND ND ND ND ND ND ND ND ND ND
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Table 2 List of DMRs identified between five anatomically discreet cortical regions and cerebellum (Continued)
4201 4300 MT-ND1/MT-TI ND ND ND ND ND ND ND ND ND ND
4301 4400 MT-TI/MT-TQ ND ND ND ND ND ND ND ND ND ND
4401 4500 MT-TM/MT-ND2 ND ND ND ND ND ND ND ND ND ND
4501 4600 MT-ND2 ND ND ND ND ND ND ND ND ND ND
4601 4700 MT-ND2 ND ND ND ND ND ND ND ND ND ND
4701 4800 MT-ND2 ND ND ND ND ND ND ND ND ND ND
4801 4900 MT-ND2 ND ND ND ND ND ND ND ND ND ND
4901 5000 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5001 5100 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5101 5200 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5201 5300 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5301 5400 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5401 5500 MT-ND2 ND ND ND ND ND ND ND ND ND ND
5501 5600 MT-ND2/MT-
TW/MT-TA
ND ND ND ND ND ND ND ND ND ND
5601 5700 MT-TA/MT-TN ND ND ND ND ND ND ND ND ND ND
5701 5800 MT-TN/MT-TC ND ND ND ND ND ND ND ND ND ND
5801 5900 MT-TC/MT-TY ND ND ND ND ND ND ND ND ND ND
5901 6000 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6001 6100 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6101 6200 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6201 6300 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6301 6400 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6401 6500 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6501 6600 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6601 6700 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6701 6800 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6801 6900 MT-CO1 ND ND ND ND ND ND ND ND ND ND
6901 7000 MT-CO1 ND ND ND ND ND ND ND ND ND ND
7001 7100 MT-CO1 ND ND ND ND ND ND ND ND ND ND
7101 7200 MT-CO1 ND ND ND ND ND ND ND ND ND ND
7201 7300 MT-CO1 ND ND ND ND ND ND ND ND ND ND
7301 7400 MT-CO1 ND ND ND ND ND ND ND ND ND ND
7401 7500 MT-CO1/
MT-TS1
ND ND ND ND ND ND ND ND ND ND
7501 7600 MT-TS1/MT-
TD/MT-CO2
ND ND ND ND ND ND ND ND ND ND
7601 7700 MT-CO2 ND ND ND ND ND ND ND ND ND ND
7701 7800 MT-CO2 ND ND ND ND ND ND ND ND ND ND
7801 7900 MT-CO2 ND ND ND ND ND ND ND ND ND ND
7901 8000 MT-CO2 ND ND ND ND ND ND ND ND ND ND
8001 8100 MT-CO2 ND ND ND ND ND ND ND ND ND ND
8101 8200 MT-CO2 ND ND ND ND ND ND ND ND ND ND
8201 8300 MT-CO2/MT-TK ND ND ND ND ND ND ND ND ND ND
8301 8400 MT-TK/MT-ATP8 ND ND ND ND ND ND ND ND ND ND
8401 8500 MT-ATP8 ND ND ND ND ND ND ND ND ND ND
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Table 2 List of DMRs identified between five anatomically discreet cortical regions and cerebellum (Continued)
8501 8600 MT-ATP8/MT-ATP6 ND ND ND ND ND ND ND ND ND ND
8601 8700 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
8701 8800 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
8801 8900 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
8901 9000 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
9001 9100 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
9101 9200 MT-ATP6 ND ND ND ND ND ND ND ND ND ND
9201 9300 MT-ATP6/MT-CO3 ND ND ND ND ND ND ND ND ND ND
9301 9400 MT-CO3 ND ND ND ND ND ND ND ND ND ND
9401 9500 MT-CO3 ND ND ND ND ND ND ND ND ND ND
9501 9600 MT-CO3 ND ND ND ND ND ND ND ND ND ND
9601 9700 MT-CO3 ND ND ND ND ND ND ND ND ND ND
9701 9800 MT-CO3 ND ND ND ND ND ND ND ND ND ND
9801 9900 MT-CO3 - - - - - - - - - -
9901 10000 MT-CO3/MT-TG - - - - - - - - - -
10001 10100 MT-TG/MT-ND3 - - - - - - - - - -
10101 10200 MT-ND3 - - - - - - - - - -
10201 10300 MT-ND3 4.68E−02 −662126 - - - - 3.14E−02 −591067 7.30E−03 −57012
10301 10400 MT-ND3/MT-
TR/MT-ND4L
3.61E−02 −132719 3.61E−02 −135759 4.02E−02 −115364 1.40E−02 −73063 3.36E−02 −105106
10401 10500 MT-ND4L - - 4.68E−02 −71246 - - - - - -
10501 10600 MT-ND4L - - - - - - - - - -
10601 10700 MT-ND4L ND ND ND ND ND ND ND ND ND ND
10701 10800 MT-ND4L/
MT-ND4
ND ND ND ND ND ND ND ND ND ND
10801 10900 MT-ND4 ND ND ND ND ND ND ND ND ND ND
10901 11000 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11001 11100 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11101 11200 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11201 11300 MT-ND4 - - 1.94E−02 −68903 1.84E−02 −79625 4.71E−02 58742 - -
11301 11400 MT-ND4 - - 4.78E−02 −139847 - - - - - -
11401 11500 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11501 11600 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11601 11700 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11701 11800 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11801 11900 MT-ND4 ND ND ND ND ND ND ND ND ND ND
11901 12000 MT-ND4 ND ND ND ND ND ND ND ND ND ND
12001 12100 MT-ND4 ND ND ND ND ND ND ND ND ND ND
12101 12200 MT-ND4/MT-TH ND ND ND ND ND ND ND ND ND ND
12201 12300 MT-TS2/MT-TL2 ND ND ND ND ND ND ND ND ND ND
12301 12400 MT-TL2/MT-ND5 4.71E−02 1787 - −197592 - - - - - -
12401 12500 MT-ND5 - - - - - - - - - -
12501 12600 MT-ND5 - - - - - - - - - -
12601 12700 MT-ND5 - - - - - - - - - -
12701 12800 MT-ND5 2.05E−02 −5702 - - 4.58E−02 −388706 - - 4.36E−02 −394978
12801 12900 MT-ND5 2.26E−02 −89668 - - - - - - - -
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difference was maintained in all Brodmann area regions,
with three conserved regions of hypomethylation and
four conserved regions of hypermethylation, with re-
spect to the cerebellum. Furthermore, four of the seven
conserved regions were adjacent to each other within
the mitochondrial displacement loop (D-Loop) (16201–
16600 bp), a region associated with gene transcription
and DNA replication.
Table 2 List of DMRs identified between five anatomically discreet cortical regions and cerebellum (Continued)
12901 13000 MT-ND5 - - 3.10E−02 −130016 - - - - - -
13001 13100 MT-ND5 ND ND ND ND ND ND ND ND ND ND
13101 13200 MT-ND5 ND ND ND ND ND ND ND ND ND ND
13201 13300 MT-ND5 ND ND ND ND ND ND ND ND ND ND
13301 13400 MT-ND5 1.48E−02 −175917 - - 9.80E−03 −144949 3.40E−02 −133694 - -
13401 13500 MT-ND5 3.64E−02 −104010 - - 3.40E−02 −81264 - - - -
13501 13600 MT-ND5 - - - - - - - - - -
13601 13700 MT-ND5 - - - - - - - - - -
13701 13800 MT-ND5 1.31E−02 −422610 - - 1.20E−03 3714 - - - -
13801 13900 MT-ND5 - - 3.72E−02 708761 2.59E−02 123249 - - - -
13901 14000 MT-ND5 - - - - 2.17E−02 −75118 - - - -
14001 14100 MT-ND5 - - - - - - - - - -
14101 14200 MT-ND5/MT-ND6 - - - - - - - - 4.18E−02 −534766
14201 14300 MT-ND6 - - - - - - - - - -
14301 14400 MT-ND6 - - - - - - - - - -
14401 14500 MT-ND6 - - - - - - - - - -
14501 14600 MT-ND6 - - - - - - - - 4.86E−02 −82767
14601 14700 MT-ND6/MT-TE - - - - - - - - - -
14701 14800 MT-TE/MT-CYB - - - - - - - - - -
14801 14900 MT-CYB ND ND ND ND ND ND ND ND ND ND
14901 15000 MT-CYB ND ND ND ND ND ND ND ND ND ND
15001 15100 MT-CYB ND ND ND ND ND ND ND ND ND ND
15101 15200 MT-CYB - - - - - - - - - -
15201 15300 MT-CYB - - - - - - 1.20E−02 254183 - -
15301 15400 MT-CYB - - - - - - - - - -
15401 15500 MT-CYB 4.38E−02 10628 - - 2.10E−02 −554527 - - 3.28E−02 −554225
15501 15600 MT-CYB 3.73E−02 −671707 - - 1.23E−02 −685630 3.82E−02 9301 3.51E−02 −695515
15601 15700 MT-CYB - - - - 4.33E−02 −746270 - - - -
15701 15800 MT-CYB - - - - - - - - - -
15801 15900 MT-CYB/MT-TT - - - - - - - - - -
15901 16000 MT-TT/MT-TP - - - - - - - - - -
16001 16100 MT-TP - - - - - - - - - -
16101 16200 D-Loop - - 3.40E−03 3014 - - - - - -
16201 16300 D-Loop 4.64E−02 380407 2.50E−02 1117943 3.68E−02 296890 - - - -
16301 16400 D-Loop 3.65E−02 −941720 1.38E−02 −112453 2.73E−02 −177146 - - - -
16401 16500 D-Loop 4.29E−02 444051 2.20E−02 1151402 1.68E−02 313156 - - - -
16501 16600 D-Loop 3.71E−02 784572 2.10E−02 764994 2.46E−02 836662 - - - -
Shown is the location of the DMR within the mitochondrial genome (ChrM) (based on GENCODE), the gene(s) residing within the 100 bp window, and p value
from paired t tests between each of the five cortical regions: Brodmann areas 8, 9 and 10 (BA8, BA9, BA10), entorhinal cortex (ECX) and superior temporal gyrus
(STG) compared to the cerebellum (CER). Results are displayed in order of genomic position. RPKM and corresponding p values are shown for windows if p < 0.05.
Key: - denotes data not significant (p > 0.05); ND denotes not determined as the window was not included in analysis due to removal in NUMT pipeline. Results
shown in bold represent those found to be present across all prefrontal cortex areas (BA8, BA9, BA10)
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Fig. 3 (See legend on next page.)
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A number of differentially methylated regions in mtDNA
can be observed between the cortex and cerebellum
We were also interested to see whether total cortical tis-
sue was significantly different to matched cerebellum
samples. Given the paired nature of the different ana-
tomical regions of the cortex, we used a multilevel
mixed effects model to compare total cortex to cerebel-
lum (see the Methods section). This analysis revealed 48
nominally significant (p < 0.05) windows (Table 3; Fig. 4),
of which eight passed the Bonferroni correction (Table 3,
bold face). Interestingly, three of these eight were adja-
cent to each other, lying between 10301 and 10600 bp
and covering MT-ND3/MT-ND4L and MT-TR. We also
saw a Bonferroni significant difference in DNA methyla-
tion in the D-Loop, where we earlier noted DNA methy-
lation changes across all three Brodmann area regions.
MtDNA methylation patterns can distinguish between
tissue types
Although we have shown that mtDNA methylation
patterns are highly similar between distinct anatomical
regions of the human brain and blood, we were also
interested to identify whether mtDNA methylation
patterns could distinguish between these tissue types.
Through unsupervised hierarchical clustering, we showed
that average mtDNA methylation patterns can segregate
these tissues (Fig. 5a). Importantly, ncDNA methylation
profiles in the same samples have also been previously
shown to separate the cortex, cerebellum and blood [35].
Interestingly, when we performed unsupervised hierarch-
ical clustering on the individual samples, we found that, in
most cases, intra-individual differences across tissue types
are greater than inter-individual differences within each
tissue type, as the cortex, cerebellum and blood samples
clustered with their own tissue type, respectively (Fig. 5b).
Discussion
The availability of publicly available epigenomic data
provides a great resource for mitochondrial epigenetics,
a field that is relatively nascent and has yet to be thor-
oughly investigated in a range of complex diseases. Here,
we present evidence that mtDNA methylation patterns
across mtDNA are brain region specific. However, data
such as that presented here is confounded by a lack of
isolation of mtDNA prior to antibody enrichment and
sequencing. As such, the potential of including NUMTs
in datasets derived from data generated using total gen-
omic DNA could lead to misleading results. Here, we
controlled for regions of high sequence homology be-
tween the nuclear and mitochondrial genomes. However,
this approach is likely over-conservative and does lead
to the generation of a somewhat truncated consensus se-
quence. PCA of the mitochondrial epigenome after cor-
rections for nuclear homology was able to separate
individuals belonging to the three main tissue types, the
blood, cortex and cerebellum based on mtDNA methyla-
tion variation among tissue types. This tissue specificity
is further highlighted by the identification of eight DMRs
that pass the Bonferroni correction for multiple testing
between total cortex and cerebellum. MtDNA methyla-
tion has been shown to be cell line dependent in the
past. [31] Although overall DNA methylation levels were
low in all tissues, it is worth noting that the study was
performed on non bisulfite-treated DNA. As such, the
low percentage of mtDNA methylation is not a pitfall
due to a lack of a total bisulfite treatment efficiency.
One limitation of the current study is the unavailability
of publicly available MeDIP-seq datasets of matched cor-
tical and cerebellum tissue from other cohorts for valid-
ation purposes. Future work would aim to replicate our
findings in additional study cohorts and also to investi-
gate the relationship between mitochondrial DNA
methylation and gene expression.
Despite a number of nominally significant windows
being identified between each individual cortical re-
gion and the cerebellum, these did not pass the Bon-
ferroni correction, although it is likely this method is
too stringent. Nevertheless, the conservation of seven
nominally significant windows across each Brodmann
area is interesting to note. Four of these windows lie
adjacent to each other and correspond to the mito-
chondrial D-Loop, a region containing the only two
mitochondrial promoters which is typically associated
with gene transcription and DNA replication. How-
ever, one limitation of this study is owed to the use
of antibody-based enrichment, resulting in the an-
alysis being limited to a window-based approach.
Despite this, studies of the nuclear genome have
shown high correlation between window-based ap-
proaches and, more sensitive, single-site assays such
as the Illumina 450K beadarray [32]. However, given
the small size of the mitochondrial genome and that
(See figure on previous page.)
Fig. 3 DNA methylation differences are seen in the mitochondrial genome between brain regions and blood. Average raw RPKM values across the
mitochondrial genome for each individual cortical brain region alongside matched blood and cerebellum samples are shown in the top panel, with gene
positions downloaded from GENCODE shown in the middle panel. For each 100 bp window, paired t tests were performed to compare each cortical brain
region and the cerebellum, with -log10 (p) shown in the bottom panel. BLD blood, BA8 Brodmann area 8, BA9 Brodmann area 9, BA10 Brodmann area 10,
CER cerebellum, CTX cortex, ECX entorhinal cortex, RPKM reads per kilobase of transcript per million mapped reads, STG superior temporal gyrus. Red
dashed line denotes the Bonferroni significance, whilst blue dashed line denotes p< 0.05 in the lower panel
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Table 3 List of DMRs identified between total cortex and
cerebellum
Start (bp) Stop (bp) Gene(s) p value
1 100 D-Loop -
101 200 D-Loop -
201 300 D-Loop -
301 400 D-Loop -
401 500 D-Loop 7.99E−03
501 600 MT-TF 4.49E−03
601 700 MT-TF/MT-RNR1 1.16E−02
701 800 MT-RNR1 3.22E−03
801 900 MT-RNR1 1.91E−04
901 1000 MT-RNR1 ND
1001 1100 MT-RNR1 ND
1101 1200 MT-RNR1 ND
1201 1300 MT-RNR1 ND
1301 1400 MT-RNR1 ND
1401 1500 MT-RNR1 ND
1501 1600 MT-RNR1 ND
1601 1700 MT-RNR1/MT-TV/MT-RNR2 ND
1701 1800 MT-RNR2 ND
1801 1900 MT-RNR2 ND
1901 2000 MT-RNR2 ND
2001 2100 MT-RNR2 ND
2101 2200 MT-RNR2 ND
2201 2300 MT-RNR2 ND
2301 2400 MT-RNR2 8.10E−03
2401 2500 MT-RNR2 7.50E−03
2501 2600 MT-RNR2 5.14E−03
2601 2700 MT-RNR2 ND
2701 2800 MT-RNR2 ND
2801 2900 MT-RNR2 -
2901 3000 MT-RNR2 -
3001 3100 MT-RNR2 -
3101 3200 MT-RNR2 -
3201 3300 MT-RNR2/MT-TL 1.51E−03
3301 3400 MT-TL1/MT-ND1 -
3401 3500 MT-ND1 1.37E−02
3501 3600 MT-ND1 4.27E−03
3601 3700 MT-ND1 5.56E−03
3701 3800 MT-ND1 8.21E−03
3801 3900 MT-ND1 -
3901 4000 MT-ND1 -
4001 4100 MT-ND1 3.07E−06
4101 4200 MT-ND1 -
4201 4300 MT-ND1/MT-TI ND
Table 3 List of DMRs identified between total cortex and
cerebellum (Continued)
4301 4400 MT-TI/MT-TQ ND
4401 4500 MT-TM/MT-ND2 ND
4501 4600 MT-ND2 ND
4601 4700 MT-ND2 ND
4701 4800 MT-ND2 ND
4801 4900 MT-ND2 ND
4901 5000 MT-ND2 ND
5001 5100 MT-ND2 ND
5101 5200 MT-ND2 ND
5201 5300 MT-ND2 ND
5301 5400 MT-ND2 ND
5401 5500 MT-ND2 ND
5501 5600 MT-ND2/MT-TW/MT-TA ND
5601 5700 MT-TA/MT-TN ND
5701 5800 MT-TN/MT-TC ND
5801 5900 MT-TC/MT-TY ND
5901 6000 MT-CO1 ND
6001 6100 MT-CO1 ND
6101 6200 MT-CO1 ND
6201 6300 MT-CO1 ND
6301 6400 MT-CO1 ND
6401 6500 MT-CO1 ND
6501 6600 MT-CO1 ND
6601 6700 MT-CO1 ND
6701 6800 MT-CO1 ND
6801 6900 MT-CO1 ND
6901 7000 MT-CO1 ND
7001 7100 MT-CO1 ND
7101 7200 MT-CO1 ND
7201 7300 MT-CO1 ND
7301 7400 MT-CO1 ND
7401 7500 MT-CO1/MT-TS1 ND
7501 7600 MT-TS1/MT-TD/MT-CO2 ND
7601 7700 MT-CO2 ND
7701 7800 MT-CO2 ND
7801 7900 MT-CO2 ND
7901 8000 MT-CO2 ND
8001 8100 MT-CO2 ND
8101 8200 MT-CO2 ND
8201 8300 MT-CO2/MT-TK ND
8301 8400 MT-TK/MT-ATP8 ND
8401 8500 MT-ATP8 ND
8501 8600 MT-ATP8/MT-ATP6 ND
8601 8700 MT-ATP6 ND
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23 of the 37 genes present in the genome are below
100 bp in size, this window-based approach may not
be the most appropriate for future studies designed to
specifically assess mtDNA methylation as it can result
Table 3 List of DMRs identified between total cortex and
cerebellum (Continued)
8701 8800 MT-ATP6 ND
8801 8900 MT-ATP6 ND
8901 9000 MT-ATP6 ND
9001 9100 MT-ATP6 ND
9101 9200 MT-ATP6 ND
9201 9300 MT-ATP6/MT-CO3 ND
9301 9400 MT-CO3 ND
9401 9500 MT-CO3 ND
9501 9600 MT-CO3 ND
9601 9700 MT-CO3 ND
9701 9800 MT-CO3 ND
9801 9900 MT-CO3 -
9901 10000 MT-CO3/MT-TG -
10001 10100 MT-TG/MT-ND3 1.81E−02
10101 10200 MT-ND3 1.39E−02
10201 10300 MT-ND3 3.53E−04
10301 10400 MT-ND3/MT-TR/MT-ND4L 1.19E−05
10401 10500 MT-ND4L 2.61E−04
10501 10600 MT-ND4L 9.05E−04
10601 10700 MT-ND4L ND
10701 10800 MT-ND4L/MT-ND4 ND
10801 10900 MT-ND4 ND
10901 11000 MT-ND4 ND
11001 11100 MT-ND4 ND
11101 11200 MT-ND4 ND
11201 11300 MT-ND4 8.86E−05
11301 11400 MT-ND4 1.65E−03
11401 11500 MT-ND4 ND
11501 11600 MT-ND4 ND
11601 11700 MT-ND4 ND
11701 11800 MT-ND4 ND
11801 11900 MT-ND4 ND
11901 12000 MT-ND4 ND
12001 12100 MT-ND4 ND
12101 12200 MT-ND4/MT-TH ND
12201 12300 MT-TS2/MT-TL2 ND
12301 12400 MT-TL2/MT-ND5 -
12401 12500 MT-ND5 -
12501 12600 MT-ND5 -
12601 12700 MT-ND5 -
12701 12800 MT-ND5 1.81E−03
12801 12900 MT-ND5 1.05E−02
12901 13000 MT-ND5 8.23E−03
13001 13100 MT-ND5 ND
Table 3 List of DMRs identified between total cortex and
cerebellum (Continued)
13101 13200 MT-ND5 ND
13201 13300 MT-ND5 ND
13301 13400 MT-ND5 1.44E−03
13401 13500 MT-ND5 9.13E−04
13501 13600 MT-ND5 1.61E−02
13601 13700 MT-ND5 3.89E−02
13701 13800 MT-ND5 2.77E−04
13801 13900 MT-ND5 2.80E−03
13901 14000 MT-ND5 1.88E−02
14001 14100 MT-ND5 9.31E−03
14101 14200 MT-ND5/MT-ND6 -
14201 14300 MT-ND6 -
14301 14400 MT-ND6 1.04E−02
14401 14500 MT-ND6 1.99E−02
14501 14600 MT-ND6 2.26E−02
14601 14700 MT-ND6/MT-TE 3.82E−03
14701 14800 MT-TE/MT-CYB 1.92E−02
14801 14900 MT-CYB ND
14901 15000 MT-CYB ND
15001 15100 MT-CYB ND
15101 15200 MT-CYB 3.30E−02
15201 15300 MT-CYB -
15301 15400 MT-CYB -
15401 15500 MT-CYB 8.52E−04
15501 15600 MT-CYB 7.43E−04
15601 15700 MT-CYB 1.16E−02
15701 15800 MT-CYB 2.24E−02
15801 15900 MT-CYB/MT-TT -
15901 16000 MT-TT/MT-TP -
16001 16100 MT-TP -
16101 16200 D-Loop 2.23E−03
16201 16300 D-Loop 5.02E−04
16301 16400 D-Loop 1.84E−03
16401 16500 D-Loop 1.12E−03
16501 16600 D-Loop 2.20E−03
Shown is the location of the DMR within ChrM (based on GENCODE), the
gene(s) residing within the 100 bp window, and p value from a multilevel
mixed effects model. Results are displayed in order of genomic position. RPKM
and corresponding p values are shown for windows if p < 0.05. Key: - denotes
data not significant (p > 0.05); ND denotes not determined as the window was
not included in analysis due to removal in NUMT pipeline; bold denotes
windows that reached our Bonferroni significant threshold of p < 7.04E−04
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Fig. 4 (See legend on next page.)
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in a window intersecting two genes in the polycis-
tronic transcript.
Conclusions
This method provides a conservative approach to deter-
mine mtDNA methylation across the genome for data
previously generated using next-generation sequencing
approaches such as MeDIP-seq. Its conservative nature
reduces the risk of the inclusion of NUMTs in the final
analysis of whole genome data but may also lead to the
inclusion of false negatives as well as potential gaps in
the reference sequence. As such, it is best suited to ana-
lyzing previously generated whole genome data and is
not a replacement for the isolation of mitochondrial DNA
[36] prior to targeted methylation studies, which would be
the optimal approach for investigating mitochondrial epi-
genomics. However, our method has allowed the identifi-
cation of novel brain-region-specific DMRs in a previously
generated publicly available dataset. Furthermore, the
identification of brain region-specific mtDNA methylation
patterns across the mitochondrial epigenome suggests the
importance of a focussed, tissue-specific study design
when investigating mtDNA methylation. As previously
discussed, one caveat when utilizing MeDIP-seq data is
the segregation of data into neighbouring windows, mean-
ing that determining the exact corresponding gene of a
DMR is difficult and, as such, future studies should aim to
sequence the mitochondrial DNA methylome at single-
base resolution to address this.
Methods
Data collection
We utilized publicly available MeDIP-seq data from
Davies et al. [35]. In brief, this data was generated using
5 μg fragmented gDNA, which, following end repair
<A> base addition and adaptor ligation, was immuno-
precipitated using an anti-5-mC antibody (Diagenode,
Liège, Belgium). MeDIP DNA was purified and then
amplified using adaptor-mediated PCR, with DNA frag-
ments between 220 and 320 bp subjected to highly par-
allel 50 bp paired-end sequencing on the Illumina Hi-
Seq platform. The paired-end, raw fasta files were pro-
vided by the authors and quality checked using FastQC.
Sample information is provided in Table 1.
Fig. 5 MtDNA methylation patterns can distinguish between tissue
types. a Average RPKM values for each cortical brain region,
cerebellum and blood samples were clustered based upon the
Euclidean distance, identifying two major clusters; the cortex and
blood-cerebellum. b When clustering RPKM values in the individual
samples from the cortex, cerebellum and blood, we observed that
individual cortex samples clustered together, whilst cerebellum and
blood samples formed separate clusters. This highlights that tissue-
specific differences between the cortex, cerebellum and blood are
greater than intra-individual variability within a tissue. BLD blood, BA8
Brodmann area 8, BA9 Brodmann area 9, BA10 Brodmann area 10, CER
cerebellum, CTX cortex, ECX entorhinal cortex, RPKM reads per kilobase
of transcript per million mapped reads, STG superior temporal gyrus
(See figure on previous page.)
Fig. 4 DNA methylation differences are seen in the mitochondrial genome between the cerebellum and cortex. RPKM values in the total cortex
and cerebellum across the mitochondrial genome are shown in the top panel, with gene positions downloaded from GENCODE shown in the
middle panel. For each 100 bp window, paired t tests were performed to compare the cortex to the cerebellum, with -log10 (p) shown in the
bottom panel. BLD blood, BA8 Brodmann area 8, BA9 Brodmann area 9, BA10 Brodmann area 10, CER cerebellum, CTX cortex, ECX entorhinal
cortex, RPKM reads per kilobase of transcript per million mapped reads, STG superior temporal gyrus. Red dashed line denotes the Bonferroni
significance, whilst blue dashed line denotes p < 0.05 in the lower panel
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Quality control and NUMT exclusion
Fasta files were subjected to adaptor and Phred score
(q < 20) trimming. In an attempt to remove any potential
contamination of possible NUMTs, multiple alignments
to the reference genome were undertaken. Paired fasta
files were aligned to GRCH37 using BWA. Unique and
mapped reads aligning to the mitochondria were then
re-mapped to a custom GRCH37 reference without the
mitochondrial chromosome. Reads not mapping to the
custom reference were then taken forward and realigned
to the full GRCH37 reference to eliminate the possibility
of homologous regions mapping falsely to the mitochon-
drial genome (Fig. 1). All alignments were carried out
using BWA mem and default settings. Reads per kilo-
base of transcript per million mapped reads (RPKM)
values for each sample were calculated using the MEDIPS
package [37]. Methylation was averaged across 100 bp
non-overlapping windows (default parameter setting in
MEDIPS), and only windows with read counts >10 were
considered for analysis. Due to the non-normal distribu-
tion of all cohorts, RPKM values were log2 transformed
before statistical analysis.
Statistical analyses
All analyses were performed in the R statistical environ-
ment version 3.2.1 [38]. For all analyses, a nominally sig-
nificant threshold of p < 0.05 and a Bonferroni significant
threshold of p < 7.04E−04 were used. Given the matched
sample nature of this cohort, two-tailed, paired t tests
were performed at each window along the mitochondrial
genome to identify DMRs between the individual cortical
regions and cerebellum. To compare the total cortex to
cerebellum, we performed a multilevel mixed effects
model in the Lme4 package in R [39], using the brain
region as the random effect and individual as the fixed
effect. To assess the similarity of the brain regions, we
used the R function “hclust” to cluster average RPKM
values for the brain regions using the Euclidean distance.
We used the R function “corrgram” within the corrgram
package [40] to order samples based upon the similarity of
their principal components.
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